0001308411-13-000297.txt : 20131113 0001308411-13-000297.hdr.sgml : 20131113 20131113111732 ACCESSION NUMBER: 0001308411-13-000297 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 9 CONFORMED PERIOD OF REPORT: 20130930 FILED AS OF DATE: 20131113 DATE AS OF CHANGE: 20131113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: StemGen, Inc. CENTRAL INDEX KEY: 0001023198 STANDARD INDUSTRIAL CLASSIFICATION: INVESTORS, NEC [6799] IRS NUMBER: 541812385 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-21555 FILM NUMBER: 131213255 BUSINESS ADDRESS: STREET 1: 6462 LITTLE RIVER TURNPIKE STREET 2: SUITE E CITY: ALEXANDRIA STATE: VA ZIP: 22312 BUSINESS PHONE: 703-797-8111 MAIL ADDRESS: STREET 1: 6462 LITTLE RIVER TURNPIKE STREET 2: SUITE E CITY: ALEXANDRIA STATE: VA ZIP: 22312 FORMER COMPANY: FORMER CONFORMED NAME: AMASYS CORP DATE OF NAME CHANGE: 19960918 10-Q 1 sgni10q130930.htm STEMGEN, INC. FORM 10-Q SEPTEMBER 30, 2013

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 10-Q

 

ý     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For Quarterly Period Ended September 30, 2013

 

or

 

o     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from           to         

 

Commission File Number 0-21555

 

StemGen, Inc.

(Exact name of registrant issuer as specified in its charter)

 

Delaware   54-1812385

(State or other jurisdiction of incorporation or

organization)

   (I.R.S. Employer Identification No.)
     

6462 Little River Turnpike, Suite E,

Alexandria, Virginia 22312

(Address of principal executive offices, including zip code)
 
Registrant’s phone number, including area code    (703) 797-8111

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES ý     NO o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding twelve months (or shorter period that the registrant was required to submit and post such files).

YES o     NO ý

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer o Accelerated Filer o Non-accelerated Filer o Smaller reporting company ý

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ý No o

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class   Outstanding at November 12, 2013
Common Stock, $.01 par value   183,927

 

 

 

 

STEMGEN, INC.

 

INDEX

 

    Page No.
PART I FINANCIAL INFORMATION  
ITEM 1. FINANCIAL STATEMENTS:  
  Condensed Balance Sheets — September 30, 2013 (Unaudited) and June 30, 2013 3
  Condensed Statements of Operations  (Unaudited) — Three months ended September 30, 2013 and 2012 and the period from entering development stage (October 1, 2006) through September 30, 2013 4
  Condensed Statements of Cash Flows (Unaudited) — Three months ended September 30, 2013 and 2012 and the period from entering development stage (October 1, 2006) through September 30, 2013 5
  Notes to Condensed Financial Statements (Unaudited) 6
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 13
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 17
ITEM 4T. CONTROLS AND PROCEDURES 17
PART II OTHER INFORMATION 18
ITEM 1 LEGAL PROCEEDINGS 18
ITEM 1A RISK FACTORS 18
ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 20
ITEM 3 DEFAULTS UPON SENIOR SECURITIES 20
ITEM 4 (REMOVED AND RESERVED) 20
ITEM 5 OTHER INFORMATION 20
ITEM 6 EXHIBITS 20
     

 

 

-2-
 

 

PART I - FINANCIAL INFORMATION

 

ITEM I — FINANCIAL STATEMENTS

 

STEMGEN, INC.

(A Development Stage Company)

CONDENSED BALANCE SHEETS

 

   September 30,  June 30,
   2013  2013
ASSETS  (Unaudited)   
CURRENT ASSETS          
Cash  $1,125   $840 
           
TOTAL ASSETS  $1,125   $840 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
CURRENT LIABILITIES:          
Accounts payable and accrued expenses  $52,926   $46,720 
Accounts payable - related parties   24,857    24,857 
Notes payable and accrued interest - related parties, net   266,966    242,603 
TOTAL CURRENT LIABILITIES   344,749    314,180 
           
           
STOCKHOLDERS’ DEFICIT:          
Preferred stock, $0.01 par value, 1,000,000 shares authorized, no shares issued and outstanding at September 30, 2013 and June 30, 2013, respectively   —      —   
Common stock, $0.01 par value, 20,000,000 shares authorized, 183,927 shares issued and outstanding at September 30, 2013 and June 30, 2013.   1,836    1,839 
Additional paid in capital   525,786    525,783 
Accumulated deficit   (871,246)   (840,962)
TOTAL STOCKHOLDERS’ DEFICIT   (343,624)   (313,340)
           
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $1,125   $840 

 

 

The accompanying notes are an integral part of these condensed financial statements.

 

-3-
 

 

 

 STEMGEN, INC.

(A Development Stage Company)

CONDENSED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   Three Months Ended September 30,  Period from entering Development Stage (October 1, 2006) through September 30,
   2013  2012  2013
REVENUES  $—     $—     $—   
COST OF SALES   —      —      —   
GROSS PROFIT   —      —      —   
OPERATING EXPENSES:               
General and administrative expenses   13,421    12,074    364,225 
Total operating expenses   13,421    12,074    364,225 
LOSS FROM OPERATIONS   (13,421)   (12,074)   (364,225)
OTHER INCOME (EXPENSE):               
Interest expense   (16,863)   (11,445)   (169,132)
Loss on extinguishment of debt   —      —      (20,000)
Gain on sale of short term investment   —      —      13,374 
Gain on forfeit of deposit   —      —      32,500 
Total other expense, net   (16,863)   (11,445)   (143,258)
LOSS BEFORE PROVISION FOR INCOME TAXES   (30,284)   (23,519)   (507,483)
Provision for income taxes   —      —      —   
                
NET LOSS  $(30,284)  $(23,519)  $(507,483)
NET LOSS PER SHARE OF COMMON STOCK — Basic and diluted  $(0.16)  $(0.13)     
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING — Basic and diluted*   183,927    177,810      

 

 

*The common shares outstanding are post reverse stock split of one share for every 80 shares of the Company’s Common stock which was effectuated on February 5, 2013. For further details, please see Note 2 to these financial statements.

 

The accompanying notes are an integral part of these condensed financial statements. 

 

-4-
 

 

 

STEMGEN, INC.

(A Development Stage Company)

CONDENSED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

       
   Three months Ended September 30,  Period from entering Development Stage (October 1, 2006) through September 30,
   2013  2012  2013
OPERATING ACTIVITIES:               
Net loss  $(30,284)  $(23,519)  $(507,484)
Adjustments to reconcile net loss to net cash used in operating activities:               
Amortization of debt discount   11,547    6,526    92,214 
Gain on sale of short term investment   —      —      (12,734)
Changes in operating assets and liabilities;               
Accounts payable and accrued expenses   6,206    2,950    96,614 
Accrued interest payable – related parties   5,316    4,919    25,368 
Accounts payable, related parties   —      —      17,328 
Net cash used in operating activities   (7,215)   (9,124)   (288,694)
INVESTING ACTIVITIES:               
Net proceeds from sale of short term investment   —      —      40,570 
Net cash provided by investing activities   —      —      40,570 
FINANCING ACTIVITIES:               
Proceeds from sale of common stock   —      —      3,500 
Proceeds from notes payable, related parties   7,500    10,000    242,500 
Net cash provided by financing activities   7,500    10,000    246,000 
NET INCREASE (DECREASE) IN CASH   285    876    (2,124)
CASH, Beginning of period   840    564    3,249 
CASH, End of period  $1,125   $1,440   $1,125 

 

 

 

 

The accompanying notes are an integral part of these condensed financial statements.

 

  

-5-
 

 

STEMGEN, INC.

(A Development Stage Company)

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

 

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation —

The accompanying unaudited condensed interim financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America.  All references to Generally Accepted Accounting Principles (“GAAP”) are in accordance with The FASB Accounting Standards Codification (“ASC”) and the Hierarchy of Generally Accepted Accounting Principles.

 

The unaudited condensed interim financial statements have been prepared by us pursuant to the rules and regulations of the Securities and Exchange Commission. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments) which are, in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited financial statements and notes for the year ended June 30, 2013 included in our Annual Report on Form 10-K. The results of the three month periods ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year ending June 30, 2014.

 

Going Concern —

The accompanying unaudited condensed interim financial statements have been prepared assuming that we will continue as a going concern.  We have suffered recurring losses from operations since our inception and have an accumulated deficit of $871,246 at September 30, 2013.  The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classifications of liabilities that might be necessary should we be unable to continue our existence.

 

In addition, our recovery is dependent upon future events, the outcome of which is undetermined.  We intend to continue to attempt to raise additional capital, but there can be no certainty that such efforts will be successful.

 

Development Stage Activities –

Since we redeemed and converted all of the outstanding Series A Preferred Stock of Comtex News Network, Inc. at the end of September 2006, starting October 1, 2006 we have not conducted any business operations. All of our operating results and cash flows reported in the accompanying unaudited condensed interim financial statements from October 1, 2006 are considered to be those related to development stage activities and represent the cumulative amounts from its development stage activities required to be reported.

 

Use of Estimates — 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents —

We consider investments with original maturities of 90 days or less to be cash equivalents. As of September 30, 2013 and June 30, 2013, we have no cash equivalents.

 

-6-
 

 

Income Taxes —

The Company accounts for income taxes in accordance with ASC Topic 740.  Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at currently effective tax rates, of future deductible or taxable amounts attributable to events that have been recognized on a cumulative basis in the financial statements. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized.

 

Net Loss Per Share —

Basic net loss and diluted loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income by the weighted-average number of shares and dilutive potential common shares outstanding during the period. Dilutive potential shares consist of dilutive shares issuable upon the exercise of outstanding stock options and warrants computed using the treasury stock method.  As of September 30, 2013, there were zero dilutive securities which are considered anti-dilutive.

 

Concentration of Credit Risk —

Financial instruments that potentially subject us to a concentration of credit risk consist of cash.  We maintain our cash with high credit quality financial institutions; at times, such balances with any one financial institution may exceed FDIC insured limits.

 

Fair Value of Financial Instruments —

Our financial instruments consist of cash, accounts payable, accrued expenses and notes payable.  The carrying values of cash, accounts payable, accrued expenses and notes payable are representative of their fair values due to their short-term maturities.

 

Fair Value Measurements and Disclosures –

ASC Topic 820 defines fair value, establishes a framework for measuring fair value, establishes a three-level valuation hierarchy for disclosure of fair value measurement and enhances disclosure requirements for fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:

 

Level 1 - Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

Level 2 - Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

The Company’s adoption of fair value measurements and disclosures did not have a material impact on the financial statements and financial statement disclosures.

 

Recently Issued Accounting Pronouncements - Adopted

In May 2011, the FASB issued Accounting Standards Update No. 2011-04, “Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs”. The amendments result in common fair value measurement and disclosure requirements in U.S. generally accepted accounting principles (GAAP) and International Financial Reporting Standards (IFRSs), and do not require additional fair value measurements and are not intended to establish valuation standards or affect valuation practices. The amendments in this update are effective during interim and annual periods beginning after December 15, 2011. Adoption of the new amendment did not have a material effect on the Company’s financial position, results of operations or cash flow.

 

-7-
 

 

Recently Issued Accounting Pronouncements – Not Adopted

In December 2011, the FASB issued ASU 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities. The amendments in this update require an entity to disclose information about offsetting and related arrangements to enable users of its financial statements to understand the effect of those arrangements on its financial position. This update will enhance disclosures required by U.S. GAAP by requiring improved information about financial instruments and derivative instruments. The requirements of this update are effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. Entities should provide the disclosures required retrospectively for all comparative periods presented. We are currently evaluating the impact of adopting ASU 2011-11 on the financial statements.

The FASB issued Accounting Standards Update (ASU) No. 2012-02 Intangibles Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment, on July 27, 2012, to simplify the testing for a drop in value of intangible assets such as trademarks, patents, and distribution rights. The amended standard reduces the cost of accounting for indefinite-lived intangible assets, especially in cases where the likelihood of impairment is low. The changes permit businesses and other organizations to first use subjective criteria to determine if an intangible asset has lost value. The amendments to U.S. GAAP will be effective for fiscal years starting after September 15, 2012. Early adoption is permitted. The adoption of this accounting guidance will not have a material impact on our financial statements and related disclosures.

 

Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the United States Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

 

NOTE 2 – NOTE PAYABLE RELATED PARTIES, NET

 

On August 8, 2012, the Corporation received an infusion of $10,000 in order to continue its operations in the near-term. The Company executed a $10,000 due on demand note with Mr. Chip Brian, pursuant to which Mr. Brian advanced the Company $10,000 at a rate of 12% per annum. Both the principal and interest are payable to Mr. Brian on or before December 31, 2013. Additionally, the Company granted 1,000,000 shares of restricted common stock and a warrant to purchase an additional 1,000,000 shares of restricted common stock at an exercise price of $0.01 per share as an inducement for Mr. Brian to make the loan. The Company recorded interest expense related to the shares inducement based on the stock price on the grant date and amortized over the term of the loan and the unamortized portion was recorded as discount on note payable. The Company recorded the fair value of the warrants using the Black-Scholes valuation model and the unamortized portion was also recorded as a discount to the note. The amount of discount on note payable recorded as of September 30, 2013 was $34,640. The expected volatility is 78.87% and based on the daily historical volatility of comparative companies, measured over the 5 years expected term of the option. The risk-free rate is 0.71% and based on the implied yield on a U.S. Treasury zero-coupon issue with a remaining term closest to the expected term of the option.

 

-8-
 

 

 

Notes payable:

A summary of the notes payable activity is as follows:

Balance, June 30, 2013   $ 175,000  
Additional notes payable issued     7,500  
Discount on note payable     (11,672 )
Balance, September 30, 2013   $ 170,828  

 

Accrued interest:

 

A summary of the accrued interest activity is as follows:

Balance, June 30, 2013   $ 90,822  
Accrued interest for the three months ended September 30, 2013     5,316  
Balance, September 30, 2013   $ 96,138  

 

Historically, all interest payable incurred is from interest incurred at the stated rate of promissory notes issued by the Company. The payment terms, security and any interest payable are based on the underlying promissory notes payable that the Company has outstanding.

 

During the year ended June 30, 2007, we received $10,000 from Private Capital Group, L.L.C., a shareholder of the Company. This note had an interest rate of 10% per annum, was unsecured and had an original due date of December 31, 2007. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $3,252 and is due at maturity. Accrued interest is included in the notes payable, related parties balance. As an inducement to make the loan, we issued 1,000,000 shares of restricted common stock with a fair market value of $10,000 (par value) and issued a warrant for an additional 1,000,000 shares of restricted common stock with an exercise price of $0.01 per share. The warrants were estimated to have no significant fair market value.

 

During the year ended June 30, 2007, we received $10,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 10% per annum, is unsecured and had an original due date of December 31, 2007. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $3,252 and is due at maturity. Accrued interest is included in the notes payable, related parties balance. As an inducement to make the loan, we issued 1,000,000 shares of restricted common stock with a fair market value of $10,000 (par value) and issued a warrant for an additional 1,000,000 shares of restricted common stock with an exercise price of $.01 per share. The warrants were estimated to have no significant fair market value.

 

On August 24, 2010, these warrants were exercised by using the $10,000 note payable, related party loan balances issued on May 24, 2007 to C.W. Gilluly and Private Capital Group, in lieu of cash. In this transaction, 2,000,000 shares of common stock were issued for a par value of $0.01.

 

During the year ended June 30, 2008, we received an additional $15,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and had an original due date of December 31, 2009. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $10,582 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

During the year ended June 30, 2008, we received an additional $5,000 from Private Capital Group, L.L.C., a shareholder of the Company. This note has an interest rate of 12% per annum, is unsecured and had an original due date of December 31, 2009. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $3,412 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

-9-
 

 

During the year ended June 30, 2008, we received an additional $15,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and had an original due date of December 31, 2009. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $9,498 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

During the year ended June 30, 2009, we received an additional $25,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and had an original due date of December 31, 2009. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $15,129 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

During the year ended June 30, 2009, we received an additional $40,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and had an original due date of December 31, 2009. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $23,448 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

During the year ended June 30, 2009, we received an additional $10,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and had an original due date of December 31, 2009. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $5,431 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

During the year ended June 30, 2010, we received an additional $15,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $7,333 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

During the year ended June 30, 2010, we received an additional $5,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $2,356 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

During the year ended June 30, 2010, we received an additional $5,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $2,213 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

During the year ended June 30, 2010, we received an additional $5,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $2,083 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

During the year ended June 30, 2011, we received an additional $10,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $1,013 and is due at maturity. Accrued interest is included in the notes payable and accrued interest, related parties balance.

 

During the year ended June 30, 2011, we received an additional $10,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $717 and is due at maturity. Accrued interest is included in the notes payable and accrued interest, related parties balance.

 

-10-
 

 

 

During the year ended June 30, 2011, we received an additional $15,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $621 and is due at maturity. Accrued interest is included in the notes payable and accrued interest, related parties balance.

 

During the year ended June 30, 2011, we received an additional $5,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $59 and is due at maturity. Accrued interest is included in the notes payable and accrued interest, related parties balance.

 

On May 31, 2011, Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer, converted $40,000 of the most recent notes into 4,000,000 shares of the Company’s restricted stock common stock.

 

On August 31, 2011, the Corporation received an infusion of $10,000 in order to continue its operations in the near-term. The Company executed a $10,000 due on demand note with Mr. Chip Brian, pursuant to which Mr. Brian advanced the Company $10,000 at a rate of 12% per annum. Both the principal and interest are payable to Mr. Brian on or before September 30, 2013. Additionally, the Company granted 1,000,000 shares of restricted common stock and a warrant to purchase an additional 1,000,000 shares of restricted common stock at an exercise price of $0.01 per share as an inducement for Mr. Brian to make the loan. The Company recorded $20,000 of interest expense related to the shares issued. As of September 30, 2013, accrued interest payable totaled $2,502 and is due at maturity. Accrued interest is included in the notes payable and accrued interest, related parties balance.

 

On January 23, 2012, we received an additional $5,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $1,013 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

On April 25, 2012, we received an additional $2,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $344 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

On August 8, 2012, we received an infusion of $10,000 in order to continue its operations in the near-term. The Company executed a $10,000 due on demand note with Mr. Chip Brian, pursuant to which Mr. Brian advanced the Company $10,000 at a rate of 12% per annum. Both the principal and interest are payable to Mr. Brian on or before September 30, 2013. Additionally, the Company granted 1,000,000 shares of restricted common stock and a warrant to purchase an additional 1,000,000 shares of restricted common stock at an exercise price of $0.01 per share as an inducement for Mr. Brian to make the loan. The Company recorded interest expense related to the shares inducement based on the stock price on the grant date and amortized over the term of the loan and the unamortized portion is recorded as a discount on note payable. The Company recorded the fair value of the warrants using the Black-Scholes valuation model and the unamortized portion was also recorded as a discount to the note and classified to other assets. The amount of discount on note payable recorded as of September 30, 2013 was $57,358. The expected volatility is 78.87% and is based on the daily historical volatility of comparative companies, measured over the 5 years expected term of the option. The risk-free rate is 0.71% and is based on the implied yield on a U.S. Treasury zero-coupon issue with a remaining term closest to the expected term of the option. Both the interest expense recorded from the shares issuance and warrants issuance are amortized over the term of the loan. As of September 30, 2013, accrued interest payable totaled $1,369 and is due at maturity. Accrued interest is included in the notes payable and accrued interest, related parties balance.

 

On October 25, 2012, we received an additional $3,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $335 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

-11-
 

 

 

On January 14, 2013, Mr. Chip Brian terminated and cancelled his warrants to purchase 2,000,000 shares of the Company’s common stock.

 

 On April 8, 2013, we received an additional $5,000 from ImaginEquity. This note has an interest rate of 6% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $79 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

On August 21, 2013, we received an additional $7,500 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $99 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

Effective February 5, 2013, the Company amended its Certificate of Incorporation. As a result of the Amendment, the Company’s corporate name changed from Amasys Corporation to StemGen, Inc and a reverse stock split was effectuated where all the outstanding shares of the Company’s common stock were exchanged at a ratio of one for eighty.

 

NOTE 3 – DEPOSIT

 

On December 24, 2012, the Company received a nonrefundable deposit of $32,500 under a Letter of Intent (“LOI”) which it entered into on December 11, 2012 with StemGen Inc. a Nevada corporation. Under the LOI, if all conditions were satisfied or waived, the following will take place (a) transfer all of the intellectual property rights and operations of StemGen into the direct ownership and control of the Company; and (b) transfer all of the equity interests of StemGen into the direct ownership and control of the Company. The LOI was subject to the Company performing a reverse stock split of 1 for 80 and changing its name to StemGen, Inc which the Company has done. StemGen will pay the Company an amount in cash equal to $325,000 at closing of which a 10% non-refundable deposit was paid after the signing of the LOI. On August 6, 2013, the LOI was terminated. 

 

 

-12-
 

 

 

 ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The information contained in this Form 10-Q is intended to update the information contained in our Annual Report on Form 10-K for the year ended June 30, 2013 and presumes that readers have access to, and will have read, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other information contained in such Form 10-K.  The following discussion and analysis also should be read together with our financial statements and the notes to the financial statements included elsewhere in this Form 10-Q.

 

The following discussion contains certain statements that may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Such statements appear in a number of places in this Report, including, without limitation, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”  These statements are not guarantees of future performance and involve risks, uncertainties and requirements that are difficult to predict or are beyond our control.  Forward-looking statements speak only as of the date of this quarterly report. You should not put undue reliance on any forward-looking statements.  We strongly encourage investors to carefully read the factors described in our Annual Report on Form 10-K for the year ended June 30, 2013 in the section entitled “Risk Factors” for a description of certain risks that could, among other things, cause actual results to differ from these forward-looking statements. We assume no responsibility to update the forward-looking statements contained in this quarterly report on Form 10-Q. The following should also be read in conjunction with the unaudited Financial Statements and notes thereto that appear elsewhere in this report.

 

Company History

 

StemGen, Inc. (“STEMGEN” or the “Company”) was incorporated in Delaware in 1992, and in 1996 received all remaining assets of Infotechnology, Inc. (“Infotech”), a Delaware company, following the completion of Infotech’s Chapter 11 Bankruptcy reorganization, in accordance with an Assignment and Assumption Agreement, dated October 11, 1996, and effective as of June 21, 1996.  As a result of a series of transactions during the 1980’s, Infotech, then principally engaged in the information and communications business, acquired equity interests in Comtex News Network, Inc. (“Comtex”) and Analex Corporation (“Analex”), formerly known as Hadron, Inc.  Our business was the maintenance of our equity interest in and note receivable from Comtex and equity interest in Analex.  

 

On September 25, 2006, we exchanged the equity investment in Comtex common stock and the Note Receivable from Comtex of $856,954, for 55,209 shares of the STEMGEN Series A Preferred stock.  We no longer have an equity interest in either the common stock of Comtex or the Note from Comtex.

 

During October 2006, we sold the remaining 21,000 shares of common stock of publicly-held Analex, a defense contractor specializing in systems engineering and developing innovative technical intelligence solutions in support of U.S. national security.  We no longer have an equity interest in Analex.

 

On December 24, 2012, the Corporation received a nonrefundable deposit of $32,500 under a Letter of Intent (“LOI”) which it entered into on December 11, 2012 with StemGen Inc. a Nevada corporation. Effective February 5, 2013, the Company amended its Certificate of Incorporation. As a result of the Amendment, the Company’s corporate name changed from Amasys Corporation to StemGen, Inc and a reverse stock split was effectuated where all the outstanding shares of the Company’s common stock were exchanged at a ratio of one for eighty. The LOI was terminated on August 6, 2013.

 

Since we redeemed and converted all of our outstanding Series A Preferred Stock at the end of September 2006, starting October 1, 2006 we have not conducted any business operations.  All of our operating results and cash flows reported in the accompanying financial statements from October 1, 2006 are considered to be those related to development stage activities and represent the 'cumulative from entering developmental stage' amounts from its development stage activities required to be reported pursuant to Financial Accounting Standards Board Accounting Standards Codification (“ASC”) Topic 915 “Development Stage Entities”.

 

-13-
 

 

 

Business of Issuer

Currently, the Company seeks suitable candidates for a business combination with a private company.  The Company has made no efforts to identify a possible business combination. As a result, the Company has not conducted negotiations or entered into a letter of intent concerning any target business. The business purpose of the Company is to seek the acquisition of, or merger with, an existing company. We intend to provide shareholders with complete disclosure concerning a target company and its business, including audited financial statements prior to any merger or acquisition where such disclosure is required by law.

 

The Company is currently considered to be a "blank check" company. The U.S. Securities and Exchange Commission (the “SEC”) defines those companies as "any development stage company that is issuing a penny stock, within the meaning of Section 3 (a)(51) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that has no specific business plan or purpose, or has indicated that its business plan is to merge with an unidentified company or companies." Under SEC Rule 12b-2 under the Exchange Act, the Company also qualifies as a “shell company,” because it has no or nominal assets (other than cash) and no or nominal operations.  Many states have enacted statutes, rules and regulations limiting the sale of securities of "blank check" companies in their respective jurisdictions. Management does not intend to undertake any efforts to cause a market to develop in our securities, either debt or equity, until we have successfully concluded a business combination. The Company intends to comply with the periodic reporting requirements of the Exchange Act for so long as it is subject to those requirements.

 

The Company’s principal business objective for the next 12 months and beyond such time will be to achieve long-term growth potential through a combination with a business rather than immediate, short-term earnings. The Company will not restrict its potential candidate target companies to any specific business, industry or geographical location and, thus, may acquire any type of business.

 

The analysis of new business opportunities will be undertaken by or under the supervision of the officer and director of the Company.  As of this date, the Company has not entered into any definitive agreement with any party, nor have there been any specific discussions with any potential business combination candidate regarding business opportunities for the Company.  The Company has unrestricted flexibility in seeking, analyzing and participating in potential business opportunities. In its efforts to analyze potential acquisition targets, the Company will consider the following kinds of factors:

 

a)   Potential for growth, indicated by new technology, anticipated market expansion or new products;

 

b)   Competitive position as compared to other firms of similar size and experience within the industry segment as well as within the industry as a whole;

 

c)   Strength and diversity of management, either in place or scheduled for recruitment;

 

d)   Capital requirements and anticipated availability of required funds, to be provided by the Company or from operations, through the sale of additional securities, through joint ventures or similar arrangements or from other sources;

 

e)   The cost of participation by the Company as compared to the perceived tangible and intangible values and potentials;
f)   The extent to which the business opportunity can be advanced;

 

g)   The accessibility of required management expertise, personnel, raw materials, services, professional assistance and other required items; and

 

h)   Other relevant factors.

 

-14-
 

 

 

In applying the foregoing criteria, no one of which will be controlling, management will attempt to analyze all factors and circumstances and make a determination based upon reasonable investigative measures and available data. Potentially available business opportunities may occur in many different industries, and at various stages of development, all of which will make the task of comparative investigation and analysis of such business opportunities extremely difficult and complex. Due to the Company's limited capital available for investigation, the Company may not discover or adequately evaluate adverse facts about the opportunity to be acquired.

 

Form of Acquisition

 

The manner in which the Company participates in an opportunity will depend upon the nature of the opportunity, the respective needs and desires of the Company and the promoters of the opportunity, and the relative negotiating strength of the Company and such promoters.

 

It is likely that the Company will acquire its participation in a business opportunity through the issuance of common stock or other securities of the Company. Although the terms of any such transaction cannot be predicted, it should be noted that in certain circumstances the criteria for determining whether or not an acquisition is a so-called "tax free" reorganization under Section 368(a)(1) of the Internal Revenue Code of 1986, as amended (the "Code") depends upon whether the owners of the acquired business own 80% or more of the voting stock of the surviving entity. If a transaction were structured to take advantage of these provisions rather than other "tax free" provisions provided under the Code, all prior stockholders would in such circumstances retain 20% or less of the total issued and outstanding shares of the surviving entity. Under other circumstances, depending upon the relative negotiating strength of the parties, prior stockholders may retain substantially less than 20% of the total issued and outstanding shares of the surviving entity. This could result in substantial additional dilution to the equity of those who were stockholders of the Company prior to such reorganization.

 

The present stockholders of the Company will likely not have control of a majority of the voting securities of the Company following a reorganization transaction. As part of such a transaction, all or a majority of the Company's directors may resign and one or more new directors may be appointed without any vote by stockholders.

 

In the case of an acquisition, the transaction may be accomplished upon the sole determination of management without any vote or approval by stockholders. In the case of a statutory merger or consolidation directly involving the Company, it will likely be necessary to call a stockholders' meeting and obtain the approval of the holders of a majority of the outstanding securities. The necessity to obtain such stockholder approval may result in delay and additional expense in the consummation of any proposed transaction and will also give rise to certain appraisal rights to dissenting stockholders. Most likely, management will seek to structure any such transaction so as not to require stockholder approval.

 

It is anticipated that the investigation of specific business opportunities and the negotiation, drafting and execution of relevant agreements, disclosure documents and other instruments will require substantial management time and attention and substantial cost for accountants, attorneys and others. If a decision is made not to participate in a specific business opportunity, the costs theretofore incurred in the related investigation might not be recoverable. Furthermore, even if an agreement is reached for the participation in a specific business opportunity, the failure to consummate that transaction may result in the loss to the Registrant of the related costs incurred.

 

Critical Accounting Policies

 

We prepare our financial statements in accordance with accounting principles generally accepted in the United States (GAAP), which requires management to make estimates and assumptions that affect reported amounts and related disclosures. Management identifies critical accounting estimates as:

 

  - those that require the use of assumptions about matters that are inherently and highly uncertain at the time the estimates are made; and

 

  - those for which changes in the estimate or assumptions, or the use of different estimates and assumptions, could have a material impact on our results of operations or financial condition.

 

-15-
 

 

 

Management has discussed the development, selection and disclosure of our critical accounting estimates with our Board of Directors. For a description of our critical accounting estimates that require us to make the most difficult, subjective or complex judgments, please see our Annual Report on Form 10-K for the year ended June 30, 2013. We have not changed these policies from those previously disclosed.

 

For the Three Months Ended September 30, 2013 and 2012

 

Results of Operations

 

General and Administrative Expenses

 

General and administrative expenses were $13,421 and $12,074 for the three months ended September 30, 2013 and 2012, respectively. The increase in general and administrative expenses of $1,347 for the three month period was mainly due to the increase in various corporate expenses.

 

Other Income (Expense)

 

Other expense was $16,863 and $11,445 for the three months ended September 30, 2013 and 2012, respectively. The increase for the three month period of $5,418 is due to the additional interest expense accrued on our additional notes payable, related party balances and interest expense recorded for shares issued as an inducement to enter into a loan.

 

Liquidity and Capital Resources

 

 Net cash used in operating activities was $18,762 and $9,124 in the three months ended September 30, 2013 and 2012, respectively.  The increase was primarily due to the increase in professional fees for the three months ended September 30, 2013 compared to 2012.

 

Net cash provided by investing activities was $-0- and $-0- in the three months ended September 30, 2013 and 2012, respectively.  

 

Net cash provided by financing activities was $19,047 and $10,000 in the three months ended September 30, 2013 and 2012, respectively.  

 

We suffered recurring losses from operations and have an accumulated deficit of $871,246 as of September 30, 2013.  Currently, we are a non-operating public company. We seek suitable candidates for a business combination with a private company.  In the event we use all of our cash resources, C.W. Gilluly has indicated the willingness to loan us funds at the prevailing market rate, assuming we find a suitable candidate for a business combination, until such business combination is consummated.  Even though this is Mr. Gilluly's current intention, he has made no firm commitment and it is at his sole discretion whether or not to fund us.  In the event Mr. Gilluly does not fund us, we will not have the funds necessary to operate and will have to dissolve.

 

Contractual Obligations

 

As a "smaller reporting company" as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements.  

 

-16-
 

 

ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

A smaller reporting company is not required to provide the information required by this Item.

 

ITEM 4T - CONTROLS AND PROCEDURES

 

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES.   Our management, with the participation of our President and Chief Financial Officer, carried out an evaluation of the effectiveness of our "disclosure controls and procedures" (as defined in the Securities Exchange Act of 1934 (the "Exchange Act") Rules 13a-15(e) and 15-d-15(e)) as of the end of the period covered by this report (the "Evaluation Date"). Based upon that evaluation, our President and our Chief Financial Officer concluded that, as of the Evaluation Date, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and (ii) is accumulated and communicated to our management, including our President and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

 

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING.   There were no changes in our internal controls over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

-17-
 

 

PART II -- OTHER INFORMATION

 

ITEM 1 - Legal Proceedings.

 

To the best knowledge of our sole officer, the Company is not a party to any legal proceeding or litigation.

  

ITEM 1A - Risk Factors

 

  The following important factors, and the important factors described elsewhere in this report or in our other filings with the SEC, could affect (and in some cases have affected) our results and could cause our results to be materially different from estimates or expectations.  Other risks and uncertainties may also affect our results or operations adversely.  The following and these other risks could materially and adversely affect our business, operations, results or financial condition.

 

We have a history of net losses and may never achieve or maintain profitability.

 

We have a history of incurring losses from operations. As of September 30, 2013, we had an accumulated deficit of $871,246.  We are currently funding our operations through loans. Our ability to continue may prove more expensive than we currently anticipate and we may incur significant additional costs and expenses.

 

  We are a non-operating company seeking a suitable transaction and may not find a suitable candidate or transaction.

 

We are a non-operating company.  If we are unable to consummate a transaction or become profitable, we will be forced to liquidate and dissolve which will take three years to complete and may result in our distributing less cash to our shareholders.  Additionally, we will be spending cash during the winding down and may not have enough cash to distribute to our shareholders.

 

We will continue to incur claims, liabilities and expenses that will reduce the amount available for distribution to stockholders.

 

Claims, liabilities and expenses incurred while seeking a private company transaction or any subsequent dissolution, such as legal, accounting and consulting fees and miscellaneous office expenses, will reduce the amount of assets available for future distribution to stockholders. If available cash and amounts received on the sale of non-cash assets are not adequate to provide for our obligations, liabilities, expenses and claims, we may not be able to distribute meaningful cash, or any cash at all, to our stockholders.

 

We will continue to incur the expenses of complying with public company reporting requirements.

 

We have an obligation to continue to comply with the applicable reporting requirements of the Securities Exchange Act of 1934, as amended, even though compliance with such reporting requirements is economically burdensome.

 

Our independent registered public accounting firm has expressed a going concern opinion.

 

Primarily as a result of our recurring losses and our lack of liquidity, we received a report from our independent auditors that includes an explanatory paragraph describing the substantial uncertainty as to our ability to continue as a going concern for the year ended June 30, 2013.

 

  Any future sale of a substantial number of shares of our common stock could depress the trading price of our common stock.

 

Any sale of a substantial number of shares of our common stock (or the prospect of sales) may have the effect of depressing the trading price of our common stock. In addition, these sales could lower our value.

 

-18-
 

 

Our stock price is likely to be highly volatile because of several factors, including a limited public float.

 

The market price of our stock is likely to be highly volatile because there has been a relatively thin trading market for our stock, which causes trades of small blocks of stock to have a significant impact on our stock price. You may not be able to resell our common stock following periods of volatility because of the market's adverse reaction to volatility.   Other factors that could cause such volatility may include, among other things are announcements concerning our strategy, litigation and general market conditions.

 

Because our common stock is considered a "penny stock" any investment in our common stock is considered to be a high-risk investment and is subject to restrictions on marketability.

 

Our common stock is currently listed on the OTC Bulletin Board and is considered a "penny stock." The OTC Bulletin Board is generally regarded as a less efficient trading market than the NASDAQ Capital Market.

  

The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in "penny stocks." Penny stocks generally are equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system). The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document prepared by the SEC, which specifies information about penny stocks and the nature and significance of risks of the penny stock market. The broker-dealer also must provide the customer with bid and offer quotations for the penny stock, the compensation of the broker-dealer and any salesperson in the transaction, and monthly account statements indicating the market value of each penny stock held in the customer's account. In addition, the penny stock rules require that, prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written agreement to the transaction. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common stock.

 

Since our common stock is subject to the regulations applicable to penny stocks, the market liquidity for our common stock could be adversely affected because the regulations on penny stocks could limit the ability of broker-dealers to sell our common stock and thus your ability to sell our common stock in the secondary market.  There is no assurance our common stock will be quoted on NASDAQ or the NYSE or listed on any exchange, even if eligible.

 

-19-
 

 

ITEM 2. - Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

ITEM 3. - Defaults Upon Senior Securities.

 

None.

 

ITEM 4. – (Removed and Reserved)

 

ITEM 5. - Other Information.

 

None 

 

 

ITEM 6.   Exhibits
    31 Certification of President pursuant to Exchange Act Rule 13a-14 and 15d-14 as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002.
       
    32 Certification of the Company’s Chief Executive Officer and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
       

 

 

-20-
 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  STEMGEN, INC.  
     
     
Date: November 12, 2013 /s/  C.W. Gilluly  
  Name: C.W. Gilluly, Ed.D.  
  Title: President, Chief Executive Officer and Chief Financial Officer  

 

 

-21-
 

 

 EX-31 2 exhibit31.htm CERTIFICATION OF PRESIDENT PURSUANT TO EXCHANGE ACT RULE 13A-14 AND 15D-14 AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002.

EXHIBIT 31

STEMGEN, INC.

Certification of Chief Executive Officer and Chief Financial Officer Pursuant to

Securities Exchange Act Rules 13a-14 and 15d-14

as Adopted Pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

 

I, C.W. Gilluly, certify that:

 

 1. I have reviewed this quarterly report on Form 10-Q of StemGen, Inc.;

 

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

November 12, 2013  
  /s/ C.W. Gilluly  
 

C.W. Gilluly, Ed.D.

President, Chief Executive Officer and

Chief Financial Officer

 

 EX-32 3 exhibit32.htm CERTIFICATION OF THE COMPANYS CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER, PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES OXLEY ACT OF 2002.

Exhibit 32

STEMGEN, INC.

 

CERTIFICATION

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(SUBSECTIONS (a) AND (b) OF SECTION 1350, CHAPTER 63 OF TITLE 18,

UNITED STATES CODE)

 

 

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of Title 18, United States Code), the undersigned officer of StemGen, Inc. (the “Company”), does hereby certify with respect to the Quarterly Report of the Company on Form 10-Q for the period ended September 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), to the best of the undersigned’s knowledge that:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of  1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

November 12, 2013  
   
   
/s/ C.W. Gilluly    

C.W. Gilluly, Ed.D.

President, Chief Executive Officer and

Chief Financial Officer

  
   
     

 

 EX-101.INS 4 sgni-20130930.xml XBRL INSTANCE FILE 0001023198 2013-07-01 2013-09-30 0001023198 2013-11-12 0001023198 2013-06-30 0001023198 2013-09-30 0001023198 2006-09-30 0001023198 2012-07-01 2012-09-30 0001023198 2006-10-01 2013-09-30 0001023198 2012-06-30 0001023198 2012-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares StemGen, Inc. 0001023198 10-Q 2013-09-30 false --06-30 No No No Smaller Reporting Company 183927 Q1 2014 840 1125 3249 564 1440 840 1125 840 1125 46720 52926 24857 24857 242603 266966 314180 344749 0 0 1839 1839 525783 525783 -840962 -871246 -313340 -343624 840 1125 1000000 1000000 0 0 20000000 20000000 183927 183927 0 0 0 0 0 0 0 0 0 13421 12074 364225 -13421 -12074 -364225 16863 11445 169132 0 0 -20000 0 0 13374 -30284 -23519 -507483 0 0 0 -30284 -23519 -507483 -0.16 -0.13 183927 177810 0 0 -12735 6206 2950 96614 0 0 17328 -7215 -9124 -288694 0 0 40570 0 0 3500 7500 10000 242500 7500 10000 246000 285 876 -2124 27061 <p style="margin: 0pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Basis of Presentation</i></b> &#151;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying unaudited condensed interim financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America.&#160;&#160;All references to Generally Accepted Accounting Principles (&#147;GAAP&#148;) are in accordance with The FASB Accounting Standards Codification (&#147;ASC&#148;) and the Hierarchy of Generally Accepted Accounting Principles.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The unaudited condensed interim financial statements have been prepared by us pursuant to the rules and regulations of the Securities and Exchange Commission. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments) which are, in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited financial statements and notes for the year ended June 30, 2013 included in our Annual Report on Form 10-K. The results of the three month periods ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year ending June 30, 2014.</p> <p style="margin: 0pt"></p> <p style="margin: 0pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Going Concern</i></b> &#151;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying unaudited condensed interim financial statements have been prepared assuming that we will continue as a going concern.&#160;&#160;We have suffered recurring losses from operations since our inception and have an accumulated deficit of $871,246 at September 30, 2013.&#160;&#160;The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classifications of liabilities that might be necessary should we be unable to continue our existence.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, our recovery is dependent upon future events, the outcome of which is undetermined.&#160;&#160;We intend to continue to attempt to raise additional capital, but there can be no certainty that such efforts will be successful.</p> <p style="margin: 0pt"></p> <p style="margin: 0pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Development Stage Activities</i></b> &#150;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since we redeemed and converted all of the outstanding Series A Preferred Stock of Comtex News Network, Inc. at the end of September 2006, starting October 1, 2006 we have not conducted any business operations. All of our operating results and cash flows reported in the accompanying unaudited condensed interim financial statements from October 1, 2006 are considered to be those related to development stage activities and represent the cumulative amounts from its development stage activities required to be reported.</p> <p style="margin: 0pt"></p> <p style="margin: 0pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Use of Estimates</i></b> &#151;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="margin: 0pt"></p> <p style="margin: 0pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Cash and Cash Equivalents</i></b> &#151;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We consider investments with original maturities of 90&#160;days or less to be cash equivalents. As of September 30, 2013 and June 30, 2013, we have no cash equivalents.</p> <p style="margin: 0pt"></p> <p style="margin: 0pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Income Taxes</i></b> &#151;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company accounts for income taxes in accordance with ASC Topic 740.&#160; Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at currently effective tax rates, of future deductible or taxable amounts attributable to events that have been recognized on a cumulative basis in the financial statements. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized.</p> <p style="margin: 0pt"></p> <p style="margin: 0pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Net Loss Per Share</i></b> &#151;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Basic net loss and diluted loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income by the weighted-average number of shares and dilutive potential common shares outstanding during the period. Dilutive potential shares consist of dilutive shares issuable upon the exercise of outstanding stock options and warrants computed using the treasury stock method.&#160;&#160;As of September 30, 2013, there were zero dilutive securities which are considered anti-dilutive.</p> <p style="margin: 0pt"></p> <p style="margin: 0pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Fair Value of Financial Instruments</i></b> &#151;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our financial instruments consist of cash, accounts payable, accrued expenses and notes payable.&#160;&#160;The carrying values of cash, accounts payable,&#160;accrued expenses and notes payable are representative of their fair values due to their short-term maturities</p> <p style="margin: 0pt"></p> <p style="margin: 0pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Fair Value Measurements and Disclosures</i></b> &#150;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC Topic 820 defines fair value, establishes a framework for measuring fair value, establishes a three-level valuation hierarchy for disclosure of fair value measurement and enhances disclosure requirements for fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Level&#160;1 - Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Level&#160;2 - Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Level&#160;3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#146;s adoption of fair value measurements and disclosures did not have a material impact on the financial statements and financial statement disclosures.</p> <p style="margin: 0pt"></p> <p style="margin: 0pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 2 &#150; NOTE PAYABLE RELATED PARTIES, NET </b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 8, 2012, the Corporation received an infusion of $10,000 in order to continue its operations in the near-term. The Company executed a $10,000 due on demand note with Mr. Chip Brian, pursuant to which Mr. Brian advanced the Company $10,000 at a rate of 12% per annum. Both the principal and interest are payable to Mr. Brian on or before December 31, 2013. Additionally, the Company granted 1,000,000 shares of restricted common stock and a warrant to purchase an additional 1,000,000 shares of restricted common stock at an exercise price of $0.01 per share as an inducement for Mr. Brian to make the loan. The Company recorded interest expense related to the shares inducement based on the stock price on the grant date and amortized over the term of the loan and the unamortized portion was recorded as discount on note payable. The Company recorded the fair value of the warrants using the Black-Scholes valuation model and the unamortized portion was also recorded as a discount to the note. The amount of discount on note payable recorded as of September 30, 2013 was $34,640. The expected volatility is 78.87% and based on the daily historical volatility of comparative companies, measured over the 5 years expected term of the option. The risk-free rate is 0.71% and based on the implied yield on a U.S. Treasury zero-coupon issue with a remaining term closest to the expected term of the option.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Notes payable:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">A summary of the notes payable activity is as follows:</p> <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 74%; line-height: 115%; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">Balance, June 30, 2013</font></td> <td style="width: 8%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 115%; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">175,000</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">Additional notes payable issued</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">7,500</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="line-height: 115%; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">Discount on note payable</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%; border-bottom: black 1pt solid">&#160;</td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">(11,672</font></td> <td style="line-height: 115%; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">Balance, September 30, 2013</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%; border-bottom: black 2.25pt double; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%; border-bottom: black 2.25pt double; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">170,828</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Accrued interest:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">A summary of the accrued interest activity is as follows:</p> <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; font-size-adjust: none; font-stretch: normal; background-color: white"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 71%; line-height: 115%"><font style="font: 10pt/115% Times New Roman, Times, Serif">Balance, June 30, 2013 </font></td> <td style="width: 10%; line-height: 115%; font-size: 12pt">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt/115% Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right; line-height: 115%"><font style="font: 10pt/115% Times New Roman, Times, Serif">90,822</font></td> <td style="width: 1%; line-height: 115%; font-size: 12pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"><font style="font: 10pt/115% Times New Roman, Times, Serif">Accrued interest for the three months ended September 30, 2013 </font></td> <td style="line-height: 115%; font-size: 12pt">&#160;</td> <td style="line-height: 115%; font-size: 12pt; border-bottom: windowtext 1pt solid">&#160;</td> <td style="text-align: right; line-height: 115%; border-bottom: windowtext 1pt solid"><font style="font: 10pt/115% Times New Roman, Times, Serif">5,316</font></td> <td style="border-bottom: windowtext 1pt solid; line-height: 115%; font-size: 12pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="line-height: 115%"><font style="font: 10pt/115% Times New Roman, Times, Serif">Balance, September 30, 2013 </font></td> <td style="line-height: 115%; font-size: 12pt">&#160;</td> <td style="line-height: 115%; border-bottom: black 2.25pt double"><font style="font: 10pt/115% Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%; border-bottom: black 2.25pt double"><font style="font: 10pt/115% Times New Roman, Times, Serif">96,138</font></td> <td style="line-height: 115%; font-size: 12pt">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Historically, all interest payable incurred is from interest incurred at the stated rate of promissory notes issued by the Company. The payment terms, security and any interest payable are based on the underlying promissory notes payable that the Company has outstanding.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended June 30, 2007, we received $10,000 from Private Capital Group, L.L.C., a shareholder of the Company. This note had an interest rate of 10% per annum, was unsecured and had an original due date of December 31, 2007. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $3,252 and is due at maturity. Accrued interest is included in the notes payable, related parties balance. As an inducement to make the loan, we issued 1,000,000 shares of restricted common stock with a fair market value of $10,000 (par value) and issued a warrant for an additional 1,000,000 shares of restricted common stock with an exercise price of $0.01 per share. The warrants were estimated to have no significant fair market value.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended June 30, 2007, we received $10,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 10% per annum, is unsecured and had an original due date of December 31, 2007. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $3,252 and is due at maturity. Accrued interest is included in the notes payable, related parties balance. As an inducement to make the loan, we issued 1,000,000 shares of restricted common stock with a fair market value of $10,000 (par value) and issued a warrant for an additional 1,000,000 shares of restricted common stock with an exercise price of $.01 per share. The warrants were estimated to have no significant fair market value.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 24, 2010, these warrants were exercised by using the $10,000 note payable, related party loan balances issued on May 24, 2007 to C.W. Gilluly and Private Capital Group, in lieu of cash. In this transaction, 2,000,000 shares of common stock were issued for a par value of $0.01.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended June 30, 2008, we received an additional $15,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and had an original due date of December 31, 2009. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $10,582 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended June 30, 2008, we received an additional $5,000 from Private Capital Group, L.L.C., a shareholder of the Company. This note has an interest rate of 12% per annum, is unsecured and had an original due date of December 31, 2009. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $3,412 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended June 30, 2008, we received an additional $15,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and had an original due date of December 31, 2009. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $9,498 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended June 30, 2009, we received an additional $25,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and had an original due date of December 31, 2009. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $15,129 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended June 30, 2009, we received an additional $40,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and had an original due date of December 31, 2009. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $23,448 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended June 30, 2009, we received an additional $10,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and had an original due date of December 31, 2009. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $5,431 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended June 30, 2010, we received an additional $15,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $7,333 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended June 30, 2010, we received an additional $5,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $2,356 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended June 30, 2010, we received an additional $5,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $2,213 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended June 30, 2010, we received an additional $5,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $2,083 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended June 30, 2011, we received an additional $10,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $1,013 and is due at maturity. Accrued interest is included in the notes payable and accrued interest, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended June 30, 2011, we received an additional $10,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $717 and is due at maturity. Accrued interest is included in the notes payable and accrued interest, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended June 30, 2011, we received an additional $15,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $621 and is due at maturity. Accrued interest is included in the notes payable and accrued interest, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended June 30, 2011, we received an additional $5,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $59 and is due at maturity. Accrued interest is included in the notes payable and accrued interest, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 31, 2011, Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer, converted $40,000 of the most recent notes into 4,000,000 shares of the Company&#146;s restricted stock common stock.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 31, 2011, the Corporation received an infusion of $10,000 in order to continue its operations in the near-term. The Company executed a $10,000 due on demand note with Mr. Chip Brian, pursuant to which Mr. Brian advanced the Company $10,000 at a rate of 12% per annum. Both the principal and interest are payable to Mr. Brian on or before September 30, 2013. Additionally, the Company granted 1,000,000 shares of restricted common stock and a warrant to purchase an additional 1,000,000 shares of restricted common stock at an exercise price of $0.01 per share as an inducement for Mr. Brian to make the loan. The Company recorded $20,000 of interest expense related to the shares issued. As of September 30, 2013, accrued interest payable totaled $2,502 and is due at maturity. Accrued interest is included in the notes payable and accrued interest, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 23, 2012, we received an additional $5,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $1,013 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 25, 2012, we received an additional $2,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $344 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 8, 2012, we received an infusion of $10,000 in order to continue its operations in the near-term. The Company executed a $10,000 due on demand note with Mr. Chip Brian, pursuant to which Mr. Brian advanced the Company $10,000 at a rate of 12% per annum. Both the principal and interest are payable to Mr. Brian on or before September 30, 2013. Additionally, the Company granted 1,000,000 shares of restricted common stock and a warrant to purchase an additional 1,000,000 shares of restricted common stock at an exercise price of $0.01 per share as an inducement for Mr. Brian to make the loan. The Company recorded interest expense related to the shares inducement based on the stock price on the grant date and amortized over the term of the loan and the unamortized portion is recorded as a discount on note payable. The Company recorded the fair value of the warrants using the Black-Scholes valuation model and the unamortized portion was also recorded as a discount to the note and classified to other assets. The amount of discount on note payable recorded as of September 30, 2013 was $57,358. The expected volatility is 78.87% and is based on the daily historical volatility of comparative companies, measured over the 5 years expected term of the option. The risk-free rate is 0.71% and is based on the implied yield on a U.S. Treasury zero-coupon issue with a remaining term closest to the expected term of the option. Both the interest expense recorded from the shares issuance and warrants issuance are amortized over the term of the loan. As of September 30, 2013, accrued interest payable totaled $1,369 and is due at maturity. Accrued interest is included in the notes payable and accrued interest, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 25, 2012, we received an additional $3,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $335 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 14, 2013, Mr. Chip Brian terminated and cancelled his warrants to purchase 2,000,000 shares of the Company&#146;s common stock.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;On April 8, 2013, we received an additional $5,000 from ImaginEquity. This note has an interest rate of 6% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $79 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 21, 2013, we received an additional $7,500 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $99 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective February 5, 2013, the Company amended its Certificate of Incorporation. As a result of the Amendment, the Company&#146;s corporate name changed from Amasys Corporation to StemGen, Inc and a reverse stock split was effectuated where all the outstanding shares of the Company&#146;s common stock were exchanged at a ratio of one for eighty.</p> <p style="margin: 0pt"></p> <p style="margin: 0pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Notes payable:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">A summary of the notes payable activity is as follows:</p> <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 74%; line-height: 115%; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">Balance, June 30, 2013</font></td> <td style="width: 8%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 115%; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">175,000</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">Additional notes payable issued</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">7,500</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="line-height: 115%; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">Discount on note payable</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%; border-bottom: black 1pt solid">&#160;</td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">(11,672</font></td> <td style="line-height: 115%; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">Balance, September 30, 2013</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%; border-bottom: black 2.25pt double; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%; border-bottom: black 2.25pt double; font-size: 10pt"><font style="font: 10pt/normal Times New Roman, Times, Serif">170,828</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Accrued interest:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">A summary of the accrued interest activity is as follows:</p> <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; font-size-adjust: none; font-stretch: normal; background-color: white"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 71%; line-height: 115%"><font style="font: 10pt/115% Times New Roman, Times, Serif">Balance, June 30, 2013 </font></td> <td style="width: 10%; line-height: 115%; font-size: 12pt">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt/115% Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right; line-height: 115%"><font style="font: 10pt/115% Times New Roman, Times, Serif">90,822</font></td> <td style="width: 1%; line-height: 115%; font-size: 12pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"><font style="font: 10pt/115% Times New Roman, Times, Serif">Accrued interest for the three months ended September 30, 2013 </font></td> <td style="line-height: 115%; font-size: 12pt">&#160;</td> <td style="line-height: 115%; font-size: 12pt; border-bottom: windowtext 1pt solid">&#160;</td> <td style="text-align: right; line-height: 115%; border-bottom: windowtext 1pt solid"><font style="font: 10pt/115% Times New Roman, Times, Serif">5,316</font></td> <td style="border-bottom: windowtext 1pt solid; line-height: 115%; font-size: 12pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="line-height: 115%"><font style="font: 10pt/115% Times New Roman, Times, Serif">Balance, September 30, 2013 </font></td> <td style="line-height: 115%; font-size: 12pt">&#160;</td> <td style="line-height: 115%; border-bottom: black 2.25pt double"><font style="font: 10pt/115% Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%; border-bottom: black 2.25pt double"><font style="font: 10pt/115% Times New Roman, Times, Serif">96,138</font></td></tr> </table> <p style="margin: 0pt"></p> 5316 7500 <p style="margin: 0pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Concentration of Credit Risk</i></b> &#151;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Financial instruments that potentially subject us to a concentration of credit risk consist of cash.&#160;&#160;We maintain our cash with high credit quality financial institutions; at times, such balances with any one financial institution may exceed FDIC insured limits.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="margin: 0pt"></p> <p style="margin: 0pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 &#150; DEPOSIT</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 24, 2012, the Company received a nonrefundable deposit of $32,500 under a Letter of Intent (&#147;LOI&#148;) which it entered into on December 11, 2012 with StemGen Inc. a Nevada corporation. Under the LOI, if all conditions were satisfied or waived, the following will take place (a) transfer all of the intellectual property rights and operations of StemGen into the direct ownership and control of the Company; and (b) transfer all of the equity interests of StemGen into the direct ownership and control of the Company. The LOI was subject to the Company performing a reverse stock split of 1 for 80 and changing its name to StemGen, Inc which the Company has done. StemGen will pay the Company an amount in cash equal to $325,000 at closing of which a 10% non-refundable deposit was paid after the signing of the LOI. On August 6, 2013, the LOI was terminated.&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="margin: 0pt"></p> 32500 -11672 325000 5316 4919 25368 0 0 32500 11547 6526 92214 <p style="margin: 0pt">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 -&#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Basis of Presentation</i></b> &#151;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying unaudited condensed interim financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America.&#160;&#160;All references to Generally Accepted Accounting Principles (&#147;GAAP&#148;) are in accordance with The FASB Accounting Standards Codification (&#147;ASC&#148;) and the Hierarchy of Generally Accepted Accounting Principles.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The unaudited condensed interim financial statements have been prepared by us pursuant to the rules and regulations of the Securities and Exchange Commission. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments) which are, in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited financial statements and notes for the year ended June 30, 2013 included in our Annual Report on Form 10-K. The results of the three month periods ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year ending June 30, 2014.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Going Concern</i></b> &#151;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying unaudited condensed interim financial statements have been prepared assuming that we will continue as a going concern.&#160;&#160;We have suffered recurring losses from operations since our inception and have an accumulated deficit of $871,246 at September 30, 2013.&#160;&#160;The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classifications of liabilities that might be necessary should we be unable to continue our existence.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, our recovery is dependent upon future events, the outcome of which is undetermined.&#160;&#160;We intend to continue to attempt to raise additional capital, but there can be no certainty that such efforts will be successful.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Development Stage Activities</i></b> &#150;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since we redeemed and converted all of the outstanding Series A Preferred Stock of Comtex News Network, Inc. at the end of September 2006, starting October 1, 2006 we have not conducted any business operations. All of our operating results and cash flows reported in the accompanying unaudited condensed interim financial statements from October 1, 2006 are considered to be those related to development stage activities and represent the cumulative amounts from its development stage activities required to be reported.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Use of Estimates</i></b> &#151;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Cash and Cash Equivalents</i></b> &#151;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We consider investments with original maturities of 90&#160;days or less to be cash equivalents. As of September 30, 2013 and June 30, 2013, we have no cash equivalents.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"><b><i>&#160;</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Income Taxes</i></b> &#151;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company accounts for income taxes in accordance with ASC Topic 740.&#160; Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at currently effective tax rates, of future deductible or taxable amounts attributable to events that have been recognized on a cumulative basis in the financial statements. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Net Loss Per Share</i></b> &#151;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Basic net loss and diluted loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income by the weighted-average number of shares and dilutive potential common shares outstanding during the period. Dilutive potential shares consist of dilutive shares issuable upon the exercise of outstanding stock options and warrants computed using the treasury stock method.&#160;&#160;As of September 30, 2013, there were zero dilutive securities which are considered anti-dilutive.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Concentration of Credit Risk</i></b> &#151;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Financial instruments that potentially subject us to a concentration of credit risk consist of cash.&#160;&#160;We maintain our cash with high credit quality financial institutions; at times, such balances with any one financial institution may exceed FDIC insured limits.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Fair Value of Financial Instruments</i></b> &#151;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our financial instruments consist of cash, accounts payable, accrued expenses and notes payable.&#160;&#160;The carrying values of cash, accounts payable,&#160;accrued expenses and notes payable are representative of their fair values due to their short-term maturities.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Fair Value Measurements and Disclosures</i></b> &#150;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC Topic 820 defines fair value, establishes a framework for measuring fair value, establishes a three-level valuation hierarchy for disclosure of fair value measurement and enhances disclosure requirements for fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Level&#160;1 - Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Level&#160;2 - Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Level&#160;3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#146;s adoption of fair value measurements and disclosures did not have a material impact on the financial statements and financial statement disclosures.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Recently Issued Accounting Pronouncements - Adopted</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2011, the FASB issued Accounting Standards Update No.&#160;2011-04, &#147;Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs&#148;. The amendments result in common fair value measurement and disclosure requirements in U.S. generally accepted accounting principles (GAAP) and International Financial Reporting Standards (IFRSs), and do not require additional fair value measurements and are not intended to establish valuation standards or affect valuation practices. The amendments in this update are effective during interim and annual periods beginning after December&#160;15, 2011. Adoption of the new amendment did not have a material effect on the Company&#146;s financial position, results of operations or cash flow.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"><b><i>&#160;</i></b></p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><b><i>Recently Issued Accounting Pronouncements &#150; Not Adopted</i></b></p> <p style="font: 10pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">In December 2011, the FASB issued ASU 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities. The amendments in this update require an entity to</font> <font style="font-family: Times New Roman, Times, Serif">disclose information about offsetting and related arrangements to enable users of its financial statements to understand the effect of those arrangements on its financial position. This update will enhance disclosures required by U.S. GAAP by requiring improved information about financial instruments and derivative instruments. The requirements of this update are effective</font> <font style="font-family: Times New Roman, Times, Serif">for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. Entities should provide the disclosures required retrospectively for all comparative periods presented. We are currently evaluating the impact of adopting ASU 2011-11 on the financial statements.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The FASB issued Accounting Standards Update (ASU) No. 2012-02 Intangibles Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment, on July 27, 2012, to simplify the testing for a drop in value of intangible assets such as trademarks, patents, and distribution rights. The amended standard reduces the cost of accounting for indefinite-lived intangible assets, especially in cases where the likelihood of impairment is low. The changes permit businesses and other organizations to first use subjective criteria to determine if an intangible asset has lost value. The amendments to U.S. GAAP will be effective for fiscal years starting after September 15, 2012. Early adoption is permitted. The adoption of this accounting guidance will not have a material impact on our financial statements and related disclosures.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the United States Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company&#146;s present or future financial statements.</p> <p style="margin: 0pt"></p> 175000 170828 90822 96138 EX-101.SCH 5 sgni-20130930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - NOTE PAYABLE RELATED PARTIES link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - DEPOSIT link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - NOTE PAYABLE RELATED PARTIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - NOTE PAYABLE RELATED PARTIES - Note Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - NOTE PAYABLE RELATED PARTIES - Interest Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - DEPOSIT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 sgni-20130930_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 sgni-20130930_def.xml XBRL DEFINITION FILE EX-101.LAB 8 sgni-20130930_lab.xml XBRL LABEL FILE Common Stock Statement, Equity Components [Axis] Additional Paid-In Capital Retained Earnings / Accumulated Deficit Comprehensive Income / Loss Preferred Stock Equity Components [Axis] Accumulated deficit during development stage Notes to Financial Statements Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets Cash Total Current Assets Total Assets LIABILITIES & STOCKHOLDERS DEFICIT Current Liabilities Accrued payable Accounts payable related parties Loan from related party Total Liabilities Stockholders' Deficit Preferred stock, 1,000,000 shares authorized, no shares issued and outstanding, no rights or privileges designated Common stock, (Authorized, 20,000,000 shares authorized, 183,927 shares issued and outstanding at June 30, 2013 and 2012 Additional Paid-in Capital Deficit accumulated during the development stage Total Stockholders' Deficit TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Preferred Stock, Authorized Preferred Stock, Issued Common Stock, Authorized Common Stock, Issued Income Statement [Abstract] REVENUES COST OF SALES GROSS PROFIT OPERATING EXPENSES: General and administrative expenses LOSS FROM OPERATIONS Interest expense Loss on extinguishment of debt Gain on sale of short term investment Gain on forfeit of deposit LOSS BEFORE PROVISION FOR INCOME TAXES Provision for income taxes NET LOSS NET LOSS PER SHARE OF COMMON STOCK - Basic and diluted WEIGHTED AVERAGE SHARES OUTSTANDING - Basic and diluted Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Debt discount Gain on sale of short term investment Changes in current assets and liabilities: Accounts payable Accrued interest payable - related party Accounts payable related party Net cash used in operating activities Cash flows from investing activities: Net cash provided by investing activities Cash flows from financing activities: Proceeds from Note Issuance of Common Stock for Cash Net cash provided by financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents - beginning balance Cash and cash equivalents - ending balance Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND BASIS OF PRESENTATION Debt Disclosure [Abstract] NOTE PAYABLE RELATED PARTIES Banking and Thrift [Abstract] DEPOSIT Accounting Policies [Abstract] Basis of Presentation Going Concern Development Stage Activities Use of Estimates Cash and Cash Equivalents Income Taxes Net Loss Per Share Concentration of Credit Risk Fair Value of Financial Instruments Fair Value Measurements and Disclosures Note Payable Interest Payable Notes to Financial Statements Accumulated deficit Additional notes payable issued Discount on note payable Note payable Accrued interest Balance Accrued Interest Deposit Purchase price for stock Document And Entity Information Notes to Financial Statements Notes to Financial Statements Assets, Current Assets Liabilities, Current Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Income (Loss) Interest Expense Income (Loss) from Continuing Operations before Income Taxes, Domestic Gain (Loss) on Sale of Equity Investments Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) NotesToFinancialStatementsAbstract Interest and Dividends Payable, Current EX-101.PRE 9 sgni-20130930_pre.xml XBRL PRESENTATION FILE EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!)Y#&3E@$``'T+```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,EEU/PC`4AN]-_`]+;PWK MAHIH&%SX<:DDX@^HZQEKV-JF+0C_WK/R$4,FA$AB;]9L[7G?9\UV^@Y&R[J* M%F"L4#(C:9R0"&2NN)#3C'Q,7CI]$EG')&>5DI"1%5@R&EY>#"8K#3;":FDS M4CJG'RBU>0DUL['2('&F4*9F#F_-E&J6S]@4:#=)>C17TH%T'==HD.'@"0HV MKUSTO,3':Q(#E271XWIAXY41IG4E%3^3H!L)Q'0C'32`)DCIZMUJPKL MF?^(M>@QYY(9X._.8`P\.\!/[4,<&)+&1FF+<='`Z;NPS8--=4>C$!@G8)<( MVY+5SA&CYNF&>]$.FC#+@;=X4Q^>A]\```#__P,`4$L#!!0`!@`(````(0"U M53`C]0```$P"```+``@"7W)E;',O+G)E;',@H@0"**```@`````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````C)+/3L,P#,;O2+Q#Y/OJ;D@(H:6[3$B[(50>P"3N'[6-HR1`]_:$ M`X)*8]O1]N?//UO>[N9I5!\<8B].P[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ. M'&%7W=YL7WBDE)MBU_NHLHN+&KJ4_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&7< ME.4]AK\>4"T\U<%J"`=[!ZH^^CSYLK$SO+=N5#9@NI MS]NHFD++28,5\YS3$$X4UD^&'!Q0]47P```/__`P!02P,$%``&``@````A`'70*\]5 M`0``\`D``!H`"`%X;"]?Z1<\PJ:!7.3`?:[Q3&MLKYI2UYI[*3*H$G<9QR^S<'VXUR1H=< M,GO(??WCN?.5;^12F:$*[ MH=6D4YX4NG/C.]1PNW_6E`PQ9?FAF5P(AM!O?Q$4S*0NALK_PZ04C`BNAG2S M#'Q02]+-I#3.CTNXG%*_Y/V3-"+\L`XZ&T5,.5D$IEE0,)O`,!L*1H16(P8W M?/2?MOL&``#__P,`4$L#!!0`!@`(````(0"%_'6R6@(``)P%```/````>&PO M=V]R:V)O;VLN>&ULC)1=;YLP%(;O)^T_(-^O0-*O1$DJDI`.J84HD%;=C>6! M4ZR"C6RG2?_]#F1A)M6B7H$_SL-[7K]F=+3[M]%.R+??0KQ9`.!JC'*MJZ%MJS2G)5$7 MHJ(<5C9"ED3#4+[:JI*49"JG5)>%W7.<:[LDC*,#82B_PA";#4OI7*3;DG)] M@$A:$`WR5+XFD<-"MBKY!:8PV5<2::#"9:X7%!D<5E8?C->HOC?K+_ZOH MDF9$Y7AA4,#NUHNK4TJTNO?"X)>7!%&(O7".IUX94R]Q?1G&0F!^],?;?GNZ/UX^/ MWNJE%AL']V&P"&9>F&!O-HO680<#M[NU8'"*.:<==S`#`^,ZIYSS$XU887"(9%U5M^IB3"SZC9A MM9M^X0:GI$CAUU(_ZKO9&&G60VV4QF9I\12R4-E*&P[?[[O9<"H4JDZ7U1X1Y. MG7OJ5EW*]=>W/-->:^;K&J[C8QQDKZ$9_ MIUS_NOWCR_K*RA=^HK32@*'@&_U45>>5:?+D1/.8&^Q,"X@<6)G'%5R61Y.? M2QKOZX?RS+0MRS/S."UTP;`JIW"PPR%-:,222TZ+2I"4-(LKT,]/Z9FW;'DR MA2Z/RY?+>9:P_`P4NS1+J_>:5-?R9/7M6+`RWF60]QN9QTG+75_=I4C+. M#I4!=*80>I_STER:P+1=[U/(`&W72GK8Z$]D%1%?-[?KVJ#?*;WRWF^-G]CU MSS+=?T\+"F[#/.$,[!A[0>BW/=Z"A\V[IY_K&?BGU/;T$%^RZ@>[_D73XZF" MZ78A(TQLM7^/*$_`4:`Q;!>9$I:!`/C4\A1+`QR)W^KO:[JO3AO=\0QW83D$ MX-J.\NHY14I=2RZ\8OF_`D0:*D%B-R0.J&_BMF'[+G&]3[#,&Q;X;ED\8VZ[ M"W^"%E/D5=L4Q56\79?LJD'M@7)^CK&2R0J86W]$-C?''AD&3B')$[)L=%@T MX`6'67[=NL[:?(6)21I(<`\A,B)L$3@+R!J)&_#9L(UQ7AD3WD(Y$T@I5,%TK@J'F^A9X\L"!@,#< M=2[)B/!#1#2&D,3#,-/%(WBC@S&=LH4L+1`0KRX92XZ%([%H."9)A?4Y72J" M%:F^+"<0D/F@U)%8-!R3I'J?D8I@1>I2D2H@PU)'8M%P3)*Z^(Q4!,O5ZRF3 M'`@(3&=7(W(RX8>(:`PAB<>NWMOLQK<)!,L^>\J.%0C(HBX)XLQM)1Y*<=M: M=+N7V.#Z<<>;VW:WJ4BZEY_1C6!%=[<3U>,&`B)TSX:$RX`!Y1)@3#J!ECW= M\QJMB+]K),BXT5OUGN\IB+!A:1%D/N]\;3J+PK$D3N>19#W!)C2Y9FJTHE^9 M]*#!#*_.L6#4!)N\X$W2ZE:3+!J;T731HG7U]VE/,2P@`O-`]$@P:IX4HHGC M]!:!K!E[T'3-HF-)FM7&2-JNAN\CG5.BHX\%HR8H-#NV^]!G;$,]S?CVY$!I MC6\L1#0O2;O:%QM,,]6.9?M*&84RPG9UO"DK!<;U72]HJU)>A6O`B(PXD5D-NBWA!CT6T*, M^HT=JZ=_8MV(/M?/8Z&4=4`$9EFWI)EE$&51A'>`KB2:K7%R-X5SV__)0C0] M*0NE;P8U<[O%$]]9VLKZ"&7$`LY`BA-XJA05./1F(:I)G!K%<2BGY9&&-,NX MEK`+G@AM\/!V]W9:?;+QW*#<#\@*3B]PW[P%X!!YCH_T[[@\I@77,GH`2LM8 M0.F7XA@J+BIVK@]A.U;!\;'^>8*_"RB`X?7SGB^F9`^(K6B%/8U0C"1+7^M.:;IM(>]C-*?LPAX7-W@IF%9& M538`'/&!WN;\1)X(D(JL%)"!*SO2O,KQ2Y2NYI@4V5B?/X(/YNH9F48-7[0H MOXF.0[&A3:X!6Z5V3OI:NE>PF=SLWHP-^*%1R2NZ;^U/-7SEHFXL=#N!A%Q> M:7E:<\.@H(`)XL21F&HA`+@B*=QD0$'H<;P/HK1-CF=QL$R2^6+Y")@M-W8C M'!,CMC=6R;]>%9U9GA*?*7`_4Z(XB)=)E"S`]3\4XD,:,UQ32XM,JP'!U("G MZ:F;P2@%\LN=O68Q5F06)V$X M?7_C"Z'=[^O$[WUG$]?[>LV5[WMC/]*^X3VM^7>J:]$9U/(*T@D#-W[:#[1? M6-6/#=XJ"W,X/C9P[G#H?AB`N%+*7A;NEYE.LN(?````__\#`%!+`P04``8` M"````"$`^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H96UE,2YX;6SL64]O MVS84OP_8=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B0-))?1O:XX`!P[IA MEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7UVH.( MH4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ M)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK59B7" M-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<)=(A9 MVP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1+(#LXS+M;K51 MK;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[QR7P M;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF9;@. M<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F8E;$ M'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8=8_Z M@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<],9&R;,UM`?H6 MG'X#0[TJ=?L>FT1.[P:3?$45*&'=`X+&(_D%,(48SVN2J# M[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5!DJZ M4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;UKD*_ MJ]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C\S210*:D`XD2+N&\:(9+ M:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D1$&W MUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K..YB1 ML;:[]5'F%N.%BW21#/&8I#[2>B_[J&:+T5';:S76&A[R<=+V)G!4ALZ%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q/M8> M\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY2\.D M-9PDU0$-D*"P'ZE0$+(/994FRE)")J(*X,K%BC\@A84-=`YMZ M;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV#4UF M_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO-3+A MP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY(%T@[ M.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4:.[6P M8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:&PO"U10+$ED12EN18#DZRV1YP=8.< M@Q1HBH*2*)LQ7U2*NK,3]+]W9OFRLWJAEM9*ZT;(6:2X,\\\,SN[.TORZOOG M*#0^^^DR2.*AV3EOFX8?3Y-9$#\,S9_NW;.^:2PS+YYY81+[0_/%7YK?7W_U MAZME]A+ZGQY]/S-`1+PISQ_&FI6QVL"$^"J9ILDSFV3F(:R7S>3#U-U$.6H,62+J^BE>1 M&V5+8YJLXFQH6M4I(__EPVQH7IA&;O(XF0&(/_]GE63?_3'_\^[;=^_:__[F MNW_^Z,_^]"#>IGG[5JQ\',NN558<'TU3V)BB`,T(5N7 M3W'R)7;Q-P@&,`\ON[Y:_F9\]D(XTT%XTR1,4B,#+X-][$SL17Y^Q=@+@TD: MX&5S+PK"E_RTA2=88!3710&X"4^V<@VGU3-!-*5-?80AV&3C&6I3!"9Y>++> M)N_7+38)NKK[=1W"GZ"+65%OES)=FW&QP>$ANBI?$3WIPV1HNB[DD$Z[C;12 MAQU)V6#J5[;*N M2,.GZ@'8X=2R&$#7K>G?/1<_IXB3$P]HQ_$8DRHD?=;U>&Z\#R)_:=SY7XP? MD\B+D5@ZJ+&KA3%9"+SCB!="0+V*(XNO@GG@7#F^@KFVYF?QBX<&,7W^Y<%3`)C6!I@)+7RZ_9<_9!Z+QV+387D M&BR3,)@ABH#!0+=1R MX:-8Z/LN?A0+=>&_L3).B^3OJ`)9R3.R`)>*[?/>8##H=R[Z_?[`L3N.PTB> M%!$=Q#/_V:^2A!H\BI!H,FK/<49N*?= MJP2!)J\2!)J\RFIL"OLJ%$0U]U6"0)-7"0)-7E4V^2PR\$"[5PD"35XE"$[M MU7)9-;Z]=5G%97-FIFQ^7.C"27QS76S5".O429+.8.>JW([IV+!&S,]=7X7^ M/(,5:1H\/.+?+%G`OY,DRV"?Y_IJ%G@/2>R%\+55MBC_UK2$G3#8]!J:V6,P M?0)EPB(\YR97<2P-5=9S<#7A])QVS^E:%_F"39'JR)\%JVC3NDKWUK@$&I'; M_883#N-*21$.O-C70B\4[I-LP5S-/"W9`&*B#`G)%BILY(5O61M)"SD;20-) M&TD+61NAZVSK7"63LV0%F[#K#G;=?KN=UQAE]=0+),"W1,QV$*3-)I][FVQA M=&^;IK9"?MGH&R,+/VQVO,72/2TV[=S38(N5>UK(VBC&3>E=07A5NL#TO`7) M&M_"Y:^#`8KRAB6>M218Y"?<^\AW/Z33G6CNAIXU4XZF9\T>7F_:/VH5`R2, MMU,_##_A"/B/>37H0AWK^NIY3FY6@#M(<#*)G[JLMM*F`IV%HO2_&C$9@;\^'T8/,21SRIQ9B[FAS3)_&G& M;GMAE?M=>.P=>#J%(!D\A^B'>S.VD@@\2?-QB'ZH]&S5#[QHU0_!):U?93S@ M#3Y%4(,+:%#7X5&)`-;S)0)P@@X$>$-2P0&$IPX$L$XJ$4"`<@0`IR8J#ND' M'9+-(`:X2M!_+)608THK!95'M')7^@7]-5:Z0OH]B&:2;R'0.+;V"SQ,ZPHAQ0AH(!%T9DD2#I2M%4@RZYWL+J9U=BR;P>]D\7SWE*T?P!5M+D:4T/@+FE;53XS%)@]]@ MD8F/@DVAF.JG)CXZF`53>N9+ZBWN_6=8BN8;/<_SW;5>0%+6-]:#442X$Q/7 M#QL%IM%$N7)^#L!R.!%[+6>+^KV%^;7($(O;>R-D+P@,2=T8L,"D&P/ZN\"@ M/`P5=5,8)$N(TM&I.EPH33!@RN4*%XC%Y+,GF^V-5:HH( MRG$IHU0Y#9!?5\LLF+\TS)RJZ3@8D7*.FD2'!;'VMAPD'3%'&5=5]]2#HP-K M(J6#[/7E:%W_=5D!66DJP16Y5BQD^&O`R_;,+F8[2;:H.]F-*:]//O;ZNEZG M,W5@V>7,>BQOQYF[>P/N<+-L50XV\*T<\!:Q]I^,,^/]%"NJ5=]#=TY600A/ MN6&=%TOU4UBI)]$H/UD45^MD5=G(PBY$9$%V;RH+).1IU\+M&R(+:&XJ"]3G MLFRPELB".XD;RX(MM4(6;JYQ7`[4&9OB@B:%+)'[KB3WSC8_LFUHC@M-EL%% M97$_XK!,9(')365Q/X+CJ"PPN:DL[D=`2&0YH*2I+.Y'\`*5!>'65%;E1P<[ M/N>K*\G]Q58_BK&*>T8RN*@L[D7&-^.9'SG4KBG0!ZQR($?Y"VJ?&2+[#J2[(Z\69EUQ8#!<48&!KSJ M:+H*X3V@";Y%E.V)XAR1&(05!BE)C_[TR1C#(RZ5(+$_X#`J(^CV>1%ZL9Y&L!+SI`8P[C_U$1,U1=$ M>O"FR"9BH'6.1HP_7)@T$0.M&F-O$;KN6HSNL(C?Z0&S_]DS?TB.\9[A6XG9XW/5>@#HG?ES;Q5F]]6/ M0Y-__QM[%!N"J;CJA^!SDC$10Y-__XC/N$,OADH3I)N/2WAN&OX:JS08FK_? MCGJ#FUO7.NNW1_TSQ_:[9X/NZ.:LZXQ'-S?NH&VUQ_\%RO`5SI?P#N`#7I', M7N4,]WITG,ME""]23@MC"_"?^+FA20YR^.S!5H`-3WR61K26U2NFK_\'``#_ M_P,`4$L#!!0`!@`(````(0"Z3P%&1"$``)")```4````>&PO[&VLKJC2!*^ND@3LZ^N_'B>&?YX8T@GX3)(!RF M2?3=C8LHO_&')__Z+X_S?!+P;I)_=^-\,AG__LZ=O'\>C<)\)1U'"=^?SD\>3)5MJ?CJ)D$K",8#N9Q).+8#=QX[/L8.E%;RNX>?OQ MG)I/SG%<&T:#Y;2\:KP0;JYU@?75MH_GE?OIJ)5A;7_3E M),J#21KLQ$F8].-P&/0FX232$O/F2+>:'_CU'T5G<3[)0G:U'XZBYE.W>HSW M+$HZ;+2_TOS6C[')A!FS[[*_-\&?HHOF<[=65U?75M M?6UU^<\+WSB,LC@5(P;!%MMN/M>%#@-CU\XP/&M^>^LT'.:M=S:G6<9FH&C> M9T-_C<)LX?BWEI=7[R]OK#9'WA6C33;"X,=H.%Q^F:2ODZ`7A3F2.PAV\WP: M97]HOG9K/VU^5!_IAW0X329A=L':AG->+Y^]E0='T3C-)FB.R<,T#_RV6G/Z M==J(P28T/$NS-O-ZHW#(E+5A-]/1.$Q:3_KA#J')_$PGL11:]INOY]-V=\XO`A/ABVUX&M9P[SX/LBB(=*BYY&S M]G![:9@$IUDZFGFP)2]NT95I)G3V3QV3F[3;-@G,6O MT+2EV4^_U*U-MVX+6;28M8<;G4?K#RY?41!.`B0J*IV$ M+1DY76^NHSL8P-TT05H.PWBP'"II/>E(&81^/-G6\'$PSF8S)><16 M7T7#=&S&$Y4\:PF$X]RUV'-\<-S="_9VNT]W]W:/=[=[07=_*^@='VS^Z?N# MO:WMHQZL$@/:TYQ\,T-_($_]$] MD%:)X&!^,H"\7NA7;H MX=UK(X^6+.'NTQ&&K@`4EQ#M:/N'[?T7V[TFA38/>L?!P4[0Z^ZUOWQV=-#K M!8='!SMMOA\<;A]UCW?WGP7;?SGCH/AY$XEF.%)@$SC((X><4T>KDY1?$2L/(TBB=Z;X`_1W2; M3^YI0T^W=PZ.MD7('W9[NP?[`?\,=OQ M>1*^:1-L?_LXT!S->8O/`]@4]+[O,CU<9L;G3&^*'2SC*7,P@(#R(!Y.YQC- M'[=WGWU_O+T5='^`V\^VW4B]X.#%<>\8$R'V7V.8RD:4HFK:L8DC%01Y+>U( MPBF6,1K<7N2Q[>E3>]K<%J&#=`MSB)7``\C)M61P/YH$0P2B29_NX&]3QUM# MYUG43T'GB$#B7Q!FU]]]K7$J7"$YN2I+FT)N><8EV# M?'U)?[P>@MM$F;_X'@[6`N6W[WMO7C^O'OT5W.=N\_V=\%&W?WCH'O5 MQC+E*&1WS0#6-^'FXGO][Y#_RW\.8"YYEM4;=YX\[J=#7`%P:D1B94V?9#MD M+-PCQ_$(F[(?O0Z.TE&8Z-O3()(N^!%,X#FL<3C(1LZT.AX'%&R2G&`5#[I$(`V'MW$#\H7!),QY6,R[] M^LL_GG6[A[_^\C^W`Q:K^;2V;&"J;VL537:ZO:<:JQ@"OT;6*\-^;)(.(P1R MDML9L M*O++?&31F4(/0["L5QOH17@N\[;VQ/:;OODT,XK$:SRZ$FAY<2WK=CK-0'_G ML.P<[`91X<\PZA._D;8(PIHS7D(TT`YC#!,F2@R*G?*68A;(+NE051.""14NK+J[KB\QP1@GG(COX8FYA*`,V!D2I# MW:HTC,MRB=4W'SY8ZZS?O:\,4%M6;"TRAG-U9$"(@1QYV<40X.AJIM!@N^W< M6V6"%*HO+D'(HRRN/X0\E;]A/8ID,BF"A15!.'))00Q8\6?[/?.@M=C#D7JD M!)MDM[*77JEA`A_C?DA#RH:6S!#UHC=8;WG>A@Q/GNQ"1)_]ZABAM58VA/8H MFO*)8/29I7_!=<`32 MU-?%WR&&;30V#Y>%,5:K6`JFM^\2<)W@9,H#\E!\E-C6V9RS[R`5$T`SA]$I M:HQ?,%&$%'PHEX).-S9MBKM5R]0!%,XBD$,1L'YN/?Y[N8`:ZNN9*L!E%"?" M:;H$+%R&6;)A\MG>RM6RLHA_1@@>=`%41;;74FIZEHAI0MT)B"J<.GF=9M04 M=BE726_D",0RGJM42(6_CI"DJY(<]">IK/":ZFRK]V4(3#.E0*QL,#7K*A4Z MF:+*<*.FW"N!,"'#2T#;[MTT0I&5RR[@<^$N^\27F(_"T5HM1;KXWJ#+[$QS M]8*6K#HGKI5Q0CZ1(A+@R&41K/-9*\6+$2H$Q]2?E>)FI#1:I[=/\D&%KMOD M,9)ZZ5"9`LEJ'<7^Y\GR"U8(';?S24S!MLA'R0E]IJCEW=MY$GP,.2`-V*D, M$.=:8#@,&U#F*A29$W3,1UI>.A:%(C#2J)K7L*<8/0I?(NT%_8R-YN+,XQ"M MR,N%.*V^8VK!C)*E4-],NT/`=:LM,5;>R8%-L8F]"4A+0!:]XV8AL"Z!RUQ" M:6S)V+SE9++24S1?#Q69W:!6JG`O27LN%(EEN1`@)X4O4C(0!)TJ8BO8]VCU MW=M!>($ERP(",@MEL1-]F:I:[@=RF@>O;&<%5>%('5AN=&J&LSV06WC1%6'. M"QNM&L-QE7S^P@@K5<>[C`T]N9#(Q0LX,:W!CV^S$`'!-5D,;BFPF$-,SHQ4 MN9?:D@%78=U5G%@RRANS>;J/>"F--'66%-^?OK9D2,U1A?B7)NT$ZDHP^OJ< M!!"%$CX;I9!P&+^,V#G&+C$([*"5V"77ZV-VV9LYXQKHDMM'%8@MAV+$//N@ M_.N>:D&'&!5K7RCU\G,YJW(!-;#EBC`)BU5@8C;45V/GZRQ'2]"2_"M7+\JOQCDP*E&68"'PQWMA%%%C-:*\QY)GW_(,14A&- MA)IXHE$FRN%/"7#<:Z,(M^;BE$46VT(=%.2U@I"?HPP0*![86JN\6YGJDH+I^9#*8_B_&4IF5^2:NR4/7-Q0C/`5.D[CY#& MA71@1?+IR=\$EZ;F(#%NS7U20-$^,_;I".:D0'ZT"!K586AI/$4(YF#-,9^C M1X%__2<0BQ+6E8W4JN()W($)_V:!C/+P!"U*F?G:BO?P\DYTELU_&;>/%WBC M`E2PL[6[B>(H73C`3()+\WF\W"%M&?R`538)K0BU6Q'JBV3I`>2=)6#!UIIZ MBOX=\]=3,=P7,NT3ZX`J,:;T+[$$H7^FS+?TT`@RN M&-92?J!8%VS5TWQP01GD8IH!_`#CH_M\9JT$R]9*4.&Z*YCYW`R&):J=+]@J M`;VO87\^^#4W5U"AJ(?KJW+7BKUK-.DHUL&V*OO/CD#W=+`J_+=,Z,BV*SY5 M5&R^8;G9Y:&2*#4<9XPH*54O`,P.C9/J5NW*6/TRHLM$!U;="3YS@&\P^Z=MJ#.02".1R=4+Y MO@&`[)[)K!ZN;T%QFEN&RU@;52`KSL*1GN2,T*]`6KL98D\T?/>6`B:IE_GK M<2Z*6N,92V#4GZ:H%P4!BFL0;8GLAR4HU:8A2I&_P.N`2MP67*12-3$XV&W> M:Q1F+^FE;(C_Y(E?T_HUUP2D4)Z_L2XM)<=6#JD.+`AT+0"HKP1S@O4H^&)1 M-_M-3W(JHH8%-*CHWV8.$DK4!BX;D#7I3W!!(@45`/>OCI$&KX3@&X(QI(OM M5\K?S`%]L2=41Y+Q%37(->O4Q+ET="/KSO[>MRT-5VVLVBNTGP')=,_R;I1G'* MZKU"B>A"MZJ[]O=NAJ/Z/GHEU.$ M=I8#^^MZ[A6?J;XI+?48>[Y4V"`51WG-,ENSLUT[;[:D==UV"U.O$NVZ`"CD M8:>$>T>6@95;J"B\9+NX[=1VX"HG?B'U7/[\'3BAE&X`%]BO*@2P$E==>J>: M49;>NFH^>NUS<97)'JLK5>:P14[H.#G'%TR=,&BZ*K;WX571+"$&^LJOB[9P M(65?3G@*7$W_))@)/1\E0Q=JFEM%H6EU?:Z4R]H7 M843'2X7YGUI]#%(8+E:.O&4FKJ]SO_[R]V`?'LS5/+"-E8F*G2_2P-X+^V99 MZCG3[E\HUOJ:%*M2$/A_0A@7')R>TM%OS07=JNUNK_)85_&TE#CZ2['MJ@KY M(R&_#9=M$E.<9'&S8V==']@9*0,+W]V@PI5F5[?Q_),P_Q-O#&:;/!R)TXK$ MDO$B2V11LNO`,#,7N>KA%'=KDJ8B126,-1>`CDY1ULR4THQQ(VK8H%KHC!'Y$/9^I9(F%.;M9+.,4+>8L-ULM>SF M'T,::DBZ6*EP;:,`>GQ%DUIA;!7>F[TV"7+=(OZ[%7Q:*MB[&:1,UKU` M2`0)9O?YN%O9OL*>5T)7J8VWT!BE6JI18.ZZ2&:)B6YCJ5=D:=>75]<)&7"+ M9\I#Y\&S-!V8"DFT#UAJ5EC>C7NRO,?*A+-:G39D>33K+>^1PQK4!J%HH<-5 M1JI=J!1GPA,DOA,J%I!P_8'Y/,Y58@$`]^-A?.JRF^3';7`CVYM2!%N+0#@8'9I\`7L2-Y(FL\T,"6 M'8_/H;%@MH3`$4<98'E?:Z_K^TYRQ(HD45GU9B#M*#6><)RV;*(UJWL:8T?5 MSEXDS918[-/-)T0N0I?M%$%LD6ES[8!XK8%!C-XU*CDTR!"5U2S:(RH0)/J< MNG.;ZGU"P8KZOH,\50G+0YYUE#%4@YY3`%EW$D*V97"[GWX&$_%]C2&<_QCX MUDW44>#/]?/,BT*4^ING2T;0PH_5U+^%@IPB$`0B6?5%8#[J88>/(WQ:W!1R MR<6UYEW0B6VZ62D(HC\*.7*J;V0N=]*L'X%_)2&$#&IW3=`GEX(TR=^D/8,P M#WGUQSM]J*+TM!-TO3M;L+ZZF[-$E3*P'D&?1$,%*>8EJ]9*"=!B\FKN.O3T M=E!VVU>ZYA&_1>1]]6`?=O_:?;JW'1QM[W5U/N6P>Z1C:\X_%O5+#H/K*$:% M`A?W@^MT>KLKVJ9:)XP#LEXR:R?0:9OFW`<)!]/.IFC*P]*0&04R2EP6\F!, M^I%9"!@)EJ!N@'RC\3?7W-%(3(-ZN4A#U'JLA&YJL-Q\F.*`,+-4HU,)3V>5 M,?I6DPC+096B9!H90NP$&J&..FK0SS-Z6<_CLBJFMK*W_3NIJ+GS$Z]@E$V`22NKR#H>F7%@9ZAV02O)5 MG%MAT]6,(DQ&A(0!B54[SW?:]UL5DDRG7_E13UN7*V.L3C6=6`U<+7SV$CRDH]*EMK0T8ZU& M(VM8/HWPFY=]S3[+U?*W[*I:%26;)I1%1M^<76M_&K86ZOM9RUI<58)[.@S[ M+Y=[?4XH8TBK*'Z4#L@G:R>7K9!&\W1FF52ZBX7"";VJQ19NT&U`]<7YFYD9 MBC57[J[LV!!=;F[<[=RG)\&V7G8.OTKAH,Z&6[_D@X8T;$O`2D]G<"S.T4^3MP0\',>]:77FP-F=E!N&0P(LXHMD'-H<.*AP715*5.Y<1@C'?F8]TA@EC M@JT"1`H42\34X"1CX1EPV0J;1GF_7BQJ'[$#%8W`AY:Q+WA;UI_PZ(1OGOQP M:5&6W2:0H`JKEQ4VYFHZ`LAFWK@F*>=[Y7*E,XU-3?\[_]WFTLVXBM.U`P#( MO"4'VX2XWASE^JX>X,GWI9[*;1$/8/B]*RS<('Y2!T7)-B!RZEDOGRB_\2VT M%OV1<9$:HNJ@SA&RPVTA7J"<(.D8I7;L3:I38B8S7R/]PASDKM4`U"U'2.FZ MG+-8E1SUC-VQ',W02JZMB8N7K,NG-K<%$[7NBA;6VYK:F1^]4AR5@!`UOJ\2 M)-()7`*I`H,8H0XMX\).77MW\"S#MG2"O96]EJPQ!(25++,=]ZLH1?IH*^2E<%8[Y;8C/ M+>$:F,_QO@0OUON#@[,.:T-LOM-]IH[7VME'UIXMQ0,K/U)&XKP-"1DR,\3' MF^?*14`39%A2^33EU&-''?]J0U+8B^`31D3TB%OLH00#67?`+N-9!M8KE8>Y MERL5DO5-I[[IE+7_64ARB4[-A%&?2*4.DB*H7Z>^2V:4.^%0`P+#AO;Z,,\2 M)%4P4A@>4P%O=6>-XX4%=85]Q*ZZFC.(V`K2-NGJ`T'?NFZ:UBUP=QADQZ3'ZR&Q&26_&C.+LN4UDZHH]C=8('(C M=?\]:VQOD@34%5'FS3^3/:KG+SA8_"'VZ)$3RB_$QR.Z]Q[^4YS\X\9=BU>C MNLNEHB84"V3^_2'>`F_T?Y;[&YV[:U\E\[^9A$\'^Q]U[CYZ^,^`_>]O$1Y= MZB?6:R;AFY^@JN`N+*BRXQ\0"Z)P:^N/OD:IN.NJ*-_0@[!?(^'PH1F"=1S( MW:_25OC:VC>I^`12<:]S=V/MBS05"M2^\D`#B/HIV;AW_QOKU.KPONG&*P.\3\ZZ];5O6O>;,L6?GW6K#[]0U@'\+W-V7P$N M_L1J1R7I8ZJ=V=YF66TVL5NO>KUW^*MS#M\8JN)BHS@^*2J6#]8>?#P'^+G9 M^0W1W%__B&'$9V;G-V[>^XCIHP]D)@4\%=)\XRAF]>.G"[GHI[PI[Z;/0?EJ M^4B-\VI6H5"N,I#Z)BCEW9U3?%-QW3>CV,';6JNJNTRD7IUK%=ZJ.F6U4S?B MM^YC"$MCZV_O/FZWU-#&4G:(?&L_'JB#R/VFCE),I<^^HA/9"MW6$,1+;1I? MIVUIO7./0U5WJX_;@;KX4M/C08S;WJ'G<>^A&+4^1U,[+0-S:,1O^-=/Q_D6=M&DN M[G,&_N_> MEFC6'3QF50V45#O/<+,6=>R.0@Z=;W.EQ813'E?WZM^?.?_"AIJM^I^8[P\^ MHM+^%A"Z[ONK+J7O`V+2+[R#^1.SZ=%G8=.VW;JM)ENLPR$SJ*:C>F>=_#-0SN*K69,;V.NENU"#&[E9N+LV1$<'M:W::;K"Q?JUUI.)=0."<<#)W'WL>ZLY12472A]TZKBN;-[Q>1:?3A9?O?#$KE;8 ML%L6%@R'02O;U_RY"UT+PW9K>-;?I`#H3;B2G>.(=HFC_UE6;>7FAO)#JUBI M@2XD"/:X"(P_^&:7LA(96?U:V][!KOU:F_^%&7YDUDI.5GJ"(+6%J":GJW'< M(67//(;JKS#V?O0J'.@FXIK\O+!YM6HFX2@!]ZO`-'+%[N8"_($8D7/&.[<[ M/*#ZZU#70[BMNN/&HJI=JS+1STB,.=S.3T2&M]UACE/MBS$]QX7"<#;NIQ8X ME,D]#)P=][^;+=;4KI'@E6(+O.9.MKO[+(/T-3_CF^MF"'-A*3=(I^4S[=`%[.5@*A`9=T$%AO_PKJ"4H[A,+-EP+C"O4WO:'+?T5 MR]7WFYR8,N&P/P2-N$$"D]!Z4+X",W]<_4Q&-3+ M+@'B_C,YG+;X[RL)Z-OF.N1X5-A;]/W[Z-]6Q/WU_"[FOJY#5!_UN+I(X"```,!P`` M&````'AL+W=O8_M3.]?98U> MN#9"-3E.HA@CWC!5B&:5X]^_GNY&&!E+FX+6JN$Y?N,&W\\^?YINE5Z;BG.+ M0*$Q.:ZL;2>$&%9Q24VD6M[`DU)I22T,]8J85G-:^$FR)FD<#XBDHL%!8:*O MT5!E*1A_5&PC>6.#B.8UM>#?5*(U>S7)KI&35*\W[1U3L@6)I:B%??.B&$DV M>5XU2M-E#76_)GW*]MI^<"(O!=/*J-)&($>"T=.:QV1,0&DV+014X&)'FIPH4VN`4NEU@Y]+MQ/,)F->`CA::26SJ9:;1&L.#!L6NK6;S(!01=+#\(]'POD MX>8\N$E^*M`&6ODRZP^GY`7B9SMD?HJD76)Q2O3B`T+`WL$CQ'6[1S<):L'H MW>/H(._+F`>D_P')NL3B$M&Q"/_ST>+E^!R<8]!^MS;N_O$\($.?;1+[3Y=8 M7"(ZUJ"^ZZTYN&LM>V]*2"T@?6_MZ-GB_+..'=@MU]MQ\)&=I)O#/"`A*3A2 MST5U$>F8&]QBSL%'YH[6^#P@NS:.>N/T:)O`B>U(?8_._?IX?(-+A(ZSPM64UC\YUR\_/FKT_K$VN?^9%280!#S6/S*$2S MLBR>'6F5\@5K:`V1/6NK5,!M>[!XT](T[QZJ2LNQ[<"JTJ(VD6'5SN%@^WV1 MT4>6O52T%DC2TC(5H)\?BX9_L%79'+HJ;9]?FH>,50U0[(JR$.\=J6E4V>KK MH69MNBLA[S?BI=D'=WR2DAH6IMU9]"O@I[XX+O!C^ST=UODWXJ:@MM0)UF!'6//$OHUES_!P];H MZ:>N`C]:(Z?[]*44/]GI'UH0:.`LW"\253QDH0`)]& M5LOT#1$4D8X1KGR$6R#IK`YOF:Y-@*(II MG+6YY$S;R=\BQ!M`?!617$,HTN`]\Z5)<&P"]T6:H[YXBY"@\Y3`DE+#R3`< M>1-V06+S-4FPILE57[I%2#BE"<->%Y[4!'MCOB8)UC1YFB:$3&K"\`U-P3V: M)%A;5EIQM@@!.\[EU1#)-82RK,)[I$FP9E>@V840M,MWEHX63X9Q+PB=B94E MA^#L)B'!FJQ0DX40E.5XD:_%D^FXXM;R'ED2K,F*-%D(Z64%P3+0[5(`GA/8 MERVC"",PGN8;UJ$U::.V*AEC$[6YGA=Z&B+I67H$\4@T44QR7\O'=@T-Z+RZ M!_T'^VK'&)O7=L!5B.J=[,&#Q28'=0#9WYA,V+F'/=;3VS]!#':'BSE=#LE$ M4)4FV_#]TK!Y*]+T]D\0@\4CD3LJ[F1<%2A[\D#@#<^P@RO"+@NZ+RUB4)CO M^&&D(1)R!:&*TV:!+*Q[N[#CH>#I0T&>X\Z;XR$*B>/I.U>#>/8RN-1`E7G7 M>"#8VA4/M>Z_[3'HX8/KN8&C99!H$.*Z@TVFRM-&Q$P7Q[-"MV@+IV_IXN09 M1(F/!SZ>O/%LV:0'^CUM#T7-C9+NH=#V(H0BM7CNQAO!FNXLN6,"SLO=UR/\ M/Z)PT+07`-XS)CYNY,G^_(]K\S\```#__P,`4$L#!!0`!@`(````(0",'0[S MW@,``$X.```8````>&PO=V]R:W-H965T&ULE)==CZ,V%(;O M*_4_(.XW8/(UB9*L!D;3KM1*JVUW]]H!)[$&,+6=R7R.C^UL/K\5N?=*N*"LW/IH$OH>*5.6T?*X];__^_SIP?>$Q&6&BY(*;4))SF6P"].M!)7MR(=8U=@ M_G*N/J6LJ,!B3W,JWVM3WRO2]9=CR3C>YS#N-S3#Z=6[ONC9%S3E3+"#G(!= MH$'[8UX%JP"<=IN,P@A4VCU.#EO_$:T3M/2#W:9.T`]*+L+X[8D3N_S!:?87 M+0ED&^HD\?X?DI-4D@PJYWNJ(GO&7M2K7^!6"$%$+5!!Q'_7,(^1BA*T8"/E,E:7OI61':S"^9D>/I@SR(2`FKWNPDWP"E5)&T6L%?#9*I"M2*X*55B`:PDA9R;A MQW6[@BBQ`E%U5&2QOF'&C9RX?<6T55@@D)[Q($H,4\48[ZQUU61:,3,4XA4V*;#+D37$M,-.3.\+YD@&UY#YL2.VS.%(^U9%XWY@S-9VXY M]7.3?0!,[:3&:G&[%Y78`>LZ2_>`EIB!D=,F25\RP+:ZATV)';;.5K-IB<7F M-$K2EW0F5AL@V.O,Q*EE=@KW;B>P?LNA=$H7-QH+T^F:Y`/-$*=:A$<7&.DE MVUQ*D-./<:.YS:=]3,T0GUJLQ_/II=WDB]RV15ICQD:]_/4U0WQJR1[/IQ=X MB\]9,V+4WP0BI[V3#S1#?##.._B4VIY_D=O!2&O,_'6QZT9*&LFB7GZB9;CH MQF@WB;-9C&R2_JX1.6M(K,Y[,)";D%JRK"'1PW05=9UF4]ZU<:#^SA$Y^8D; MC4D7N2O-!YK.QN:[:_.`XWJOQ-W`]4+8:"R^7HO\>@O1IW5]^"P(/Y*$Y+GP M4G96IV\$B6_OMG\GFG-^^P`.YA4^DK\Q/])2>#DYP*OA9`G%X_IHKR\DJ^JC M[9Y).)+7/T_POXW`B3"<@/C`F+Q>J/-F^T]P]S\```#__P,`4$L#!!0`!@`( M````(0`!,[P[HP(``)L&```9````>&PO=V]R:W-H965T2C_WX7B)VX MV:KL!0P<#N>>"]?SQZ.HT9XIS663X3B(,&(-E3EOR@S__+&YFV"D#6ER4LN& M9?B5:?RX^/AA?I#J15>,&00,C8J5LX9%%PRM:2[@1KC"=1K"8&].N*M[IC$_06.D'4 MRZZ]HU*T0+'E-3>OCA0C06?/92,5V=80]S&^)[3C=H,K>L&IDEH6)@"ZT`N] MCGD:3D-@6LQS#A%8VY%B18:?XMDJQ>%B[OSYQ=E!7WPC7[-RX!WQ3*64%VM?DN#Y\9+RL#V4XA(!O7+']=,TW! M4*`)$B>#RAH$0(L$MS<##"%'UQ]X;JH,C\9!^A"-8H"C+=-FPRTE1G2GC12_ M/2BVHGJ2Y$0"_8DD3H/[)'V8_`_+Z,0"?<<"A.]+"'TXSITU,60Q5_*`X,:! M8-T2>W_C&1!VMO@@>J/^Y1/$9DF>+$N&X:F`!1IRNU_$T\D\W$-"Z`FS]!AH MSY@A8M4A;!Y!7J\1HKO4^/>4=5(LV$JQOEMM2S]Q>6[RYMQKQ"CJ(0,EX-#M M2BP8KLEEP,E;4SSF_@*3]B<[^:OW$`-M0'*[-@O.,`1^3L9T.CQYZ3%CE\YT M%(^'RRN_#&U/<98^$`;OXW9A%CP4!G5R>/+28[RPZ3@>O3$5RHCE.*U'D^2< M;Z_+%PG_#`13)5NQNM:(RITM`#$$W,_VM>DI<>6E7X#:T)*2?26JY(U&-2M@ M:Q0\P-G*5Q<_,+)UCVPK#50%]UG!3X#!S8P"`!=2FFY@[WW_6UG\`0``__\# M`%!+`P04``8`"````"$`*FRW3D4"``!"!0``&0```'AL+W=OQT!AZ$)?U$:K)<12$&/&&J4(TZQQ_^[KL MC3`REC8%K57#F(ISBX#0F!Q7UK89(8957%(3J)8W\$^I MM*06IGI-3*LY+;I%LB9Q&`Z(I*+!GI#I1QBJ+`7C"\6VDC?60S2OJ07_IA*M M.=,D>P0GJ=YLVQY3L@7$2M3"'CLH1I)E+^M&:;JJH>Y#E%)V9G>3.[P43"NC M2AL`CGBC]S6/R9@`:3HI!%3@8D>:ESE^CK)Y@LETTN7S7?"]N7I&IE+[#UH4 MGT3#(6QHDVO`2JF-D[X4[A4L)G>KEUT#/FM4\))N:_M%[3]RL:XL=+L/!;FZ MLN*XX(9!H(`)XKXC,56#`?A%4KB3`8'00S?N16&K'">#H#\,DPCD:,6-70J' MQ(AMC57RAQ=%)Y2'Q"<(C"=(%`?QJ!_U!_]!24X4&"^4?UD@OIPNG06U=#K1 M:H_@Q(%ATU)W?J,,@"Z6](^Q0!YNS;-;U"T%M8%6[J;1.)F0'>3/3IK9O2:^ M55V;_'W/SN:<&+J#T96Y],+M"IAY37JEZ=\JYG]3W'B# MC1[WYL0Y!O:5MS<[S[QFT,7:&PVC.!V\\7:K2,/QX%>TWIN_!K[1+5WS5ZK7 MHC&HYB7L'`9#:+'VE\!/K&J[AJZ4A+0[3``<:F4/4_<-;M\_:8_ M`0``__\#`%!+`P04``8`"````"$`:Z-:4OX$```X$P``&````'AL+W=OV M6%WP75D?-O;??ST]Q+;5=GF]RT^\9AO[!VOM;]N??UI?>//2'AGK+&"HVXU] M[+KSRG':XLBJO%WP,ZLALN=-E7?PLSDX[;EA^:Y?5)T0?ZVV-Y;J]L53&'KLJ;E]?S0\&K,U`\EZ>R^]&3 MVE95K+X?:M[DSR?(^YWX>7'E[G_X/^*=FEU;Y;[9%??FG*W6]ES'80;D#R$@DMMK]R%A;@*-`LZ"! M8"KX"03`IU65HC7`D?R]_W\I=]UQ8WOA(HAF9M]U0*2MLJ7MN.5_]* M4)_10$(5B0?J59PN:!R0(/P"BZ]8X/^5)5SX-(CB&5HQ0JP$'L]3R(/Z.W MB"`8E$BQMY"1!&F%+IBO58"AYS0+(@^?.)$0J-WH$D:D=Q'9%`*)A]/,%R_` M&QN,&91%8_UZUQ()"?N6>?!<&AN`%`&H%Y`E3BY#@,"-_'@T"$F'ZU67+CK= M@_UDNE?$(L-_H_")A(",(4L#D=Y%9%,(E$2(DY@6+\"&_R%V+Y&0J/>?D,"/ M<#S5XV%`C>69'EY22L;J(=715U0+,%8=&H8F$N+WJEU#\40LDS&9[0.AD3<2 M([UB^AN;XOU6$8N,5C'<3"1DJE7N(K(I!$IBB9.8;A4!QJ9',38VD1!I7DA= MHQ52/4R7@5&63`\OP_"S3B%P17[=^GZ5(=_8)Q*%D?H#CYCZ4=Q?WNPS*$X# M+QS]0;83,;6TYIGVO4=CY;%A7:(P'[?[5#!3075Y1Q[]3+,87O,URU&G[^NQ M,CGKX'/8K^-Q M4LNI1*;FH=)_%Y)-LN`,Q!#3,I@WFX@AS,0K&&R[ M&&=?ST$.093#N".KUI$8><'",R)NC)3HX3@RBI>IL-IVJ;ZK(OWT?XW9?I4Q MK,PQJS!2?^P;C9VB0#"8$' M:\-_'/?-_,2[#'&.#];+!.2+"OD$7K'FP%)V.K56P5_%2P@*=[3#T>$%R2,5 MCZK&\82LX($9CCM#`-Y;G/,#^SUO#F7=6B>V!TIW$<%&V,@W'_)'Q\_]<_\S M[^"-1?_U"&^H&#QRNPL`[SGOKC_$"89W7MO_````__\#`%!+`P04``8`"``` M`"$`1;"H'>X%```0'```&````'AL+W=OC_%R<6++]E'2*.V16JFJ>GDF>&VC&&,!N7W[S@P+WJN! MERB>S,Y_9W;V-\2LOW\6)^^=5W5>GC<^F\U]CY^S?#QO_G[^?O]W[7MVD MYUUZ*L]\XW_QVO^^_?FG]4=9O=9'SAL/(ISKC7]LFLLJ".KLR(NTGI47?H:_ M[,NJ2!OX6!V"^E+Q=$>+BE,0SN>+H$CSL]]&6%5C8I3[?9[QIS)[*_BY:8-4 M_)0VL/_ZF%_J+EJ1C0E7I-7KV^5;5A87"/&2G_+FBX+Z7I&M?AS.996^G"#O M3Q:G61>;/ACABSRKRKK<-S,(%[0;-7->!LL`(FW7NQPRP+)[%=]O_`>V>DR6 M?K!=4X'^S?E'+?WNUGSE4&\X)3^"E+%_1]<<.3;`X,%8_TPG\ M67D[OD_?3LU?Y<=O/#\<&SCN!#+"Q%:[KR=>9U!1"#,+$XR4E2?8`/STBAQ; M`RJ2?F[\$(3S77/<^-%BEMS-(P;NW@NOF^<<0_I>]E8W9?%?Z\1H4VTLVMI3 MVJ3;=55^>'#>X%U?4NP>MH+`W9[:"/TN79N$W6&0!XRR\:%10;^&RKYOEVP= MO$,Q,N'RV+K`S][EZA'`9OH=P2[D'=FKTPFC,PICM7`GCZU!E@G[C2@RD2J# MB0W?;J!UB267Q+X!=:EVF%$T7\SN!CN!5FHR@AM*3G>.G":A@PE4 M+*[PZ$R6G/!:2SG=[@?60@"N:W]I.I/2$?>./#0T4$LL@/5#-XGUF+CJ"I-2 MOZ5#%V_V^"316SLL8;+4SP*'N[L138[(TU6$24Z)S>>.G"8!@IF$Z$R6G"8Q M@IF0Z$QR3["Y8RPR&R=&-87)"8H%1Z=6\#K)%,*&DTA!WFI7=":S@J%&BMNW MBKRUT((.:@6O@U%-!"^\U-YTK6*(,""+RS1985+KYYA0(7C)L@-JZ*VI"9.E M?AHH!D*;=`B%2:V?8U#A))<3P?HE;`36::&6DR"%6D''K`HU>`RD:1*#`L`& M+!6;PE+`VH" M!M*C!06@TX*IKQ`OFL0'\M82L?&!.2949.'#J!E/"S5A&Q^88T)%D_A`WIJ: M0(:E`R?Q(3+YT)D4PC+'A(HT9"!AQU70?+B@6-05UW]!&'/,J$BCQT`/FL2@ M`*!F5C#6\(`Y(31O2]`J]9`ZDUI)QZS"L2Y?*IKUH_ZKHI6:LJ"(@D/F&%8Q MWOW1UYF\-;4>'OIUCC52C![`M%!3$1Q1)`I2(%!5$W+,K'@2,`FHD+"D#E,[I.8\/XKC,Q$0N3DE/H&(R)1H[;.9&W>DB=B;Y,509C M8L'#,)1HE29A>\`('0,RT="`E0R39,0S&JW4E'M,2'P/'1,R@8++MVR@E.BM MJ0F3V>_))#:0MQ9:L,%\@DXL;!AQ2B8;*!"H@A*4O/V"FH6.(9QH;*!36MP/ M?_M""[7<^@<+6=@QA!,+.<)1PB8\*!;L1;UHCF&93(('>6MI"IY8NL,"#S8/ MQ[2\20]X.4-]J2:ES^'V_4O[DJ/@U8'_PD^GVLO*-WRW$L+;B=[:O_=Y"'$P MZ?9X]="^#PKZO\#[F$MZX'^DU2$_U]Z)[R'FG-*IVCFO$")X*U,V<"; M&/KU"&_>.+RBF&,G[=O_`0``__\#`%!+`P04``8`"````"$` M*0&QJKP"```X!P``&0```'AL+W=O'][S'/EG%?/Q]NIAAI0YJ*D;Q[ M2=1^%`2)+PAOL"/,U34,612YI@EZ#$T0][]H; M*D4+B"VON7GKH!@).G\L&ZG(MH:Z7\-;0GMV=W&!%YPJJ65A/,#YSNAES3-_ MY@-IN<@Y5&!C1XH5&5Z%\TV"_>6BR^6ZJ#$\2+TZ#20ARM&7:/'"+Q(CNM)'BCQ.% M!Y2#1`<(G`^0,/9NHSB=?H0R.5#@W%,`^+X%WY73I7-/#%DNE-PC6'%@6+?$ MKM]P#L`^%E?$$-3__]VRWHH56RNVA=;;VMTX_6XT^NZE8A(,DC,GD-#U3JP8 MELEIP=%TX#IS3G-[HHG/%9OW%&?>`'*]-RO.,!1^;,9D].6UTR1=.],X.$;2 M6=^XQW`<$$?`F3'8']<;L^*QL?%*CA[C`X M5U$W^X8',+A:4K(GHDK>:%2S`EX-O!1R46[TN0LCVVX";*6!D=7]K.`?BL&V M"3P0%U*:_L)NRN$_;_D7``#__P,`4$L#!!0`!@`(````(0`%V^#4@`T``*9+ M```8````>&PO=V]R:W-H965T&ULK)Q1;^.X%87?"_0_&'[? MV+(LVPF2+"86V2[0`D6Q;9\]CI,8$\>![=G9_?<]%"F1]QYN)O+D9;/S\9*^ M]XCBD6C)US__OGL>_+8Y'+?[EYMA<3$>#C8OZ_W]]N7Q9OB?7^U/B^'@>%J] MW*^>]R^;F^$?F^/PY]N__N7ZV_[PY?BTV9P&&.'E>#-\.IU>KT:CX_IILUL= M+_:OFQ>T/.P/N]4)_SP\CHZOA\WJONFT>QY-QN/9:+?:O@S]"%>']XRQ?WC8 MKC?U?OUUMWDY^4$.F^?5"?D?G[:OQW:TW?H]P^U6AR]?7W]:[W>O&.+S]GE[ M^J,9=#C8K:]^>7S9'U:?GU'W[\5TM6[';OY!P^^VZ\/^N'\X76"XD4^4:[X< M78XPTNWU_185.-D'A\W#S?!3<647U7!T>]T(]-_MYMLQ^?_!\6G_[6^'[?T_ MMB\;J(WCY([`Y_W^BPO]Y=XA=!Y1;]L<@7\=!O>;A]77Y]._]]_^OMD^/IUP MN"M4Y`J[NO^CWAS74!3#7$R:--;[9R2`_PYV6SEF6(XO MII-JOB@0/_B\.9[LUHTY'*R_'D_[W?]\5.&RZD:9A%'PMQUE=E'-QV6?0N7IU6M]>'_;7Q=N=.KN,)8[4'S(W2'\<^. M(H1W@WQRH]P,<2;C^!PQ]7Z[+2;SZ]%OF"[K$'.7B9$1RS;"'4\W;*V!T<`F M8(2*NK)P^#^@+#>**ZM-Z*X%L5;Q74A M77%$#!&;$E$."VYJ:#_[SA,DW)(ED9J((6)3(O*#7N_/SP7+ M_#PII>J7:KYT06T1-1%#Q*9$I#SOD[(+EBE[4LZCI$1J(H:(38G(SUW$Z&5T M5EU$NWCW4NI&DLE[4HK5M1PKO;N@3F\BAHA-B:@'YI/6\_84=L$R94]2O8G4 M1`P1FQ*17X'+D_=/R;QX6\?"NQG6L_8@W@4D MTO11":HYRC"R`LDTG06]/TUO6")-CY!3LA*7A9JC11?5UEOQF.UYMAVH&9L69SSGO<7YYU*%.?1!',]*4Y?E+C; M"ZP\DTE2'"'31I5-):X06:IM`YIA9!W.D)(Z_.5QLZR?GK;K+W=[9(<<,^>U M^[1P<>Q=3907D#QV,YG7$CV:A34]=AY-IEW%)D2Y&XQ$*G7U;=NQY"?&"T%9 MMO.Y'R[;FZ4HVR-U5/6E0Q&BTJ,:$*I/:J0I&Z+F8!"0]+V-NS!.LJ%1$0)G`\$:?:+D/' M2;)PM6.)CJ4^@]N.WG0N<0*KH6T;P9XS<8:<'"!7Y@0KPOL7ZF8$-;>\RSMQ MDWJUR8:.9;-!YKJK)0Z[UM`YH^\A`ZRU:U%=C7ZE5= ML/WDZA(VTAQ@<5"FZJ`L0Y0XFKYC"76B+'PT0]2T*?AR5I1Z.19#RXJ=C^N* M_0U5B(J+B2=!U;9#C*"B2K<@:;5/6=Y)RM ME'GP[E1\0G7HF!PBP\@*)-+$(DCB%V/81L\MY68<*7U`2GIUI;N,49WTC`PC M*Y"LJ9?WE^S]`26B+AG5C`PC*Y!,,V/TYRTZ)3M_0$I\M:`O8U04WX^5U&XX MR@HDJU*^_O:BXRQ)G;$!)0DL&=6,#",KD$S3F9U:=&;E.3N`97#E9,4/2(FO M;YQB5!0_6'`\YPU'68%D5>.24>.24]% MIFRM`:EIK^_!8U14GCS9<)052);4RVVG[+8!B04_&'#T@)JC#",KD$PSX[;G M*,]6.\U:K;X!CU%1^:YCBPQ'68%$254OJVVBI=4&E"K/J&9D&%F!9)H9JSU# M>==%74X&I.:\OO^.4:W,-2/#R`HD2^KELQ7[;$!">;+>FJ,,(RN03#/CLZZH MGJM-Q28;D%)>WWS'J*@\FRQ'68%D2;U,MF*3#4@H3[Y;_9-CC*,K$`RS8QOGO,UV8R-,R`EO=X4B%%1>C]6 M4KGA*"N0K*F7<<[8.`-*$E@RJAD91E8@F:8RSC,W!6;LJ`$IY?6F0(R*RONQ MDL(-1UF!1$GS7B;;1$N3#2A)8,FH9F0868%DFA]CLG,VV8"4\GI3($9URC,R MC*Q`LJ1>)CMGDPTHO0IC5#,RC*Q`,LV,R1:7Q3G/1,S9:`-2ZNN-@1@5U6>C MY2@KD"RKE]'.V6@#$O.>C9:C#",KD$PS8[1GW)ZZMTG4EDQ`2GF],1"CHO)L MLQQE!9(E];+9.=ML0$)YMEF.,HRL0#)-9;-OWR3-V4P#$J=GL,GX=67-48:1 M%4BFV79.CG* M"B1+ZF6="[;.@!*9EXQJ1H:1%4BF^3'6B1\^T-89D%)>[P[$J*@\6R='N9]: M:!YJ:;Y3\R7YGT[PK]_O-H?'S7+S_'PZP_\V&N\4$/]K0 MO`A#+25:2O?0!K5,T=*\($0M5?L3$+IE/KMR+IH9;3Y'2V-UU&>!EJ8\:KE$ M2_.$OFY9C)%!\Y@\M;B?IVB>?-9:H#5N M##,M%?I@^SC7@C[8LXVY%FB-[;U<"[3&+EFFI4(??)&6 M:T$??!^5:X'6^`HHUP*M\4U*K@5:X\N+7`NTQG<`F98I^N"1@EP+^N";^5P+ MM,:7X;D6:(WOE#,M%;3&U[BY%F@->\FT3-$'3UGE6M`'3RKE6J`U'@[*M4!K M/&"3:X'6>*8EUP*M\5Q(IJ5$'SQ)FFM!'SR\F6N!UG@`,M<"K?U5MUX/2FCM M78=:H#4>E:2FA-9X)S[5`:SR&G6N!UGB4.=<"K?'T M<*:E0`9X/2[3,D$&>",MUX(,\%)2K@5:XS637`NTQKL=N19HC=ET];OZY M.CQN7XZ#Y\T#+A?&S:/E!_\[2_X?I_"*ZN?]"3^/A)L4_)X/?@]K@Y?/QFY7 M_V&_/[7_0&&C[A>V;O\/``#__P,`4$L#!!0`!@`(````(0`%R&3O)@8``$D< M```8````>&PO=V]R:W-H965T&ULE%E;KZ-&#'ZOU/^`>-\# MPR4W)5EEN]IVI5:JJEZ>.622H!-"!)P]N_^^MF>`N<#)\!(EQF./_=G?.,SV MX_?RZGWC=5-4MYW/GD+?X[>\.A:W\\[_Y^\O'U:^U[39[9A=JQO?^3]XXW_< M__S3]JVJ7YH+YZT'%F[-SK^T[7T3!$U^X676/%5W?H,GIZHNLQ9^UN>@N=<\ M.]*B\AI$8;@(RJRX^<+"IG:Q49U.1\*N]@XKFX%NT/,NI[9;[Y>KY5=?9\A;B_LR3+.]OTPS)?%GE= M-=6I?0)S@=BH'?,Z6`=@:;\]%A`!IMVK^6GG']CF4[KP@_V6$O1OP=\:Y;O7 M7*JW7^OB^'MQXY!MP`D1>*ZJ%U3]>D01+`ZLU5\(@3]K[\A/V>NU_:MZ^XT7 MYTL+<*<0$0:V.?[XS)L<,@IFGJ(4+>75%38`GUY98&E`1K+O.S\"Q\6QO>S\ M>/&4+L.8@;KWS)OV2X$F?2]_;=JJ_$\H,=J4L$5;^YRUV7Y;5V\>X`W:S3W# MZF$;,-SM25CH=SFU2=@=&CF@E9T/A0K^&\CLMSU;+K?!-\A&+G4^"1WX''1Z MC0!VTV\)MJ%N:3P]G6=41L^8+MS*)R%0W43C;N(Y;E`9\JUN?KGJ[0K/0B=1 M=-)>0PL05-P#1&4`9Z&89Z)ZC5:8<-,]%%7*+A0]RHE*JCK19]8#3&D8*5+WB]) M5-8]28GH1#5O:]TN1A.'BZ?EPVAPH>Y#2K1HAA;4HF%`7>[AD#;Y&M!AJ[!/ ME*A`J>50@@R)P#F9I*U'*D5V%;)9S$':AF5)'EHA#FVN)Q';70F#*G$!A/RH M$)G@">CHOJTZD0;>T..Z7^QUQ>_[M<@$,VC.I,BN1CR,5-,8TG+IT%NTT$@E MV@*1&A(+AZK18YK%'\B%HOC5@F1F00HMEX(T..5!1FTB84(T4I"S>(/9Q-&) MU()DX1"JGL41-F%.%6FS"1NA$Q9.G*31+#XA;2H6%;[!M#S&T>;.=X`OFL4G MI*V7JA39\$6S^(2T#J1EAEO),'KO)1-ND0Z< M^222Y`'-U1_5;#5$),$36B[@&93S(%9)*@IUXL%/=0)DJJ=S%J=$/:?TI-R) M]-Z;&$LB@T.0.E/F<)#30@,^R3`Z?!.3232+8DB;O*GP#94AX1-$Y`*?03D/ MX+-Y)A(BN_?B69Q"VGH6.Y$.W\1$%!L<0H=Y&CO@1RL-SV@,1#I^$V-$/(MC M2-O";ZA)@9_4:M7T?&(><*E!'AB4T\1'"_6FZ$1Z3$/_:S&ELZB%M`UO_7QBQ63P M!L:TACC?3ULJR$)]Q]")](`FFBT%+;7+'WA#;2,@*8JM*20=(1`\-1ZXL-F# M#(%7/:"AQ76$9K%'*B<.I>HZT4A`!C6X5YW-$G#709G48HK,44=<9X@[@Y+7 M9_X+OUX;+Z]>\:H"WL7MM[U8WJ-$J\T!YF*H+O-)',$3NMNPGBPV!SA.1]8D M#)X0E9EKDG1S$!KC1#?+9ZJJNU^H(/^$G#_/P```/__`P!02P,$%``&``@````A`+N# M9D]@!0``?Q0``!D```!X;"]W;W)K&ULK%A=CZ,V M%'VOU/^`>-\0(!^3*,EJPD>[4BM5U;9]9HB3H`$<`?/U[WNOC8FOS4XSU;SL M;(ZO#^?XVO>"-U]?J])Y9DU;\'KK^I.IZ[`ZYX>B/FW=O[ZG7^Y^ZZR]KSVOS,JJR=\`NK8>3(FRKK MX&=S\MI+P[*#F%257C"=+KPJ*VI7,JR;6SCX\5CD+.;Y4\7J3I(TK,PZT-^> MBTNKV*K\%KHJ:QZ?+E]R7EV`XJ$HB^Y-D+I.E:^_G6K>9`\E^'[U9UFNN,4/ MB[XJ\H:W_-A-@,Z30FW/*V_E`=-N,`,/G#]BZ+<#0C#9LV:G(@-_-,Z!';.GLON3 MO_S*BM.Y@W3/P1$:6Q_>8M;FL*)`,PGFR)3S$@3`OTY5X-:`%MVX`#RX. MW7GKAHO)?#D-?0AW'EC;I052ND[^U':\^D<&^3V5))GU)/"W)_$G=_/Y;'&W MO)T$(H42^-N3?%S(HN>`OX.0&\UX6K0NG#A:SA6WRO/-7TXWW#*G-^YC]2`R-B%0$YA%I M8Q-(3"#5``\<#;8@X9]@"UG0EA*T5\#59V!X4!%J2FP"B0FD&D`\A)_B`5E@ MV^NI">ZHZ'T?`WMSR-^(.S]`GY01;8N+!O!]W^RJ?* M]S(H?,_<$#*8LY#$0E(=(>;@4;JY\6*EC@X&"P_JV7N)@&"%1!826TAB(:F. M$'VP7K?KPV"J3R+A4E_UT%CU:`A2)F(+22PDU1$B&1YVNV0,II(E8D@VC^X0 M-$BVD,1"4ATADO$=1*NL[^\"#*:2>X34U#"D>SOJ@T0'EB5S=-J,3DMD4#"5 ME7HYGTZ-8IWJQ,35ZB.N,)BZDD@`9?MZ8D.SUO1!P7``8@M)>B04%M`!M9CJ M,X@!'UY"]+S(CC?!5MZ=B_QQST$9Z!O)%SZL[W=(0IT)7H!@Y31K"RHK4E%: MQGHHF`UV$P6AIJ&AADO*E2HN^L1K;:>VL5-JV_'_V9;M%@JN.B)[7T)&1E=4 M:J2BM)0J"(Z\YM'^!<4V ME-A02B`J$WOE[3)E9R4R^V8+U?:Z6V;&H8_\(>JZP!:4V%$I@:AR[**W*Y<] MERB7$/0>I2G"+QBH'AH4VU!B0RF!J$SLG+?+E'V6R!Q:K[[`9E>'&99R"TKL MJ)1`5#DV4$VY5IC^8S/+SDM,]!"IB#/CJ$:^C`KT&CPV,;2*43]1]LT5U"*# M.B74U"9V5,-F`'P?Z#G(8/0<"='B.S-?$K`EX783G]K]AU4/R0]=_-9*5%0@ M*NT\](W6E:H`,8=ZPV9K>//A\_9#[F3#)MGL(="JG7DC*1%OD_`EO(>!\ M[C8#K*Y(@O6]O",Q1J!GP.V):%O62`@C(58,:V0&(^)5P1J9PXCX:+!&%C`B M>K8Q`M[QIY@21_='WS?^`=7/R(]X`S7/0Q.`M3 MW+I'SCOU`Q\P7!WN_@4``/__`P!02P,$%``&``@````A`)JA>L&E`@``.`<` M`!@```!X;"]W;W)K#A^-SYN9A<_6HZN!! M&"MUDY$XC$@@&JYSV909^?']]N*2!-:Q)F>U;D1&GH0E5]OW[S9';>YM)80+ M@*&Q&:F<:U-*+:^$8C;4K6C@2Z&-8@ZVIJ2V-8+EW2%5TR2*EE0QV1#/D)HI M'+HH)!']H)KU0+%7M;2/76D)%`\ MO2L;;=B^AK@?XSGCS]S=YHQ>26ZTU84+@8YZ1\]C7M,U!:;M)I<0`:8],*+( MR"Y.K]>$;C==?GY*<;0G[X&M]/&CD?EGV0A(-I0)"[#7^AZA=SF:X#`].WW; M%>"K"7)1L$/MONGC)R'+RD&U%Q`0QI7F3S?"RQ>QYE[JJ,),MP%4?KV0I8]L*Z6XF4).`'Z[3ZY4%Q3^5)DIX$GCW);!DN M5M$L!LU_D%#O4!??#7-LNS'Z&$#/@*1M&79@G`+QZP%!)(C=(3@CT-/@JX4B M/&SCU6Q#'R!SO,=<>PRL+Y@!04%T4`:UZ6P^:(`W],%T:P9WTD%QO MF7=7XK1DX-UT6@2/:7O+:A3C7Y('H.E2"!Y+]9;960@XD$_Z'2]RLKP,(>*W M6Q_/C25ZR[A9EJ^WPGJL^K84@L=2O>4D&C^I_$U6PI3B@ZAK&W!]P"F4P-T< MK,.`W"68C3_M\W37#4XZ?(#!U;)2?&&FE(T-:E$`913BI#)^]/F-TRVX"9-' M.QA9W6L%?R@!US/"A!9:N^<-"-/AG[?]#0``__\#`%!+`P04``8`"````"$` MR^X-J#$!``!``@``$0`(`61O8U!R;W!S+V-O&UL(*($`2B@``$````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````G)%!2\,P&(;O@O^AY-ZF:66, MT&:@LI,#P8FR6TR^;<$F#4FTW;\WZ[HZT9/'\+YY\GQ?JD6OF^03G%>MJ1') MCY_4RG:/$!VXD;UH#-3J`1PMV?54)2T7KX-&U%EQ0X)-(,IX* M6Z-]")9B[,4>-/=9;)@8;ENG>8A'M\.6BW>^`USD^0QK"%SRP/$1F-J)B$:D M%!/2?KAF`$B!H0$-)GA,,H*_NP&<]G]>&)*+IE;A8.-,H^XE6XI3.+5[KZ9B MUW595PX:T9_@U]7#TS!JJLQQ5P(0.^ZGX3ZLXBJW"N3M@?5OKDF\WU?X=U9) M,=A1X8`'D$E\CY[LSLE+>7>_7B)6Y*1,"4E)N28S2N;TIMA4^-P:[[,)J$>! M?Q//`#9X__QS]@4``/__`P!02P,$%``&``@````A`'4>>K%$`@``A@4``!`` M"`%D;V-0&UL(*($`2B@``$````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````G%1;;]HP%'Z?M/\0Y;T$.C1-E4D50F@C08)(Z-2]6%YR M`E:#'=DN*OOU.R$#PIHQ;6_G^IW/YV)R_[8MK1THS:48V8->W[9`9#+G8CVR M5^GTYHMM:<-$SDHI8&3O0=OW[LZA M6Z"GD&K+#*IJ[,8.O=.<\4U++PEC!6P8E<=I.@NP2R%X5-WNW3YRV2I*, ME>`CL%NP4@-QS@;R"*QNVH)QI5VR,W<[R(Q4EN8_L&VWMO6=::CIC.P=4YP) M@[3JL$8YR&6EC7*_2O6B-P!&$P<#&N-!;,>V93YT!\-#!$J7D35"PP0=EQQ3 M;DK0<;%@RG10'@S;G`\L&L8-H>,4*>XS!?M%0--/FLLW\]`9?XJ"%AIR. M6AX%?M+$#_S+-9WI#IYWX\?+! MB\)O7AK&$?6B"1U[29C0>$H7RR#I3(GB-*`+[]D;SP*Z#&9>&DQ07Z;A'Q(F MP2).PK03+%G-Y][RN2Z8A`]1.`U]+TJIY_OQ*NI.N5:?=J=T`D8QDM-(Z;J">_P$$]C/8BGA?]MQ6=\7Q568/X&R;6D!]CWCOJ'^>I^5;Q-GO]3WW\3%HVXIP_4/7!E&UL4$L!`BT`%``&``@````A`+55 M,"/U````3`(```L`````````````````SP,``%]R96QS+RYR96QS4$L!`BT` M%``&``@````A`'70*\]5`0``\`D``!H`````````````````]08``'AL+U]R M96QS+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`)&X`DRO"@``J%H` M``T`````````````````YAD``'AL+W-T>6QE&POUN+I(X"```,!P``&``````````` M```````V1@``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`,%8I&:\`P``M@T``!@`````````````````^D@``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`&NC6E+^!```.!,``!@`````````````````5E8` M`'AL+W=O&PO=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`+N#9D]@!0``?Q0``!D`````````````````LW@``'AL+W=O>K%$`@``A@4``!`` M````````````````C8,``&1O8U!R;W!S+V%P<"YX;6Q02P4&`````!<`%P`3 )!@``!X<````` ` end XML 11 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Statements of Operations (USD $)
 3 Months Ended 84 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Income Statement [Abstract]      
REVENUES $ 0 $ 0 $ 0
COST OF SALES 0 0 0
GROSS PROFIT 0 0 0
OPERATING EXPENSES:      
General and administrative expenses 13,421 12,074 364,225
LOSS FROM OPERATIONS (13,421) (12,074) (364,225)
Interest expense (16,863) (11,445) (169,132)
Loss on extinguishment of debt 0 0 (20,000)
Gain on sale of short term investment 0 0 13,374
Gain on forfeit of deposit 0 0 32,500
LOSS BEFORE PROVISION FOR INCOME TAXES (30,284) (23,519) (507,483)
Provision for income taxes 0 0 0
NET LOSS $ (30,284) $ (23,519) $ (507,483)
NET LOSS PER SHARE OF COMMON STOCK - Basic and diluted $ (0.16) $ (0.13)  
WEIGHTED AVERAGE SHARES OUTSTANDING - Basic and diluted 183,927 177,810  
XML 12 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE PAYABLE RELATED PARTIES (Tables)
 3 Months Ended
Sep. 30, 2013
Debt Disclosure [Abstract]  
Note Payable

 

Notes payable:

A summary of the notes payable activity is as follows:

Balance, June 30, 2013   $ 175,000  
Additional notes payable issued     7,500  
Discount on note payable     (11,672 )
Balance, September 30, 2013   $ 170,828  
Interest Payable

 

Accrued interest:

 

A summary of the accrued interest activity is as follows:

Balance, June 30, 2013   $ 90,822  
Accrued interest for the three months ended September 30, 2013     5,316  
Balance, September 30, 2013   $ 96,138
XML 13 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 14 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
ORGANIZATION AND BASIS OF PRESENTATION ACCOUNTING POLICIES
 3 Months Ended
Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND BASIS OF PRESENTATION

 

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation —

The accompanying unaudited condensed interim financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America.  All references to Generally Accepted Accounting Principles (“GAAP”) are in accordance with The FASB Accounting Standards Codification (“ASC”) and the Hierarchy of Generally Accepted Accounting Principles.

 

The unaudited condensed interim financial statements have been prepared by us pursuant to the rules and regulations of the Securities and Exchange Commission. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments) which are, in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited financial statements and notes for the year ended June 30, 2013 included in our Annual Report on Form 10-K. The results of the three month periods ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year ending June 30, 2014.

 

Going Concern —

The accompanying unaudited condensed interim financial statements have been prepared assuming that we will continue as a going concern.  We have suffered recurring losses from operations since our inception and have an accumulated deficit of $871,246 at September 30, 2013.  The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classifications of liabilities that might be necessary should we be unable to continue our existence.

 

In addition, our recovery is dependent upon future events, the outcome of which is undetermined.  We intend to continue to attempt to raise additional capital, but there can be no certainty that such efforts will be successful.

 

Development Stage Activities –

Since we redeemed and converted all of the outstanding Series A Preferred Stock of Comtex News Network, Inc. at the end of September 2006, starting October 1, 2006 we have not conducted any business operations. All of our operating results and cash flows reported in the accompanying unaudited condensed interim financial statements from October 1, 2006 are considered to be those related to development stage activities and represent the cumulative amounts from its development stage activities required to be reported.

 

Use of Estimates — 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents —

We consider investments with original maturities of 90 days or less to be cash equivalents. As of September 30, 2013 and June 30, 2013, we have no cash equivalents.

 

 

Income Taxes —

The Company accounts for income taxes in accordance with ASC Topic 740.  Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at currently effective tax rates, of future deductible or taxable amounts attributable to events that have been recognized on a cumulative basis in the financial statements. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized.

 

Net Loss Per Share —

Basic net loss and diluted loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income by the weighted-average number of shares and dilutive potential common shares outstanding during the period. Dilutive potential shares consist of dilutive shares issuable upon the exercise of outstanding stock options and warrants computed using the treasury stock method.  As of September 30, 2013, there were zero dilutive securities which are considered anti-dilutive.

 

Concentration of Credit Risk —

Financial instruments that potentially subject us to a concentration of credit risk consist of cash.  We maintain our cash with high credit quality financial institutions; at times, such balances with any one financial institution may exceed FDIC insured limits.

 

Fair Value of Financial Instruments —

Our financial instruments consist of cash, accounts payable, accrued expenses and notes payable.  The carrying values of cash, accounts payable, accrued expenses and notes payable are representative of their fair values due to their short-term maturities.

 

Fair Value Measurements and Disclosures –

ASC Topic 820 defines fair value, establishes a framework for measuring fair value, establishes a three-level valuation hierarchy for disclosure of fair value measurement and enhances disclosure requirements for fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:

 

Level 1 - Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

Level 2 - Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

The Company’s adoption of fair value measurements and disclosures did not have a material impact on the financial statements and financial statement disclosures.

 

Recently Issued Accounting Pronouncements - Adopted

In May 2011, the FASB issued Accounting Standards Update No. 2011-04, “Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs”. The amendments result in common fair value measurement and disclosure requirements in U.S. generally accepted accounting principles (GAAP) and International Financial Reporting Standards (IFRSs), and do not require additional fair value measurements and are not intended to establish valuation standards or affect valuation practices. The amendments in this update are effective during interim and annual periods beginning after December 15, 2011. Adoption of the new amendment did not have a material effect on the Company’s financial position, results of operations or cash flow.

 

 

Recently Issued Accounting Pronouncements – Not Adopted

In December 2011, the FASB issued ASU 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities. The amendments in this update require an entity to disclose information about offsetting and related arrangements to enable users of its financial statements to understand the effect of those arrangements on its financial position. This update will enhance disclosures required by U.S. GAAP by requiring improved information about financial instruments and derivative instruments. The requirements of this update are effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. Entities should provide the disclosures required retrospectively for all comparative periods presented. We are currently evaluating the impact of adopting ASU 2011-11 on the financial statements.

The FASB issued Accounting Standards Update (ASU) No. 2012-02 Intangibles Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment, on July 27, 2012, to simplify the testing for a drop in value of intangible assets such as trademarks, patents, and distribution rights. The amended standard reduces the cost of accounting for indefinite-lived intangible assets, especially in cases where the likelihood of impairment is low. The changes permit businesses and other organizations to first use subjective criteria to determine if an intangible asset has lost value. The amendments to U.S. GAAP will be effective for fiscal years starting after September 15, 2012. Early adoption is permitted. The adoption of this accounting guidance will not have a material impact on our financial statements and related disclosures.

 

Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the United States Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.
XML 15 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
DEPOSIT
 3 Months Ended
Sep. 30, 2013
Banking and Thrift [Abstract]  
DEPOSIT

 

NOTE 3 – DEPOSIT

 

On December 24, 2012, the Company received a nonrefundable deposit of $32,500 under a Letter of Intent (“LOI”) which it entered into on December 11, 2012 with StemGen Inc. a Nevada corporation. Under the LOI, if all conditions were satisfied or waived, the following will take place (a) transfer all of the intellectual property rights and operations of StemGen into the direct ownership and control of the Company; and (b) transfer all of the equity interests of StemGen into the direct ownership and control of the Company. The LOI was subject to the Company performing a reverse stock split of 1 for 80 and changing its name to StemGen, Inc which the Company has done. StemGen will pay the Company an amount in cash equal to $325,000 at closing of which a 10% non-refundable deposit was paid after the signing of the LOI. On August 6, 2013, the LOI was terminated. 

 
XML 16 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)
Sep. 30, 2013
Jun. 30, 2013
NotesToFinancialStatementsAbstract    
Accumulated deficit $ (871,246) $ (840,962)
XML 17 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Sep. 30, 2013
Accounting Policies [Abstract]  
Basis of Presentation

 

Basis of Presentation —

The accompanying unaudited condensed interim financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America.  All references to Generally Accepted Accounting Principles (“GAAP”) are in accordance with The FASB Accounting Standards Codification (“ASC”) and the Hierarchy of Generally Accepted Accounting Principles.

 

The unaudited condensed interim financial statements have been prepared by us pursuant to the rules and regulations of the Securities and Exchange Commission. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments) which are, in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited financial statements and notes for the year ended June 30, 2013 included in our Annual Report on Form 10-K. The results of the three month periods ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year ending June 30, 2014.
Going Concern

 

Going Concern —

The accompanying unaudited condensed interim financial statements have been prepared assuming that we will continue as a going concern.  We have suffered recurring losses from operations since our inception and have an accumulated deficit of $871,246 at September 30, 2013.  The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classifications of liabilities that might be necessary should we be unable to continue our existence.

 

In addition, our recovery is dependent upon future events, the outcome of which is undetermined.  We intend to continue to attempt to raise additional capital, but there can be no certainty that such efforts will be successful.
Development Stage Activities

 

Development Stage Activities –

Since we redeemed and converted all of the outstanding Series A Preferred Stock of Comtex News Network, Inc. at the end of September 2006, starting October 1, 2006 we have not conducted any business operations. All of our operating results and cash flows reported in the accompanying unaudited condensed interim financial statements from October 1, 2006 are considered to be those related to development stage activities and represent the cumulative amounts from its development stage activities required to be reported.
Use of Estimates

 

Use of Estimates — 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents

 

Cash and Cash Equivalents —

We consider investments with original maturities of 90 days or less to be cash equivalents. As of September 30, 2013 and June 30, 2013, we have no cash equivalents.
Income Taxes

 

Income Taxes —

The Company accounts for income taxes in accordance with ASC Topic 740.  Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at currently effective tax rates, of future deductible or taxable amounts attributable to events that have been recognized on a cumulative basis in the financial statements. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized.
Net Loss Per Share

 

Net Loss Per Share —

Basic net loss and diluted loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income by the weighted-average number of shares and dilutive potential common shares outstanding during the period. Dilutive potential shares consist of dilutive shares issuable upon the exercise of outstanding stock options and warrants computed using the treasury stock method.  As of September 30, 2013, there were zero dilutive securities which are considered anti-dilutive.
Concentration of Credit Risk

 

Concentration of Credit Risk —

Financial instruments that potentially subject us to a concentration of credit risk consist of cash.  We maintain our cash with high credit quality financial institutions; at times, such balances with any one financial institution may exceed FDIC insured limits.

 
Fair Value of Financial Instruments

 

Fair Value of Financial Instruments —

Our financial instruments consist of cash, accounts payable, accrued expenses and notes payable.  The carrying values of cash, accounts payable, accrued expenses and notes payable are representative of their fair values due to their short-term maturities
Fair Value Measurements and Disclosures

 

Fair Value Measurements and Disclosures –

ASC Topic 820 defines fair value, establishes a framework for measuring fair value, establishes a three-level valuation hierarchy for disclosure of fair value measurement and enhances disclosure requirements for fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:

 

Level 1 - Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

Level 2 - Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

The Company’s adoption of fair value measurements and disclosures did not have a material impact on the financial statements and financial statement disclosures.
EXCEL 18 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\S-3(W86,U-E]F.3(P7S1F-S%?8F4Y,U]B9&$T M9&8U83-B,V4B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E M;%=O#I%>&-E;%=O#I% M>&-E;%=O#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D1%4$]3250\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP M/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7S,U,C=A8S4V7V8Y,C!?-&8W,5]B93DS7V)D831D M9C5A,V(S90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S-3(W86,U M-E]F.3(P7S1F-S%?8F4Y,U]B9&$T9&8U83-B,V4O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)U-T96U'96XL M($EN8RX\"!+97D\+W1D/@T*("`@("`@ M("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)S$P+5$\2!A(%=E;&PM:VYO=VX@4V5A'0^)TYO M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)SQS<&%N/CPO'0^)TYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)TYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO3QS M<&%N/CPO2!0=6)L:6,@1FQO870\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)U$Q/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^)SQS<&%N M/CPO'0^)SQS<&%N M/CPO&5S/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4@+2!R96QA=&5D('!A'0^)SQS<&%N/CPO2!I;G9E'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3L@=&5X="UI M;F1E;G0Z(#`N-6EN)SX\8CX\:3Y"87-I2!W:71H(&%C8V]U;G1I;F<@<')I;F-I<&QE2!!8V-E<'1E9"!!8V-O=6YT:6YG#0I0 M6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M86QI9VXZ(&IU'0M:6YD M96YT.B`P+C5I;B<^5&AE('5N875D:71E9"!C;VYD96YS960-"FEN=&5R:6T@ M9FEN86YC:6%L('-T871E;65N=',@:&%V92!B965N('!R97!A2!T;R!F86ER;'D@<')E2!P0T*86-C97!T960@:6X@=&AE(%5N:71E M9"!3=&%T97,@;V8@06UE65A6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^/&(^/&D^1V]I;F<@0V]N8V5R;CPO M:3X\+V(^#0HF(S$U,3L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^ M5&AE(&%C8V]M<&%N>6EN9PT*=6YA=61I=&5D(&-O;F1E;G-E9"!I;G1E6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT M.B`P+C5I;B<^26X@861D:71I;VXL(&]U<@T*6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T* M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO"!.97=S($YE='=O6EN9PT*=6YA=61I=&5D(&-O M;F1E;G-E9"!I;G1E3L@=&5X="UI;F1E;G0Z(#`N-6EN M)SX\8CX\:3Y53L@=&5X="UI;F1E;G0Z(#`N-6EN)SY4:&4@<')E<&%R871I M;VX-"F]F(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN(&-O;F9O'!E;G-E3L@=&5X="UI;F1E;G0Z M(#`N-6EN)SX\8CX\:3Y#87-H(&%N9"!#87-H#0I%<75I=F%L96YT3L@=&5X="UI;F1E;G0Z(#`N-6EN)SY792!C M;VYS:61E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'0M:6YD96YT.B`P+C5I;B<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+S$Q-24@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^5&AE($-O;7!A;GD@86-C;W5N=',- M"F9O"!AF5D('1O(')E9FQE8W0@=&AE(&5S=&EM871E9`T* M9G5T=7)E('1A>"!E9F9E8W1S+"!C86QC=6QA=&5D(&%T(&-U2!E M9F9E8W1I=F4@=&%X(')A=&5S+"!O9B!F=71U"!A2!T:&%N(&YO="!T:&%T('-O;64@ M<&]R=&EO;B!O9B!T:&4@9&5F97)R960@=&%X(&%SF5D+CPO<#X-"@T*/'`@6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M86QI9VXZ(&IU'0M:6YD M96YT.B`P+C5I;B<^/&(^/&D^3F5T($QO2!D:79I9&EN9R!N970@;&]S2!T:&4@=V5I9VAT960M879E M2!D:79I9&EN9R!T:&4@;F5T(&EN8V]M92!B>2!T M:&4@=V5I9VAT960M879E2!S=&]C:R!M971H;V0N M)B,Q-C`[)B,Q-C`[07,@;V8@4V5P=&5M8F5R(#,P+"`R,#$S+"!T:&5R90T* M=V5R92!Z97)O(&1I;'5T:79E('-E8W5R:71I97,@=VAI8V@@87)E(&-O;G-I M9&5R960@86YT:2UD:6QU=&EV92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO M2!S=6)J96-T('5S('1O(&$@ M8V]N8V5N=')A=&EO;B!O9B!C2!F:6YA;F-I86P@:6YS=&ET=71I;VYS.R!A="!T:6UE M2!O;F4@9FEN86YC:6%L(&EN6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E'0M:6YD96YT.B`P+C5I M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6%B;&4L(&%C8W)U960@97AP96YS97,@86YD(&YO=&5S('!A>6%B;&4N M)B,Q-C`[)B,Q-C`[5&AE(&-A6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^/&(^ M/&D^1F%I3L@=&5X="UI;F1E;G0Z(#`N-6EN)SY! M4T,@5&]P:6,@.#(P(&1E9FEN97,-"F9A:7(@=F%L=64L(&5S=&%B;&ES:&5S M(&$@9G)A;65W;W)K(&9O0T*;V8@:6YP=71S('1O('1H92!V86QU M871I;VX@;V8@86X@87-S970@;W(@;&EA8FEL:71Y(&%S(&]F('1H92!M96%S M=7)E;65N="!D871E+B!4:&4@=&AR964@;&5V96QS(&%R92!D969I;F5D(&%S M(&9O;&QO=W,Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO3L@=&5X="UI;F1E;G0Z M(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2<^3&5V96PF(S$V,#LR M("T@26YP=71S('1O('1H90T*=F%L=6%T:6]N(&UE=&AO9&]L;V=Y(&EN8VQU M9&4@<75O=&5D('!R:6-E2P@9F]R('-U8G-T86YT:6%L;'D@ M=&AE(&9U;&P@=&5R;2!O9B!T:&4@9FEN86YC:6%L(&EN3L@=&5X="UI;F1E M;G0Z(#`N-6EN)SY4:&4@0V]M<&%N>28C,30V.W,-"F%D;W!T:6]N(&]F(&9A M:7(@=F%L=64@;65A6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ M(&IU'0M:6YD96YT.B`P+C5I;B<^/&D^)B,Q-C`[/"]I/CPO M<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\8CX\:3Y296-E;G1L>2!) M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^26X@36%Y(#(P M,3$L('1H90T*1D%30B!I3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE3H@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2!5+E,N($=!05`@8GD@2`Q+"`R,#$S+"!A;F0@:6YT M97)I;2!P97)I;V1S('=I=&AI;B!T:&]S92!A;FYU86P@<&5R:6]D2!E=F%L=6%T:6YG('1H92!I M;7!A8W0-"F]F(&%D;W!T:6YG($%352`R,#$Q+3$Q(&]N('1H92!F:6YA;F-I M86P@2`R-RP@,C`Q,BP@=&\@2!A9&]P=&EO M;B!I6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ M(&IU'0M:6YD96YT.B`P+C5I;B<^3W1H97(@2!T:&4@1D%30B`H M:6YC;'5D:6YG(&ET&-H86YG92!#;VUM:7-S:6]N(&1I9"!N;W0@;W(@87)E(&YO="!B96QI M979E9"!B>2!M86YA9V5M96YT('1O(&AA=F4@82!M871E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ M(&IU'0M:6YD96YT.B`P+C5I;B<^3VX@075G=7-T(#@L(#(P M,3(L#0IT:&4@0V]R<&]R871I;VX@6%B;&4@=&\@37(N M($)R:6%N(&]N(&]R(&)E9F]R92!$96-E;6)E2!GF5D(&]V97(@=&AE('1E2!R96-OF5D M('!O6%B M;&4@65A MF5R;RUC;W5P;VX@:7-S=64@=VET:"!A M(')E;6%I;FEN9R!T97)M(&-L;W-E6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL M93TS1"=F;VYT.B`Q,'!T+S$Q-24@5&EM97,@3F5W(%)O;6%N+"!4:6UEF4M861J=7-T M.B!N;VYE.R!F;VYT+7-T6QE M/3-$)W9E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG M:'0Z(#$Q-24[(&9O;G0M6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W9EF4Z(#$P M<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/CPO='(^#0H\+W1A8FQE/@T*/'`@6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E MF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T6QE/3-$)W9E6QE/3-$)W=I9'1H.B`W,24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T+S$Q-24@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)W=I9'1H.B`Q,"4[(&QI;F4M:&5I9VAT M.B`Q,34E.R!F;VYT+7-I>F4Z(#$R<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D M('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT M('-T>6QE/3-$)V9O;G0Z(#$P<'0O,3$U)2!4:6UE6QE/3-$)V9O;G0Z(#$P<'0O,3$U)2!4:6UE6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24[(&9O M;G0M6QE/3-$ M)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!L:6YE+6AE:6=H=#H@,3$U)3L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X M="`Q<'0@6QE/3-$)V9O;G0Z(#$P<'0O,3$U)2!4 M:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E.R!F;VYT+7-I>F4Z(#$R<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E.R!B;W)D97(M8F]T=&]M.B!B;&%C M:R`R+C(U<'0@9&]U8FQE)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+S$Q M-24@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU M'0M:6YD96YT.B`P+C5I;B<^2&ES=&]R:6-A;&QY+"!A;&P- M"FEN=&5R97-T('!A>6%B;&4@:6YC=7)R960@:7,@9G)O;2!I;G1E6EN9R!P6%B;&4@=&AA M="!T:&4@0V]M<&%N>2!H87,@;W5T3L@=&5X="UI;F1E;G0Z M(#`N-6EN)SY$=7)I;F<@=&AE('EE87(-"F5N9&5D($IU;F4@,S`L(#(P,#2X@5&AI M'1E;F1E9"!W M:71H('1H92!S86UE('1E6%B;&4@=&]T86QE9"`D,RPR-3(@86YD(&ES(&1U92!A M="!M871U2X-"D%C8W)U960@:6YT97)E6%B;&4L(')E;&%T960@<&%R=&EE3L@=&5X="UI;F1E;G0Z(#`N M-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^1'5R M:6YG('1H92!Y96%R#0IE;F1E9"!*=6YE(#,P+"`R,#`W+"!W92!R96-E:79E M9"`D,3`L,#`P(&9R;VT@1'(N($,N5RX@1VEL;'5L>2P@;W5R($-H86ER;6%N M(&]F('1H92!";V%R9"P@4')E&5C=71I=F4@ M3V9F:6-E6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT M.B`Q,'!T+VYO2!L;V%N(&)A;&%N8V5S(&ES3L@=&5X="UI;F1E;G0Z(#`N M-6EN)SY$=7)I;F<@=&AE('EE87(-"F5N9&5D($IU;F4@,S`L(#(P,#@L('=E M(')E8V5I=F5D(&%N(&%D9&ET:6]N86P@)#$U+#`P,"!F6%B;&4@=&]T86QE9`T*)#$P+#4X,B!A;F0@:7,@9'5E(&%T(&UA='5R:71Y M+B!!8V-R=65D(&EN=&5R97-T(&ES(&EN8VQU9&5D(&EN('1H92!N;W1E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F M;VYT.B`Q,'!T+VYO65A<@T*96YD960@2G5N92`S,"P@,C`P M."P@=V4@2X@5&AI6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^1'5R:6YG('1H M92!Y96%R#0IE;F1E9"!*=6YE(#,P+"`R,#`X+"!W92!R96-E:79E9"!A;B!A M9&1I=&EO;F%L("0Q-2PP,#`@9G)O;2!$6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO65A<@T*96YD960@2G5N92`S,"P@,C`P.2P@=V4@2P@ M;W5R($-H86ER;6%N(&]F('1H92!";V%R9"P@4')E&5C=71I=F4-"D]F9FEC97(N(%1H:7,@;F]T92!H87,@86X@:6YT97)E M'1E;F1E9"!W:71H('1H92!S86UE('1E6%B;&4L(')E M;&%T960@<&%R=&EE3L@=&5X="UI;F1E;G0Z M(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^ M1'5R:6YG('1H92!Y96%R#0IE;F1E9"!*=6YE(#,P+"`R,#`Y+"!W92!R96-E M:79E9"!A;B!A9&1I=&EO;F%L("0T,"PP,#`@9G)O;2!$3L@=&5X="UI;F1E;G0Z(#`N M-6EN)SY$=7)I;F<@=&AE('EE87(-"F5N9&5D($IU;F4@,S`L(#(P,#DL('=E M(')E8V5I=F5D(&%N(&%D9&ET:6]N86P@)#$P+#`P,"!F6%B;&4@=&]T86QE9`T*)#4L-#,Q(&%N9"!I6%B;&4L(')E;&%T960@<&%R=&EE3L@=&5X M="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT M.B`P+C5I;B<^1'5R:6YG('1H92!Y96%R#0IE;F1E9"!*=6YE(#,P+"`R,#$P M+"!W92!R96-E:79E9"!A;B!A9&1I=&EO;F%L("0Q-2PP,#`@9G)O;2!$3L@=&5X="UI M;F1E;G0Z(#`N-6EN)SY$=7)I;F<@=&AE('EE87(-"F5N9&5D($IU;F4@,S`L M(#(P,3`L('=E(')E8V5I=F5D(&%N(&%D9&ET:6]N86P@)#4L,#`P(&9R;VT@ M1'(N($,N5RX@1VEL;'5L>2P@;W5R($-H86ER;6%N(&]F('1H92!";V%R9"P@ M4')E&5C=71I=F4-"D]F9FEC97(N(%1H:7,@ M;F]T92!H87,@86X@:6YT97)E6%B;&4@=&]T86QE9"`D,BPS-38@86YD(&ES(&1U92!A="!M M871U2X@06-C3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^1'5R:6YG('1H92!Y96%R#0IE;F1E9"!*=6YE M(#,P+"`R,#$P+"!W92!R96-E:79E9"!A;B!A9&1I=&EO;F%L("0U+#`P,"!F M6%B;&4L(')E;&%T960-"G!A6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ M(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO65A<@T*96YD960@ M2G5N92`S,"P@,C`Q,"P@=V4@3L@=&5X="UI;F1E;G0Z(#`N-6EN)SY$=7)I;F<@=&AE('EE87(-"F5N M9&5D($IU;F4@,S`L(#(P,3$L('=E(')E8V5I=F5D(&%N(&%D9&ET:6]N86P@ M)#$P+#`P,"!F6%B;&4@86YD#0IA8V-R=65D(&EN=&5R M97-T+"!R96QA=&5D('!A6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT M.B`Q,'!T+VYO65A<@T*96YD960@2G5N92`S,"P@,C`Q,2P@ M=V4@2P@;W5R($-H86ER;6%N(&]F('1H92!";V%R9"P@4')E&5C=71I=F4-"D]F9FEC97(N(%1H:7,@;F]T92!H M87,@86X@:6YT97)E6%B;&4@=&]T86QE9"`D-S$W(&%N9"!I6%B;&4@86YD(&%C8W)U960-"FEN=&5R97-T+"!R96QA=&5D('!A6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[ M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+S$Q-24@5&EM97,@3F5W M(%)O;6%N+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H- M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^1'5R:6YG('1H92!Y96%R#0IE;F1E M9"!*=6YE(#,P+"`R,#$Q+"!W92!R96-E:79E9"!A;B!A9&1I=&EO;F%L("0Q M-2PP,#`@9G)O;2!$3L@=&5X="UI;F1E M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I M;B<^1'5R:6YG('1H92!Y96%R#0IE;F1E9"!*=6YE(#,P+"`R,#$Q+"!W92!R M96-E:79E9"!A;B!A9&1I=&EO;F%L("0U+#`P,"!F6%B;&4@ M86YD(&%C8W)U960-"FEN=&5R97-T+"!R96QA=&5D('!A6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI M9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T* M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO2`S,2P@,C`Q,2P-"D1R M+B!#+E6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO M2`D,3`L,#`P(&%T(&$@2!G6%B;&4@=&]T86QE9"`D,BPU M,#(@86YD(&ES(&1U92!A="!M871U2X@06-C6%B;&4@86YD(&%C8W)U960@ M:6YT97)E3L@ M=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M86QI9VXZ(&IU'0M:6YD M96YT.B`P+C5I;B<^3VX@2F%N=6%R>2`R,RP@,C`Q,BP-"G=E(')E8V5I=F5D M(&%N(&%D9&ET:6]N86P@)#4L,#`P(&9R;VT@1'(N($,N5RX@1VEL;'5L>2P@ M;W5R($-H86ER;6%N(&]F('1H92!";V%R9"P@4')E&5C=71I=F4@3V9F:6-E6%B;&4@=&]T M86QE9"`D,2PP,3,@86YD(&ES(&1U92!A="!M871U2X@06-C3L@=&5X="UI;F1E;G0Z(#`N-6EN)SY/ M;B!!<')I;"`R-2P@,C`Q,BP-"G=E(')E8V5I=F5D(&%N(&%D9&ET:6]N86P@ M)#(L,#`P(&9R;VT@1'(N($,N5RX@1VEL;'5L>2P@;W5R($-H86ER;6%N(&]F M('1H92!";V%R9"P@4')E&5C=71I=F4@3V9F M:6-E6%B;&4@=&]T86QE9"`D,S0T(&%N9"!I M6%B;&4L(')E;&%T960@<&%R=&EE6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P M+C5I;B<^3VX@075G=7-T(#@L(#(P,3(L#0IW92!R96-E:79E9"!A;B!I;F9U M2`D,3`L,#`P(&%T(&$@2!GF5D(&]V97(@=&AE('1E6%B;&4@ M2!I2!H:7-T;W)I8V%L('9O;&%T:6QI='D-"F]F(&-O M;7!A'!E8W1E9"!T97)M(&]F('1H92!O<'1I;VXN(%1H92!R:7-K+69R964@ M2!Z97)O+6-O=7!O;B!I6%B;&4@86YD(&%C8W)U960@:6YT97)E6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^ M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ M(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`Q,'!T+S$Q-24@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P+C5I;B<^3VX@2F%N=6%R>2`Q-"P@,C`Q,RP-"DUR+B!#:&EP M($)R:6%N('1E28C M,30V.W,@8V]M;6]N('-T;V-K+CPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#`N M-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q M-C`[3VX@07!R:6P@."P-"C(P,3,L('=E(')E8V5I=F5D(&%N(&%D9&ET:6]N M86P@)#4L,#`P(&9R;VT@26UA9VEN17%U:71Y+B!4:&ES(&YO=&4@:&%S(&%N M(&EN=&5R97-T(')A=&4@;V8@-B4@<&5R(&%N;G5M+"!I6%B M;&4@=&]T86QE9"`D-SD@86YD(&ES(&1U92!A="!M871U2X@06-C6%B;&4L M(')E;&%T960@<&%R=&EE3L@=&5X="UI;F1E M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I M;B<^3VX@075G=7-T(#(Q+"`R,#$S+`T*=V4@6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[ M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO0T*-2P@,C`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`P+C5I;B<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$)VUA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\S-3(W86,U-E]F.3(P7S1F-S%?8F4Y,U]B9&$T9&8U83-B,V4- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S4R-V%C-39?9CDR,%\T M9C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQP M('-T>6QE/3-$)VUA6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P+C5I;B<^/&(^/&D^0F%S:7,@;V8@4')E3L@=&5X="UI;F1E;G0Z(#`N-6EN)SY4 M:&4@86-C;VUP86YY:6YG#0IU;F%U9&ET960@8V]N9&5N2!!8V-E<'1E M9"!!8V-O=6YT:6YG(%!R:6YC:7!L97,@*"8C,30W.T=!05`F(S$T.#LI(&%R M90T*:6X@86-C;W)D86YC92!W:71H(%1H92!&05-"($%C8V]U;G1I;F<@4W1A M;F1A2!O9B!'96YE6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS M1"=F;VYT.B`Q,'!T+VYO2!U M&-H86YG92!#;VUM:7-S:6]N+@T*5&AE(&EN M9F]R;6%T:6]N(&9U65A M'0^)SQP('-T>6QE/3-$)VUA6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^/&(^/&D^ M1V]I;F<@0V]N8V5R;CPO:3X\+V(^#0HF(S$U,3L\+W`^#0H-"CQP('-T>6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P+C5I;B<^5&AE(&%C8V]M<&%N>6EN9PT*=6YA=61I=&5D(&-O M;F1E;G-E9"!I;G1E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^26X@861D:71I;VXL(&]U<@T*'0^)SQP('-T>6QE/3-$)VUA6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^/&(^/&D^1&5V96QO<&UE;G0-"E-T M86=E($%C=&EV:71I97,\+VD^/"]B/B`F(S$U,#L\+W`^#0H-"CQP('-T>6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P+C5I;B<^4VEN8V4@=V4@'0^ M)SQP('-T>6QE/3-$)VUA6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^/&(^/&D^57-E(&]F($5S=&EM871E6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I M;B<^5&AE('!R97!A6QE/3-$ M)VUA3L@=&5X="UI;F1E;G0Z(#`N M-6EN)SX\8CX\:3Y#87-H(&%N9"!#87-H#0I%<75I=F%L96YT&5S/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@3L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\ M8CX\:3Y);F-O;64@5&%X97,\+VD^/"]B/@T*)B,Q-3$[/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`Q,'!T+VYO&5S(&EN(&%C8V]R9&%N8V4@=VET:"!!4T,@5&]P:6,@-S0P M+B8C,38P.R!$969E"!A3L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\8CX\:3Y.970@3&]S&5R8VES90T*;V8@;W5T6QE/3-$)VUA3L@ M=&5X="UI;F1E;G0Z(#`N-6EN)SX\8CX\:3Y#;VYC96YT3L@=&5X="UI;F1E M;G0Z(#`N-6EN)SY&:6YA;F-I86P@:6YS=')U;65N=',-"G1H870@<&]T96YT M:6%L;'D@6QE/3-$)VUA'0^)SQP('-T>6QE/3-$)VUA6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^/&(^/&D^1F%I'!E;G-E6%B;&4L)B,Q M-C`[86-C6%B;&4@87)E(')E M<')E3L@ M=&5X="UI;F1E;G0Z(#`N-6EN)SX\8CX\:3Y&86ER(%9A;'5E#0I-96%S=7)E M;65N=',@86YD($1I6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F M;VYT.B`Q,'!T+VYO'0M86QI9VXZ(&IU2!A2!T:&4@9G5L;"!T97)M(&]F('1H92!F M:6YA;F-I86P@:6YS=')U;65N="X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO M'0M86QI9VXZ(&IU2!A6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$ M)VUA3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\S-3(W86,U-E]F.3(P7S1F-S%?8F4Y,U]B9&$T9&8U M83-B,V4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S4R-V%C-39? M9CDR,%\T9C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^)SQS<&%N/CPO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!O9B!T:&4@;F]T97,@<&%Y86)L92!A8W1I=FET>2!I6QE/3-$)W9E6QE/3-$)W=I9'1H.B`W-"4[(&QI;F4M:&5I9VAT.B`Q,34E.R!F M;VYT+7-I>F4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W=I M9'1H.B`X)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@ M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24[(&9O M;G0MF4Z(#$P<'0G/CQF M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P M.SPO=&0^/"]T6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E.R!F;VYT+7-I>F4Z(#$P<'0G/CQF;VYT M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6%B;&4@:7-S=65D M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@F4Z(#$P M<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W9E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E.R!F;VYT+7-I>F4Z(#$P<'0G M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6%B;&4\ M+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L M:6YE+6AE:6=H=#H@,3$U)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O M;&ED.R!F;VYT+7-I>F4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E.R!F;VYT+7-I>F4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E.R!F;VYT+7-I>F4Z(#$P<'0G M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE M.R!F;VYT+7-I>F4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L M:6YE+6AE:6=H=#H@,3$U)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T M(&1O=6)L93L@9F]N="US:7IE.B`Q,'!T)SX\9F]N="!S='EL93TS1"=F;VYT M.B`Q,'!T+VYO'0^)SQP('-T>6QE/3-$ M)VUA6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT M+7-T6QE/3-$)W9E6QE M/3-$)W=I9'1H.B`W,24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL M93TS1"=F;VYT.B`Q,'!T+S$Q-24@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H.B`Q,"4[(&QI;F4M:&5I9VAT.B`Q,34E M.R!F;VYT+7-I>F4Z(#$R<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE M/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE M/3-$)V9O;G0Z(#$P<'0O,3$U)2!4:6UE6QE/3-$)V9O;G0Z(#$P<'0O,3$U)2!4:6UE6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24[(&9O;G0M6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE M+6AE:6=H=#H@,3$U)3L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@ M6QE/3-$)V9O;G0Z(#$P<'0O,3$U)2!4:6UEF4Z(#$R<'0G/B8C M,38P.SPO=&0^/"]T6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E.R!F M;VYT+7-I>F4Z(#$R<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U M<'0@9&]U8FQE)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+S$Q-24@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VUA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S-3(W86,U-E]F M.3(P7S1F-S%?8F4Y,U]B9&$T9&8U83-B,V4-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,S4R-V%C-39?9CDR,%\T9C'0O:'1M;#L@8VAA7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA6%B;&4@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X- M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L'0^)SQS<&%N/CPO3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S-3(W86,U-E]F.3(P7S1F-S%? M8F4Y,U]B9&$T9&8U83-B,V4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO,S4R-V%C-39?9CDR,%\T9C'0O:'1M;#L@ M8VAA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA&UL/@T*+2TM+2TM/5]. M97AT4&%R=%\S-3(W86,U-E]F.3(P7S1F-S%?8F4Y,U]B9&$T9&8U83-B,V4M #+0T* ` end XML 19 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 9 78 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://SGNI/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 00000002 - Statement - Condensed Balance Sheets Sheet http://SGNI/role/CondensedBalanceSheets Condensed Balance Sheets false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://SGNI/role/CondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) false false R4.htm 00000004 - Statement - Statements of Operations Sheet http://SGNI/role/StatementsOfOperations Statements of Operations false false R5.htm 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://SGNI/role/CondensedStatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) false false R6.htm 00000006 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION ACCOUNTING POLICIES Sheet http://SGNI/role/OrganizationAndBasisOfPresentationAccountingPolicies ORGANIZATION AND BASIS OF PRESENTATION ACCOUNTING POLICIES false false R7.htm 00000007 - Disclosure - NOTE PAYABLE RELATED PARTIES Sheet http://SGNI/role/NotePayableRelatedParties NOTE PAYABLE RELATED PARTIES false false R8.htm 00000008 - Disclosure - DEPOSIT Sheet http://SGNI/role/Deposit DEPOSIT false false R9.htm 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://SGNI/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) false false R10.htm 00000010 - Disclosure - NOTE PAYABLE RELATED PARTIES (Tables) Sheet http://SGNI/role/NotePayableRelatedPartiesTables NOTE PAYABLE RELATED PARTIES (Tables) false false R11.htm 00000011 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://SGNI/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) false false R12.htm 00000012 - Disclosure - NOTE PAYABLE RELATED PARTIES - Note Payable (Details) Sheet http://SGNI/role/NotePayableRelatedParties-NotePayableDetails NOTE PAYABLE RELATED PARTIES - Note Payable (Details) false false R13.htm 00000013 - Disclosure - NOTE PAYABLE RELATED PARTIES - Interest Payable (Details) Sheet http://SGNI/role/NotePayableRelatedParties-InterestPayableDetails NOTE PAYABLE RELATED PARTIES - Interest Payable (Details) false false R14.htm 00000014 - Disclosure - DEPOSIT (Details Narrative) Sheet http://SGNI/role/DepositDetailsNarrative DEPOSIT (Details Narrative) false false All Reports Book All Reports Element us-gaap_EarningsPerShareBasicAndDiluted had a mix of decimals attribute values: 0 2. Process Flow-Through: 00000002 - Statement - Condensed Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2012' Process Flow-Through: Removing column 'Jun. 30, 2012' Process Flow-Through: Removing column 'Sep. 30, 2006' Process Flow-Through: 00000003 - Statement - Condensed Balance Sheets (Parenthetical) Process Flow-Through: 00000004 - Statement - Statements of Operations Process Flow-Through: 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) sgni-20130930.xml sgni-20130930.xsd sgni-20130930_cal.xml sgni-20130930_def.xml sgni-20130930_lab.xml sgni-20130930_pre.xml true true XML 20 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Balance Sheets (Parenthetical)
Sep. 30, 2013
Jun. 30, 2013
Statement of Financial Position [Abstract]    
Preferred Stock, Authorized 1,000,000 1,000,000
Preferred Stock, Issued 0 0
Common Stock, Authorized 20,000,000 20,000,000
Common Stock, Issued 183,927 183,927
XML 21 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
DEPOSIT (Details Narrative) (USD $)
Sep. 30, 2013
Banking and Thrift [Abstract]  
Deposit $ 32,500
Purchase price for stock $ 325,000
XML 22 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Statements of Cash Flows (Unaudited) (USD $)
 3 Months Ended 84 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Cash flows from operating activities:      
Net loss $ (30,284) $ (23,519) $ (507,483)
Adjustments to reconcile net loss to net cash used in operating activities:      
Debt discount 11,547 6,526 92,214
Gain on sale of short term investment 0 0 (12,735)
Changes in current assets and liabilities:      
Accounts payable 6,206 2,950 96,614
Accrued interest payable - related party 5,316 4,919 25,368
Accounts payable related party 0 0 17,328
Net cash used in operating activities (7,215) (9,124) (288,694)
Cash flows from investing activities:      
Net cash provided by investing activities 0 0 40,570
Cash flows from financing activities:      
Proceeds from Note 7,500 10,000 242,500
Issuance of Common Stock for Cash 0 0 3,500
Net cash provided by financing activities 7,500 10,000 246,000
Net increase (decrease) in cash and cash equivalents 285 876 (2,124)
Cash and cash equivalents - beginning balance 840 564 3,249
Cash and cash equivalents - ending balance $ 1,125 $ 1,440 $ 1,125
XML 23 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Balance Sheets (USD $)
Sep. 30, 2013
Jun. 30, 2013
Current Assets    
Cash $ 1,125 $ 840
Total Current Assets 1,125 840
Total Assets 1,125 840
Current Liabilities    
Accrued payable 52,926 46,720
Accounts payable related parties 24,857 24,857
Loan from related party 266,966 242,603
Total Liabilities 344,749 314,180
Stockholders' Deficit    
Preferred stock, 1,000,000 shares authorized, no shares issued and outstanding, no rights or privileges designated 0 0
Common stock, (Authorized, 20,000,000 shares authorized, 183,927 shares issued and outstanding at June 30, 2013 and 2012 1,839 1,839
Additional Paid-in Capital 525,783 525,783
Deficit accumulated during the development stage (871,246) (840,962)
Total Stockholders' Deficit (343,624) (313,340)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 1,125 $ 840
XML 24 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE PAYABLE RELATED PARTIES - Interest Payable (Details) (USD $)
 3 Months Ended
Sep. 30, 2013
Jun. 30, 2013
Debt Disclosure [Abstract]    
Accrued interest $ 5,316  
Balance Accrued Interest $ 96,138 $ 90,822
ZIP 25 0001308411-13-000297-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001308411-13-000297-xbrl.zip M4$L#!!0````(`#5:;4/%?)ZBVC$``$I^`0`1`!P`K$SV=+X9V,9C:[5?,%(B$).Q2I)4C;VE]_W0V0A"3*>J-G MQCM)JA)9!+H?=#>Z&PV`^OFOCU.?W8M(R3!X=>34ZD=,!&[HR6#\ZNC#H-H? MG%]?'[&__O+?_\7@GY__IUIE5U+XWBF["-WJ=3`*S]@-GXI3]D8$(N)Q&)VQ MOW$_P6_"*^F+B)V'TYDO8@$/-*=3UJR="%:M;D'V;R+PPNC#N^N,["2.9Z?' MQP\/#[4@O.1=`=Q./L('9*I"&+X MRAOSZ&-_RM5=^KPC^[^,[*3I_A?!FH+ MU.FCDJ^.+'$\-&MA-#YN0+?CO__V=N!.Q)179:!B'KCB*.WER^!343^GU^L= MT].TZ4I+9)[R:![CXR%7.64$^$3[%23PU(NS#G;CDV/]<*&I+&S:UDUEVM03 M2^V4<&OC\/X8'ARC'-SG77`/Z@-3IJC=$Z@'9TJLM9W8L3(!$\GI!B< M9M6T0^U1>4?F,;*#QQ)=RQ$[3DGI.>*&02P>8R:]5T=743C5J#H`+`[ALU-U M&M6^NAT!CT:UWJ@ZS@N3K?9,L182V4?&PCPI54B@B/;+,\`%(=$`GEM( MO981D?'_#\OWUE^_[&_OX_L9S^GXM9]`EB/<_)L:F MP_DJ8^S+#A^-SQ`^&B_<,R[/V,.%E`122^C#X&)%+%/!51*)7\P:YA3:I,32 M1XLLD-H:^H,)CX1:R\),)VJT-P_`=[>&CR?O01^KLL6^-[BBP2J%]7AW&2QC M+*)J,;T003B5P2:VF^6RS+>(<[,98JCL"ZL!#!C/&\ MP_774ZNG02RF;T108=>!6_OY>!V]57[G,"<]+!:WY@)._W=-W^Y>1/:.IMZE=O%;T[>#Q%IJ-KL^//6PQ97/QUNS&7%? M";=G>A+8!K*&VRO9OH9\$$,7G5)=4>[);HE)@WEH.[\0LC&(9C'5=;T]N MQ<16F1*8Q1)N1IV(M#^8VA`72!<,-I],P&,2A^TD[Y-LD MQE"%1>0%($L5`H;.B!X8/\X\X4H`I%X=X33L-GN-SH(HGF!4-#VU(>II=07? M;:^"WYW%J;E":3T[M/O=F,'G5A&[C%+*S)0-3\^YFO0##_]W^:]$WG,?Z]7] M^)Q'T1QD0?7C(LFG98=<\I@)+(J]VX+9O!.G,N'U-L%SG,;)%\*7K;6?PM=L MM'I?2GZ-+=1[TFY]07B;U=LZV/SZ2HE8&;=9RBQ8H+@/NQVM>@M^)8YK)P9[ MC62%@^N&$$'5'9_SH2\.5%6KW6G8@RHD?A"$C8,^:?0:[0,AO!,^1%COCD,8 M%H>:;Z/5/>FL!53(JD1X&^55`KR;,!9K.OA<*5R*>P<+L=&N-W.8.[`L'^UF MF;;;O7:[%+1O)1]*7Y9@ATVGY72MR;E*>6_>FR-QJ]6Q8_%FWG>1&`EXXE&* M>5`698VY@.K^C#>.>C?&5D9]T'`Q5[?"]A+5/;ENCC4[<>U['B@_#""/Y]*[ M#L[Y3,;>\57(,'KM1HYH,ZO2P&V45K7;<1JM]B'@R+XFH>_!RA]STGB^MZ2: M3K-IIV.KI/=FOED2S5:SW6CMPMSRGY"3ER>'A91T$Y.20.V8QNZ*:M'SZEI% M/XDG823_+;SM!%5<$ZG3/^M\_#*G4G#UO@PNJN$=(JL-:#3]@Y%L(YV]D*P4 MNTHQH$9]65-/\#D*Q;E'9D>H(N]F1XB[:>8TJT`'Y30 M]Z8RH&WA6-Z+R\>9"-36&XU/YFK-5L.QP#S-L02`NZK':=0[K<\(<&=5-MNM MAIWO[HCP=H:''V#]=!VXX52\!6,H0Z_5)<46L-D3R:X*K"YIL#0D.VNJNJRJ M+:!<`U=(%^(RIUR[V[:J#DL<]@"P\Y1R6JV3$@'LK`BGW7.:C:T1O.$R4*@< MH6Z#RT=46"+5!#=[;T<78EAZ[-G$KQ2`A\2ISP%P]^G56%R)[(42V]\&F"_> MCJZ#>S`*ND_V#!I>P^E`4`=J]5E`[3X_F\V%F+L]L-R1(NMS@"*#!!1O/&T8 MJ-=B%$9"MWO/'X6Z@`\JEFXI4:]9;W1;MF/9&\XSCVSG*-IHGCB]%S"RW=W& M":0'W>8S#@V:F,CR&G*S\M04]^- M[Z%3=$^^AT^@]8S3K9H[$5$9[#57TH65RH7TDUCL5VVY6RW`-0!4O>98>T4; M&)>`WUQII,V]D?XAY'@"W_?OP3F-Q4TR'8KH=K1RQ)+(["[?K8J; M.V$H?0!/"[YX`)U.UZF7-(#E[$3O*GV^W'&%7RD`2\PCGP7@[E[*:72:)P>@ MA%@2":[$A=#_OPZ6CCYAQ<5UHT1XUI9C&N(84 M#"^0>:_G'Y3PKH.LTMAW8WE?FF>J=AJ.Y5.W9UXN[)TSY9YC'Y_Y0K#W*'!U MN^W>WMF@#NKN-%J'"+"-2[@2@9@':5[^45M;\^[7-0'VL`7@KV'9;1+PEU\ M3T]?EUU.1LLPDT9WXQW08N9E`]_54KJ=]E^&V[17)85EMR`\ETD%*"D[1<\$R;'@1Q)EP>Q61V! MB=^%0`0,_#U`>NWOD*;\\H,?G\V8BN>^>'4TY=%8!J>L/HN/?AC'9S_PZ>SL M+TZ[?H;-CF?TW5^('$A,+ M1\P6%.&5:;OC88Y<#^G$^7J&]'XB&`=5TOL+0)F$)`EXXDE362?^K[/(CPK+B`) M4RP.S?MUD7C?$&>YX8+2,A0_&BJMSMF;?O\N_:M[]A.#X:2(<`21ARF>'A%* M[ZH_>&T3'6#1FD>>8N>A1Y,%;<)FT!^<+]`//!KJ_TJ`&KF3.0[S2>`$)P=? M>WYK*I@+7]_T1&T4F*Y1WF[F.YRS1+%9$F%&'Z,IH8JB!&T%%1:),5YYPEUI M5!<^I,10)QK8XO+1G?!@+/#E(%.I\!7.-8*","7-#&T9HR0*I)H`TPE8+E@9 MF+`O7,`%^F?^)O=?R)/4RD.T%+ MKMB3*YS)`!$`+=`"'Y,X*BP0,'L4C^8X[!&7$5CA3/LWT\W4.8"U2GP`!H/1 M\A%J)C#C$4R_84O5V+F(\+Z8/63"@!A'81@'D$@S3RK7#_&E3!R-)!T@FUP.9:9A.#4L(UM'RH!"1<:2`W]!*04A>C5)$Q\ M;:-#%"!/7><_D\`E^Z"!(+#4L@OI($\49:Z,N>`1$S`)//9_22!8LUZAUVP# M?==//#W@,(E8GX1+$/0K;1APO0(MP)RM_DKH,TT;6X\GD1`,EK@`S6C:L,+W M?0O+SA\Y0B+Y*1I@!>59< M\.DP)AN!;:7.&^.6DN@GT0/@AQDY&W0C1(:3,TTO]L)"0E\BALGZ7;?C5&`= MS`#PPFPG#&B\A1A1A(52\4+R#L8K`>/Y0M"+<-^%)&1BL'!#/"]`FWAS`NR: MES.85`LP8J/(,[&?XPM5&)_2;@X#7Y)^7.U+#LZWMBI)+5,\IH`>*8^,VFVC MPH:4=&#A"0!FBD.IBD>(U9B*_IF@:4C78%/FKGT%)41(C#XA)(`IB)F@7BR9 M4684@Z-D>'\L!N:4>R0Q'BU#->F6ENZ)(Q=(H]16-;$`._0%]I"?`NWI9H@VZA#F&CAS7%";C"JU7#B)C M0-1GV65KIC=,H"TL8(`AHD7(,?YVC'Y]*48`)(0S"]KEP0"+915&[WY.@^6M M&X?XR*G04T1)<09=/X;/A#(]=/[#!`(33!HK5-587\-&M[JZ_*`1T!\>N"ER+H\`TUI:D'D4;G7.&D]")73,TM]YN6TAQ3'"R>PJ50\@ MMM97)NIB;IQ&*@(@,5@^00[(@$_(L:1R*-OU[.5.EGW2!X6'O\">I[3,^G:< M#0P<+3D;^C9I\-A1T.:0*[NQR2N-U\@2Q1'C^K5^V-5."O'OO&*!#752 M,<99J?MD4WNAG^;DXNY9?!RG2M^EU(Z&/UX-;2"*]B$@[I:Y.+\YK M&,P2JA5IC^E2]NI)7"IHYZ(=5R:NLGW&XG3?>T?GVYT`6@2,+GF]M#J1 M>1EX&M"TP6,)4^I!Q3BHHF)U?W#.WHEF:'@",W>)Y0\LTO)'JH1D!98XCB2LG=/RB%[)ZP"-X3`;CNCZ'8A"K_11'B\EH.JK6`&,`0NZZ`$(BVPJES?PV(!7<32>2V>8]04U4+!(,\X%_+,]*8>\C#^ M;AM(",/JLAF80:0S<6`)CD+C"&.0FJ27@VZ&SA9@T[9EUM]T-%NNR#-EE#Z2 M>-P3/1L5*\G-/HK(A75PNARRN2I=3C&K#P3^P"/\N1?D,9V1U+#RH8'%$?V& MS=QTFPK(SXN+F^NRGXHN6.IT"RN7_Q91:(TAWZW.-H?M<@8`D]6T==F>:X-' M6G9@5UQ&]'K:V]%5ZO^O`Q5'^D>'=>]OR(VA//0/'J>&EHF%67)Y*7[M-HFL MN"ZM`5"*GD]`S-8K65[%9OKT;46?>Q#697$2B!T.N/-5SR M?H8=H5O/TF1DLVS[.-OJ!N7AJ8J4I:?W(O0#-8'4HHJ[&=:JJ.39M]5T2N<@ M_OAPWN,W_&@)]Z='$9\*W!6@@QKZQ]=P2JWO0<='JC[6D:W,?9(=@$,ZBP4VI$4P MB)YA0J+6A;!@PNG,G]7+E`9-!3^T)YW=7Q_/*80!^0K^4KN7!WC\?3:%._>! M.T]]KPP@>*MT>SJG@_7#P"P'L(0ALRWK[!B-/0RL"FHH^G`-24>OZ[0:L'P) MX\#EC3K]:@SFLTQ4^M>102$T@O$6I95C<5@5(J&EE\QVM&YT/A7ZX7A.$OY7 M$M)YK@C?>,E^3`)]`D%X/Y'EZ%^JA-PU77U;^I3I8IX\/$#^)-;5D?[43XJE ML8-^TH,ABSI"M2@YE3Z/UI5$5K12H2;I?*7Z/WJ7H1+1/8;LK%)#NX8K$Q>\ MF,2<&IQ,)%PLCE!1)_VKHC$E0_K)44F[&]FI-8KH*S7_/-?YTV">-ICFCA,Z M"7*UDM95?FXO==7%\>`;T\3>]7IMFT;K@DB[M'&&T9J29G/B M##->0(?S`CBX=`SUR3VR@@>F(I*Q*&OENG,:O'H&9QC_!Q[^7,R,;V[?7[*& ME=7[-WEV_[[RPL"===_]_[Z([%.@9K">B!X1.M.G8.FFQCB4;A4FN(I43W#\(AC`(GI-%WWZBV,WZ(: M.Y_(&7L-\QB$81^0UV4F;$$/&??N,6?76]TIOQ0YQF;:;<#A.(WOJ8J(MP`` MW^LPGF3B,&<%,#4+S"D>6&M0#$@7XL`[YXH"BMB0WB3(+D!^NFCFZ*)9C>4_ M!H01W88VQF(=P'408":)M+Z(._,0S*6KCQ7IVB/5[NC@05KL0S`@%'>"=PQY M8!\VS.BR+6CBLF>QW$AY$2F_7JL[5M45SQ"C>7B)JU<:F*;D`DE/2N!0_9`' MB_K/-DZ'3 M,#MQ0GC9X0C(T;/69C]&USJYM:7#]8H0*SG(D@PU+0D5CW,I,3"8)[[/9PHZII_.6$:MJNLD2"'(OH\C$;N3 ME.I1CAQ!1RDB/(^,_B--B89A'(=38`MN=1R!@_.0=1B=LF@\_+%1;X'_:F(V M='+R4TX3^7!HF&;T$_M2P;".#W>ZK9;,[ZF,U4%@\Z0 M7);;QMYF[-TBZ$4S8QMBSN>5PW?[#?G_VWO2IL:1+/^*8F,V@HHPM"UC#-T3 M&^$&BO8,51!E:COVHVRE0=.RY-9!-?]^WY&7;,D7QMBTOE0!MI0O,]]]ML[^ MNZ@A)PCL3B%O=3NDU6T&_YI71C\FKR8-T*DSL8@:=GA^1G.>X6LD8OTUS_7U M^/_Z-[PO/G8;G;6Q\1U0<#WNO,/SNZK0D]\?$;5LY5.%TT5;PFE-,;TL#/PW M0M3%B[[=11RU6HVSKOO:^G$.]+L_ MNLLKR&Y'.VIUFXUS]WRW4N0GLDP*?]H_,W@C^TWF&2E?V`ZB\.^ZW5ESU9O9 M_[Y9K.N8I2NPZ=W:JPLLB&I&L-R9L\`X=38T=9K++4JWW&?T2DOJU>>PJ7': M7=$XW1*8%\BTU]675C?W%U_.!BK/6IK-ELYHEA?K)D%6:Z(%/8FVJXQN@N[+ M7SFG.OP`:1#_0$3U;9HZK*I&0,FR.EL!A%WC%&F7+6 MB"SUX5Y9&.R>@PS3!`IA5&RIE(0OW(QA9G&=5O$DH54Q]">O4&=5)](M`.G* MU*!A")P`F>O5V.PVN)N/S/)1R3&$//=)\(SX<0)8 MR-D?3W'H<\7<#*8$*3M%GSR9/<0H08#HO)NFE7?3H,R!/$JY_[WL%$X2UZ):7K5%:_S1FK)AT( MC@M/L]UP.RZG#7$5#K9ZXZ*;%V[5.J=D4B&RZ9XY%\-MZ+28J9Q4-&392Y`6 MTW!F$V_HKB5EKYMC)/,7*'&%DYU-_HK"FB,`B?_Z26Z:EC*I2:A!5Z0DK06& M24QRJI*2&!=T5@W5)^H:=3P9V:3!3MLU52CV#FLN\Z90IX1*$JF.2O( M,W=[\NS"R#.=\[Q(GWYK><;(#.3:.:]4J+-[%;3.VW91,'2IR:,P\M-KR771Y5<%XW3B_-:P!2C=;;1>OF>8W6>P#2:FC=^A#6Z`[PNM5H;I-=Z^RLV95K2[)& M]G=']FZKNUU45VL6:A<^+*I_I$CS'H*T%6*O-39%[&?N%AVA?S]BWWM4KS%= M87IGBT'E&M&WG=&-6=7RKEN1:?5N)08T160#MY`-ZUN-79. M2[*QK51$JUF]74#`B=IVUG:-`2OE]!>1H&Y+OMVVY/,QT[HO>55?\G^XFD54 MM2CG2^$>SM;H1N&_+K'7;72:JV>[,ZM:0V+5[H;7\JI_>5&.W:OW)56H_"FXA:X9^BXG141V*T16%5=G)Y^#/0]&$PM M&5FD:C`,^<2`!H48S+AMA(R/'Q3$VSN(1 M-IUNH]TY7W6$C1[ENGR*C4)2:Y*-\_93;&8`9"R=&6;C[&"0C>9=11(1@I!P@:H6(QAB( MT@+"UC7+.JI4^/!KE_W:(&EOPCE?%S.>U;QA_8D'BU__F1.K61Y*/%O*+%F: MOV7?A>Y2+:#(;?^V_')7;:!:-K-8@'BQ'ASVJ\NL4,X]HUCW.A'(Q,>Y79\Z#?)PTSA<`\?1G]$ MHUKD\1O@7F$E`@/$9O2H;+'>Q$M?TD(<%H3K`%#O1L!Q``C2S9,(L+Y2Y>M( MP<3,N%4.[34G'/GQA,W+O#!DT]`T]2V*9H)BB7A6+=X4L,IO%L3XDC@2Y.RA M=M0OVYK6OF3H^NQL]L'H2?AY*.[&^,`#DHO^[@$-:*>5ZHFF]433A:WEZXFF M]433>J)I/=&TGFA:3S3=&B+6$TTW.[6W`K">:%I/--U$=]G6?*,//M%TK5J/5BT2 MP7N,BZQ'J]:C5>O1JO5HU=T*A&V9'ML2%(M'J^[(2%A?\9\U(OK1"+-%Q97@ M__M17[)U^7K8Y`AKHQ=M/)":D09KIL6#6I>J??@?U MR`.]R<.ZECRA+W).]A-P,?DZ@N7/W*,T]7$!VB#+J>;E%YH$S*>1YJ,G,^), MCKE[X6MA,$DR-)]K%G:G%4N(-U9*K\2TS@- M,HMSFM2`]!`=)Z5D423NKW1>9M"[W M5.=-NL7$'Y/(ADZ11(Q!2R5WC,\81_5N;9?2VFBP-GSQ5F09#\Q"P0B*RI'* MG^G^"!/79(!=$CI_,% MF"J$-5I3T,B$<^1]XFF)8]PM?";=7&A2AB&E&84X67PJ<(@CJ7O<5=XJ^\/4 M.;D-:O%!93M!@OPZ_A&)),5<8THM!FQ(XE")+.MJ?J'/CX;EP`C*9]5F[OHK MELP[XY0H.%%*J5+R1;Y+(0SL$4SJ":93E:=C80(B6=WG35X/%UW4U'LI9JY%JC8+Q!:)+('B"132D%W#^N`3I?\@DWZD7`&6,,XEL-%&57R)Q[\0Q2:)G=F*=.D63 M27ZRASSBS43;:O*J0LJE!3G62^_&+,IY89W'SM_ZSBT'<1 M:M52H]^&RG[<:IUUW7_^5+U*`8Y[63EPC_6:G^-DD,T*\'4WWI1KE[YYN6E% M1H:$]!NGV]YSMNUEGB3(YG=@:2T%XHWVX5K[:*ZPC].+UL4>[J-Y=@S@KW$? M;J=]=K[5C=R`^7`;I^E==(F"QAME#Y(%HGJ_!12R"'SA6J\&;%VU[W29W=C:9Y&CYO!_DN>?0B^1R@$?G6Z9=?O30`P84%+<`=^$]8U"_2]$JD MHR2@4FUV!N*;8;%[>'@4'*8=6V*RMIQCL_3@^Y] MKP].[_+R[OO7A_[7&^?^[K9_V;\>[-*J/0@#=M[+1[B%VK>-766N/09Z_]Q[ M#YPMP::+LC_SR,O!;J4>)/A$JL*7P<1RDJ6P6VKZD3I/WK-PA@(LHFDBIAZ; MU?@P&69@%;*?3=.7:NB'?30>!=B"Y#^$SS'LH^JXR&KY'A$<`UR+#KHW$=AB MHM1?V`-K#&PGL#_)N0<&UXU^>4^^W#%4CM.X%126P^"FU[NW/0:P'041[B#Q MJ04#[0A/[W-O\*O]T@'6]GB)C\5#/E`$C@%^'WV0[X7+):AKR@+70-_A"[JQ[79&>$5)CKB"%Y:(QSPTKA7\<(`% MC619TC>N98T6^@4F08JMFDX(E`?RW"!E,&:,\R0*TB>LY0;,#;#AYQB=.BEY M5SA!B.$\DDYS:?'+PTQP7>J:3&E/(%:Y-,T\J+Q>L+.&35SQ-(BD:QYNP7L4 M7#(7":">%-.I8-O8&0>P<,K\33Y&7B58D*ON4IW2`+]/984??">(_?2$BO?0 M@6]MF6!`&,=QG%'JM6]L<;DM:TTDO"A"%TKI[=DL9Y9`E[`70IT]Q'C*.#O$`/<4Z_Y-'(VXP4!]1)G?-8-E^0*'%J*X9Q-8QVUHW$.!*&VA7=J[^NT M9H-56LI-C(=%P9VDUDZHZ#Q-\PGW]?(R;-M`GES=,H_*T1_IU$9\:A7Q2>D7 MAO>G^7A,\03#CH&AI4B/6$]L>>+!],!^:$!X^`,9'[((_ID[Q(U&^23GZG)? M@`(A8Q[GW5;#/3U#WW&!R%0*O:G%EHI,NL)3#'BH'^>?);X2&MF+PU,5?X&(%'4_20U2WW2$H)8/!(F\3\J(]L54T%,.]3X;YUF. M1>;/B`@-5;,.5"A,L():./B"@PG%4((=OD>ZC/S"%6%J``C/R12E)H/B84M# MJVG%R)L&F14U1XGR@,-+DQ0V:.=#8B=4@<47P!O\[5V:28? M6&%*N_L"+@P0]=!Z!^:=D-:'WAY,U8DGL"!"BR!G/^+DCX8,`+,6C'A=Z$>" MKJ\&Z0L07'B]!AL9&KS.C>W M@4J?G#&6,L"?47,S6NSKQ2;)K=D=H"Y'5HA/PHX5M>PI+O8']0UNX1L?=>^" M0'8,90W9-BJDS$.%4,D)`@"#;XM>!Z_Y,P\,+.H<:L*O(OSO*?'Q:WAN@B;. M*@KA_NWK@<9"".XI:C+L2C&YQ!J8V2A' MO7/**@^)+X_:Q$@-2U*P5IG&LN$K/6JK1_B[,9DIAX[$ZR/U:Z)G-)D5GLMD MN]9,FUV5QF052)AA`7*M0VRQ1%DJBGN-2(_S`U2: M5?=39"+ZN&KZKR%E9AY(6NGO1HP`B3T+:7;(]"<@ MT#@)X+VPONS2%3#9733-'?G>"]D5(#DIMW[9Q#MQD`9@7%OB#4/.#8)@Q,E@?OK]5DW+[LQ&Y2+F42TP6ZP0+> M5(:;*G-X]@:7SD,\#49.][1I667.E=)PX=%*L9*PG?\845_I+%:N:%9X)6MF M!5L:B?@V;G4&^QYYX4@Z+C#!C=,Q0,0*W?<-OXY=U^#+**SY';Y`13A`6QX= M?=Y?W.U*>0NR+`G`$%2V/INE)@/=>']--$WIL]19A=BG\;8(3!\+@#Q&2J4I-1J3-BE>H^L)+ M.3S_;K9F\2%V#(>XLP/B03LF=ZR\P202YUX.2AQ@;[U#D8<82!XY$>P!O89Z MF(`?A#2-@_YH)CP`=EFT-GP!1>HY()-6OV'(2:D_J-Y+^,<>.N_`X4 MP*:0E'Y>/FC5H*B%"@WXD>.01XS;_%MCV,@JM]HXLM=`*O:%GOUHA=.IF3D2 MF1HXP(]-!*B^Y1ZTZI:GY!5C;0G=8SBZP-J#B43JP)]MM0-@P;'Z=MVQM*[K MJNNZ#J&N:S\(X#..ROE?')6CL-^@4M]"I0.A@SO`OW$E+5&("30/\N3A](%JYCG[%[7U4M*57ZJL])TG!TNSPP[XE;8 M'.$+4)*#3DI#P2RKNZ:$%2GA"X\R,AXTJ\#D4((IQGP\=YL4?8ZDQ]X@30,M M04`RS%G"./DX\28"XR.4I\$#G1"IJY^@[)'C$+WZEM'UI//?\#U%]R:^B\#@ M&5T3<]3LAHR>F.];3TG'K(QEQ#;:V\_+:5IE8.@A4EH'I+HWS""(1GJP51"! M?I>J,+EY#WIO(VG)H9,JT*%SG45C;P-]L@P*Y];0Z;!)SM?@K]*XZF/J;.RB M"J+J$MU;/"T#2\LY!EEDW8O&';X;5KGC,'Y\H1/^,X\IG0OKDU+G*(\X$T+X MGPAS:`X"S363CA/K/@/EAR$>"R#_(7:B/1ST_;AKW(]*4"G>$5Y+"II:Z"55 MWJRY6VG(D9&\+D5?D+L,4Y$\4[,1Y62C^.DQ@F),_CCU6X-A MRH=H%4K-62>MV9/9RK2-&F$6(TQ[38+.(W.M=.M4*(OI1B:9MUP>_,UN8F/7 MM#6@@D.-/KL_E+0ND;0S84N4UJ2VRLPWU#D!.J0+6&&4J>&2E1'*D@^DTTPO ML4>WN32>LB]0%I7<;V+$3GSN]D.@%4HHX@A^'LEK.79ZB`>RF_N^QHKZD?,% MK'^LVVIH9D)U'-R*OKRH](O;)MFJCN,5>!8%H%SI-7J3S^; M^33$SGHCT#F?N5!`^I0J7E*T*IQOMHH+XH[&F6+Y"GVQ__G;(#6%)FIJK%Y9 MCLRAY`ARIY:3K4XDJ-*MU<(KIU0<(8A<]T)]K+C.$V[;.!*^J1P"<_X$QQ%M MZA-+:)I;^G^N(Q=94B6#-"9XJ5JJB-S!TM M!9HP19)1!IH3/JA`*RFO@[2%\!M[;$]6F+EW"UPR1H.+^)\%F@W07;`[O[>),]SK8M/!Y[ M8#2\_+SX(*64(%A-RR(E+IR"J!A\=[@`&#Z4_2N=P9,0FN6[+63YEC/(\89Q MGN$,/3`QB,GUC`5C-2@Q'7"J68MF?A$V-$+W0A;3B:LVB\XK3T%R_4+)&L-$ MFXC-)CBG4X;_,?KU*+2($YRJGX-.3KP#LSI+]3KX+C5U(N[+<3?)IL8R0\Q^ M-3.>:.9UBEO)V9KRI"B:+AU%!2U4)Y`.7RP).GR1'Q"OGDR3^)D29DW='A^` M7I93`8S_F$44G.,SNU^MCU1)E25$:7L5$F.K]PGP2XD><3Z>$K3SP@<%2B)% MD!Y2JV\%0#7\C64"57DH@LB55- M806ZL9:;)J]6ELUOX)\[O?()6!HJ4VC("RP:&\N"QZ8)D:&AYD?%Q4KB0 MO1%U#T7.-*NISRFR1[#=3ZC..MQFPD5M##MC#5%)NXECGT@&+_J._!Z2G[4[ MR,\>!->A]B-R3P:9.+ZEMFWF)9*M:;=*'TX]2+C&%([W7SE,G\11Y'RMUY';5RTC_#T4`L<%5XOD"73YPHE,OHR(66XGE M="*D8.Z49FEOPM=J'Y83Y%1%CH&:F&-`EC[+R5AZ[V'`[&$&*/1\`_8&NMB4 M6X)18![C]OAR2A$*GN"\:5_ZD-#_C+H4@<>UQ)0#,@DR72X@8S\QW4]L=<`@ M3CH.@(\BTU4A7)5),4H"4@(Y5U\6\5#3NFAN#S2<-<0#H+.?TW7A%89KJ@(< MH^V2YQU(V^/*S;18(,',Q20XM.08>V`7'I8=:Z]"H+9.]$T@%)1>G.M@+N2*4'$ MO([8WZO:\UU/1$*]^D@K39T'+_T#:Y-'XE-#C7K%//R(8L\8VR?N("?&PKOO M>2.F#``IH]*S)3,M2NTN51:# ME,,9DM52:'L-\MZT?TYI=VIXY#8&Q5XV\RIK(F8ZSITM[=74Y8YS*RSQ>FB6 M]K]K=9OG[OE&T*C>WM3L"-6CR-_2$5T`3*[=6VW90EL#;>EY79RUVN=K@O;/ MG_X:)F'P,_X+O_X_4$L#!!0````(`#5:;4/"LSO&@0@``&U3```5`!P`&UL550)``,FIH-2)J:#4G5X"P`!!"4.```$.0$` M`.U<47/BMA9^[\S]#RI]V3X0(.RV&[IIQP&2\0P+7$PZ[9W,=!1;@&:-1"4[ M(?WU/3*&Q<:6#0ZQ=^;RD(#1.?K.^8ZDR^77MWJH;5M+^XFY4[OPO%6GT7A^?KY@_`D_<_%%7M@\GSJ+^\(F.UW=SL.]!%`/ M?4%MR^.K!Q#PEX1Y<,F98_%@++%\D0^MYG^1158>:K4?_KB9#![DG-'UHW!; M[>95NWFQGH'=/>R!SLMFJ]UHM1JM]K1YU6E_[+2O<22(""2R>VQ=N4*4)M M4MM**2U)G&;ZEFO9[2"3MR`#>@-O8"^(Q MLQN4VD)]JF^;U=6E>NNRWFY=K*53VSH_\*#@+IF0&5+_(:YVO5IW0[.A+C:V M,6`PI\\\ZKTHEL0R``G``RT+06;7-14%=47X)@BD\T,>6>]E!>-*4C4L:JAQ M)+HN9PYADC@WV%6NM!:$>#(+EU[J'(C&6(`?%L2C-G9/@Y>HHAA6-,_A,8#7%]@R6%3L:" M2.AN<]6VN0_ASN9C[E*;DDS<1706LV;(/3+&+_A1-73!:0Z$F9<#ID33+19P='@+Y=8O(QF%H6.9C#,8.8Z\'M>3D_3=B8VI^K2Z9Q&Q=_" MRSWB8>K*(19J>GDBK^/M-*UG\GI][YNPZY,IT.@Z%WJ3>02F(.^U+-#K>Y7Y MXMBPR1#388)%V/;=8'(>P.>(!%E[D*D39ZM'03PQM8++2K:Y>;50'6VE]M]" M@8(V*E!$QZM#SLB<(F`O`>%N(8;W.UD4"J-0.@2YA>ER.P+-52DQ%U$N0V1! MWCO#\C%(?GU9GV.\:@15!W$]N;T2L%YOML(<^(?P\E^&E`"@ZPN56FT[L+`C`7-8DH0M&E)-U$I1G4)@;.5G@B]U'@^]RT\Q9I\9 M0%%#SX3.%Q[@+Y7)C859,5<=+E)(2":J:LX>4/Q(7:J6H2SJ/26U+A#X&702\ MZP2X,C*]Q,;EKP'I[H_%FL;8RL54ER^7G.5AY;!E^1-[;DK2S*P<'X;C4&4W M=L>8.B;KXA7UONZ9)ZS!:0+E3\ZYV"R-.'PL&Q9J$M,%?^L&B MTB,S:E/-`IM'-A]U[ZM`77Y75([%O=P!2O%C%M=LR?)7J[S6Q?C4)%2Y^"LU MN3_&4$U#K:&?&DG[D6^S5YE\&S6R<=G.N7&)WD64_7B&_=:,>ZT1V.]CL+_* M(CY#>]+E31=W@DLY%GRFF]TCC:3(=$`/FA8_LR5X.CXV$VV MKG(K3!BW;&XRFR_)`.Q*9R*Q`13^;R0P%Z]7/J^6G8+UL/:!N;Z8/'7!>*&S+@@FW93 MO":R!V\DK''IU!926OX`?06?Q,)#%TA5&]#;&_.9`_B@8?D#]O692_%&]0;R M'12-4EE.Y(CUURK8?"H7*N,;S7KD49=B98N6O_7Q^M3F]ECEAJA"KH"/F,K; M1C.3/8&A07*O9SE5J/S]D?/PF^&E"C.K/""P[4V)@(0B<@I(QVVB6#YV/WRC M[&H\53E^-\F\OFS9;U-^,G2(^&"%+$YMU6C:80V7_1M([[6[%*D"Y>=$.0E, M-38CU7GCW3O]6?[(#MB'U(V[Z%Z84H,"/>C=/<.^`^YT?BQQ7VQ(/(4)B'NB MX)J;EWL`;;)=$6'84%K2_>/U":<.CM#Q__GPB.%T/#D'][(/QF/5IC]CR847 M_@)E-+N%19798%J72T_=$>A1N3G4H[F'FEM#^1-D84:/=5?E^(YGRIN[-R=5 M%0FBY=>.A1G.[:#*40N+NR!8DA[9_#=9[$2>VK*T;>$39^^VGS;1.4E?^05F MX2`HYLIO(#(T)_JR#CF>I*S\LO0,,9';B=]`0&@/[Q:8(^**\@7"3]]6(.1R M7N6"(,41NZ2F0.V1J*/E M_)%\BM7Q7VH^C&L$P+C6[1>-*W M^L-I^$VW.[H?3LWA'1J/!F;7[%MG.-F:_0"9B#$_QXT9CJ9]-#;^-&X&?33I M#XQIOP>?)]/SP(T_:28"[F,<7*\_'EGF]!P'@D][K$P$[E4&UL550)``,FIH-2)J:#4G5X"P`!!"4. M```$.0$``+U977/B-A1][TS_@TI?L@_&=KQI`YMTQP&2\0RQ*8:=W0XOBBU` ML[;$2"*0_OI*!KMV`I@OXX<$2SKGGOLAH3ON+Q:).Z"M<4/:3UP.Z'YU/YRQ`&5>K.1IR*6K483CP!9V- M)&`>(R+D4#B!;&3'D+_QD6G\#7PT$\"T1M\?^MT1GQ"\?&&1:1D-RZ@OQ]+O M-A22\]HP+=TT==,:&(VF==NT&GMJ$U#,>:;-6-X:AFG(9P6_BS#YV51_7B!' M0":2\.:2X_M:+B(+JT[91+^62/W[<])O)+*7MY("_+I8T07^^=U)_HTA1Z;0(+_39R6=?T`.99&>@QQ:6XU&@1T M+LN=3'HTP@%&I;I/X3S-&Y<*U(-O\$4MC&300EEF8@_)I<#3=+71C'(L2@^8 MXK(3=\,\CB%[\\8^EH;&47GB?8VUHJBKN5FUJ:/3L$.KJK4.T0@>02)UIZ7507M)M$SE12L&#^@K00RV\OGER3UH;R?F6M!C%+X@=*+<(K5XKC*+#%":`ZG41*NQ# MI:68B]8D&L-Y)(XNRA1>U"R',<'J;M:5KP7=:"ED3X_"5+DB/+*SDL,*:ZP> M$V@@1>4_0A*"%04H<)Q;<4G?5-!Z+05FUW#Y.<."-1BDZ,NHW-P^%21;>TH& M5P6R3^=WH:3%*JC^_$[U_UA`QR"/KBS0N]NM@MJ;K3$NZE8T(.$!5T,"YR&6 M-XD*(GU2ZU7P[`^U(S$/(LKG#,D7K_]DN\X_]L#Q7&"[;?!@^XX/O$?0ZW?\ MCCM8S[1:WM`=..X3Z'E=I^5T_/.[6=ZN%7SY\[TOKC?H@)[]PW[H=D"_T[4' MG;9\[P\J4?N^K2MHNWVOK=WI>;XSJ&`7'M?"%=0VWJOUA\_/=O^'*@/?D:8> MG9;M#C95@3QFUM05U/V^O5[>&=,XI"S`U8JJBN/QM&ZOX)-Y2H+6)D!FXY*9 MVM42%ER\/BAM60=ZEW)?PL.R_K+@R.&UL550)``,FIH-2)J:#4G5X"P`!!"4.```$.0$``-U= M;7/C-I+^?E7W'W#>JDM298WM<=U>QLEL2K9E1Q>/I9,TD^SM7*4H$9)Q0Q-: M@O+8^^L7`$F)+WBC;(.=2U426>IN/@T\;+PW?OSI\3Y"#SAAA,;O#T[>'!\@ M'"]H2.+5^X./TUY_>C$<'B"6!G$81#3&[P]B>O#37_[U7Q#_Y\=_Z_70%<%1 M>(8NZ:(WC)?T!W0;W.,S=(UCG`0I37Y`GX)H([ZA5R3"";J@]^L(IYC_D#WX M#)V^^0^,>CT'LY]P'-+DXV2X-7N7INNSHZ.O7[^^B>E#\)4F7]B;!74S-Z6; M9(&WMB[./G]D'-3G04(6TY2N/W.%S3V.4_Y5N`J2S_W[@#VQSR?'_XVF>)VB MD]//OYU/;CZS54P>YTET.2^WT9I-SFV^.3TZ.3DZ.3T]GQN[/3 M[\].WSEB2X-TP[;8CA^_/SX^.>;_9.H_1B3^?3;AYOIX@[?!ST2BPI=X(-"2UA1Z9V\>_?N2/Y:B#8DA=/% M,TZ/"CA;R_Q78I`O(6'DC$EX-W01I)*/UL<@K83XJU>(]<17O9.WO=.3-X\L M/"@*7Y9@0B,\P4LDW3Q+G]:*D&$R7)D=`_BO&*5W8H'O1. M/.CDS^)!?\J_O@GF.#I`0I(S5^O7NXJM7.G(-]@Q3@@-!_%^J.O:'<'G[TZ2 M/L.!LKYW%V8T#:*]P)O"73`Y)P1^/=I:ZXX?HGV#1-QK\?4/2 M)]&MXQU$WE7J/Q*F\=:BXY,W3O#+'#(J@.&3"\HZM[8ZARC30CLU]#>A^+\P M*-$MGC$\671\4LX)?IER1@4PE'-!6:?<3@<))3[P M0;D:#*9-#((GY8)@9*:83]LDM,^`RJ=228-ADA%>G42&,"FETA/H+ M/F3?1**7AB[QDBQ("H-3(J@F^`['C#S@8;R@]]C6L=+)>^Y@F6'7.EIJ83#\ MLB%4=+QV\BA3X"R[H8S!H-68V\))@D-[5UTMZI-,)K!E'JGDP%#(`*[.GJVH MO>?^Q^GKOO5:$P\XF=/M8'N/3N];3=T`[^ONFK&\%;O<)+R)N\0/.*)KX2UW M>V5N0MH:\=H;WLO!2O>XE04PX6,OV(T.=*F7$V964"C-\#^W=L3*S0H_E]!B M<4/2-%O;X"2=7M\.?R_61OIQ.(A3_BJ)U8OD7D[>]^$#]:VD?9%.S\,+]ZLZ,-1B$D6(/F' M>ESD7_V>.3#!*R)PQZE8**OYK!?S02@;2,$?G4SG=+$`:S2?4A3M9.6Z97>T MN."L3()H&(?X\1?\I'6N(>>7&!J856;4A`!10XU,PXU<&$EIQ,6[8$<1`&?< MK,*MZL^^N*`"55"@_!N(FE<`JE=X(8*$3)>UO%V`%KLO#+[4Y'S7NQ)FG0`5 M(5!,4"'34B(31EQ:;HGI@AU]#B048*ZB8*7PJ_:[+S8H814LJ/P(HO95B!KC MDD(&":$NZOIBDR0"(V&+(/HK#A)],-"+^F*`#6Q!!IT<"%Y8P#5F5#-QE,DC MH=!I<,@Z*[_B*/HEIE_C*0X8C7$X9&S3F%AQD/?;G;3`KG8K-<(@2.2"L,ZD M(4-Y3S-`0K/W1:BB0A=ERC]U1ZI/--K$:9`\R:VO]5T1!CF_)-+`K)*G)@2( M-&ID)K)L-9!4Z9`A>3"TRG=P$O MCM$FE4=Z>.S2AT6CDN?VQL&!6JMCT`!$)`>8NJG5TG[@0Y0IHY)VEW-PV<`N MF_:YXM^INC,&6=]S<5JX]?FXAB`()MG0:>?E\O%W/CTG5;IGC9@-<.-,2;(; MQC2@JOFR%0/(ECHV&U?D7,V+,^4%SB",EMLUZC%EQ+`%H9UJ)R<2')Q1;M8R MZ'7.O3W`:H\I(+HL;4DHM-'?"GTH.[@8PRFST+`NY'4'EA)@98=510(,B92P M&BL1T^E@-H5$A7Q^P(D1#5G_Q-#`;?*C)@B,)FITND6)3`<&:RX"=M>/0_$_ ML5?U(8CDGM;T(DB2)]['EYD!-+X[ZGH]2-#&GHP0EDCDU=NI*5#^/9BTQ!!GN1'$(-2AL7H6A=4T',`8N4;:QU2;=^0 M8$XBWK_&C,M^EQ1A<*J_6-`-[[^-@Z=@'F%+AT@C[/E8E0%P[?B40A(,AXSP%,>A MD@T.T3H3!LF="9;'M<9!4GHOW)S7J';(*Z,S!I8I]:!RS@16P4"I6E`0)9DR M_SN!$\[DD2ZU=U'`&%D2')J9V9&]XX&,1+E6*'K MBVY8>OCN[7^: M"8F"%/W7)L;H]/A0YA"7`OS#6Q@TU"3]TXVK=-(`TB\J!ZUJ43`4->.S)5LD MP),M-A/D:(K!1;'+)(QZ1TP)&9M:8'CG#+6QD3!/4124TQ9EZ8K2._SR*8M> M:T3AW.'M>@3A-G*`-0#5XE,/0`$/&FR+;GNNU<%:)MUG>106X1S1-N@WFO5O M4'EEM'][65D7_0;6PFAU5)4=%MGU5YV&8DVE[D:V.@?T@]RZ!I@&U0FF):GH M(=IIP.6;/(O?AFN%0M<\JP*W<2R3!LVO"D0KMS)I&+QJ')>S!C&C1DZ45?I@I1&%RR9CF*HR"5*,RC+$;\\J69:@ MM-(^662!7&:11A0,B\SX&MD\LFS^NX-ET(Z038,(LPE^P/$&WV+M.F9=RNO4 M@QIB9=ZA*@*&+&I#*Z@C(_-%J+NYI)O!H\KG',L.W0LD'>)T6L ML,N$T0J#"2@VA'4>C<:#27\VO+U&@]_&@]OI8'H&@T[9W=\1CXK]\)[$,CU\ M2AYP[I?NQ;%I>8T^;BY4(I)9!0S-W'`V@E:F)7@#RH/7Z!9(3V@8IY@73FJ. M40TIO\-T)<3J\+PBXH>W]0["QXQN^0?6$H6QB6` M/2WZ7W9YENO-I9F]S,$:3CS?$>6PXWQP-9H,Q+S;I^&4#SP0_Q,-;R]&'P9H MUO\-RI3LUJN\DWS.!][ZZ5FMM'\B:R$W2=H0!1-BS?B:FV7H`V$D"Z^\$9>K MB:D@)`PN9=/0ABF0LH#??59U8-5]5<6OL`)3`U?CPM3!#(E8`Z/VBTWZ8YS( M'17G`2.+?AQ>DFB3:O>U6+5\\L31A3)Y+"I@(HT;3AW#T'@P0=.?^[Q!&UTA MWH9]X`V:W(&,>DB:DC.U868,!A]_Q>)\)0[[#[P=7^';C;C>>K1L)+Z7\#6E MUM*&3Z[NY5Z9N:T,@.'Q/JCKK/YU,+S^>3:X1/U/@TG_>I`Q>XI&'V?36?_V M4JQQ@:5U*:.U2-]Y%=&OMO53LTI'.<>UX#6YQAOR8"CI`-*86UPH(:D%;D/8 M+4X%.MGQ#'%X_O21X7`8;U=@^HN4/&0'6LP4W,>0UVP^>SM:2>K3V@H8$N\- M7953&"TEFV6B'UI80,'6A''C`(1QP%LP]:(`U>BDX11%7`!&R.B'_[?))Z9G M=()%K9!(['?A.'\'Q;?B\T)$P0U_"A+SX6U#H,>W]5[<*?D/.<^YO2(E7HG-IDR.#EF6 M9E!7],[J7M^JEDY5WA1'73CL;P>XF2EAGO(!3B8$@Y/UI<[L<'3[Y6>%7I>+ MT%HW3$O1#26OO.-C[#EEV+C_V!'P'WAUFC0CR0UR?(>:)HE]\!2//>=+B6 M24SB7GINQ;BG=QF$SO5TL`:9Z"_BV9--0R6U(4&Q,Z+N7I6YI M[>RJF=-6,X`)[8I=E[R?%!M_BQ3J/8A9J:TOD@&LS2FM<:MFK:VS9*"IFPUR7V`5S&@( M`)4=''6@M,$*F'"\-W3;*A@I+,";`G;W^=F%!I7-SV/Q'Y"]MIB\SDV@^9.2 MNJ"9NYT#?VY<-AH"P&0'1QT8;;`"G=EVZ+:XO"PLP(O+W-D%QJ$\E3#%BTV" MP_*(5[]?P*SE>=^UBPNU31@F%3",=,.IV,$OM3+R"05X7!/9[?@[@4?+4HX\ MAU+0Z'7%-Z,;.L8IE4!RSH2T<<(]EY6;#4N9#.4Q$CAWP+L'^6>W$E";[^J*K!AD%?X6P_#L7_Q"+X0Q")Y>\Q3@@-Z]-\FB)K9\)K.KT] MG*LDV&NA#XO&>R!7$9GDHNC;,!?^3JXB"WZ+M6/Y`>\>T-$.6;6W??XF)\D3 M?^OTUVNY*'K>5[N6E31-@R1M7\,ZZ,H1A:H&40_-\8K$XM@5F@>1:('_?];J M:0>U.HB-J7_:`6]3ISB[+\VA0CTF(4M609SO`;R@,:,1">4?O`C&O(PY].K^ MP"#:GD"Q)E]\&=M>$YV]9'%44J.]A&$PPXF7]*:1++)D^Q!5K,L7JVQ?#$NV M3]AEQX9W&DI;8.*H(!LMRTZ=;QB),6.7F"T2LLZ+-5^HY0%DS)47O.\ZPX_I M>:0?8;_R,T&\EB]9?$ZOZTL\$/YK_()>-E[OR77_=O@_,J.BO(WJO#\=3L79 M\/%D,!W_?&6/N9KLI^XU<;AZKAS$43#!=;P6TTG(/Q:`KE:H=F5])VAMN@X/7, MJ!5XY92H5AH,IZP0-9N(19`K-,"%.,601ER&0U8Q69)%$*?M!]C/,^FW^7V^ M\]4F>G][8&C^`DXTFWIN4DQ*E8W"X/\-^?N&A"1]B*-1ZX0PG%_$TJHGN9(GL*3+=`YZ@+8IJ-VQV%_3E41#.': MH-6N[":',7$:791QH2P+Q<)YJ,A\4D7NTT: M?F^(MD*O7A&M%0?#+3O&1FM8UI#G`Z0&$BHP&'85D$3NUBMM0QK&+$TV][M& M7U,>CKH^6=?*G3+_G!3!,+$-VCHGA2Z2RM6=827]YU*3K6(B"7?\[O18TFUZ M?3O^C[H-W>;@GJM5;NG'[[(C90L&Q$CAM*9F!$ MR.GB#H<;D7Q1[)*8B>.'MLZ>6<7KC0`.X"LW`ACD.Z=?"Y"-#AY-,1I#2J^V M<\(E31[1MU//SAK>6O$ MW5W8-MUV%2C9A-O!5<5.F7E==8J@HR-7$YP&),9A,=SG[\?F?B.SLEWB)5FH M[RNT:WD^0N>0`;H%9L66DT(4A9DLC+9/,DHZR&9(I-HK-0U%@OR1S">J3JYB$O36`!B!;F.^ M4JIS%EBA-9:36"+GG'NT"UV3UZM4NTVGZ_>&7,2WZ8>&-:U`&M+0`V%@AD: M.5,F\JW$H5ML@F)@?A]#MT=K] MW,%A%.6^K.(W,,&I!JBY64_^_$H]ZC'WY(Y'Q'%"%OB*)JH$-SE]7!O/6#P:O600^*(,D`E/-I9110&U*`"MX`KE[P9=%O M4":,^FF:D/DFE1/^/(2/@P[KHT0-<9C4J79L.H#JRAFJX9616Z$R\8XJZ3JA MC(T3NE0OI99^!E3T*E2-\Z&)W.@MA3HJV^TU3KLKU%5EK!`#5-8F=(V$9MO+ MI_+S'-\*\>\Z*OYB.F[PN,:Q.J%R3010L>N0:;?^Y(*=E75!#I%6_X**5`$; M3H2<$31FYYB/%O'V6!!FE_P#2\E"72][FP-5A\_W0G-0*GNQL@LP=H;1SC*: M2].H?+#J$!7FNVIL7N9-[7JOB9HG\0O>\7U>RT%'5>;N?$4YE M[@%:=>!,GI`=ERY?^/9C=E?C=VC77KH=\_=?OR]_NP;X^C6!;EF_6U/=UZ_7 MJR?@U/%>L)T/NQ^BS!(:;N^E*(SY[O2^XK2VWXL)M,MT+9`JI[2-JAT/45Y\ MDP6<-[`%6.W8)CLPEBL7AQQ,TXWEKV[X)_YU\17_SYR_G_R;?P)02P,$%``` M``@`-5IM0PQ>)EP2#P``O\<``!4`'`!S9VYI+3(P,3,P.3,P7W!R92YX;6Q5 M5`D``R:F@U(FIH-2=7@+``$$)0X```0Y`0``[5WK<^(X$O]^5?<_^+)?YCX0 M(.QCDIVY+0(D16T&."#[N$K5E&(+T(V16,G.8__ZDVSSMF7)F$CL33[,)$8M M=_>O6VJI6^+#3R]SWWF"E"&"/Y[5SVMG#L0N\1">?CR['U6:HU:W>^:P`&`/ M^`3#CV>8G/WTK[__S>$_'_Y1J3@W"/K>E=,F;J6+)^1'IP?F\,JYA1A2$!#Z MH_,+\$/QA-P@'U*G1>8+'P:0?Q"_^,IIG'\'G4I%H=M?(/8(O1]V5]W.@F!Q M5:T^/S^?8_($G@G]PLY=HM;=B(34A:N^6EU>J-:KU?KC7'M\JKQ_JIQJHU_A.3?_`1_G(E_GD$ M##H<2,RN7ACZ>+:AD>?&.:'3Z@6GK/[VZ6[DSN`<5!`6@+KP;$DE>DFCJU]> M7E:C3Y=-]UH*H9?O:%27[*QZYI\B2?L-3ABZ8A%[=\0%062/N:]Q,EN(ORK+ M9A7QJ%*_J#3JYR_,.ULJ/](@)3XIE1./EX)JR@(@"/C8!YWZC0!J\+[E<,";A9/!R,'[D_Y"C%@< MF%SMR:E*TM[F2UJ`S6Y\\JR.JY3Z,`[[=`HP^C,2FMOU-6"(OV1`(>.OBY^Z M+@FYN>/I@/C(13"7[T/Z/$R:'@G@`+R"1]'0YTKSN)D%"BSG$A[&5QLN"$-! M[@"SW>Q`;PCG>WE4Q+=;;D=`M8W'=Q`/D0%)0E@;R_4L8+7;/) M(9/QM-@8G>_X@RT2^!+P4!UZRXX$CP5C*_Y8T-;BG[I3<994F[_R%8H3=^%L M]I%PO.39)^X6F[X(-@G-=2[.\&<9K\U'%E#@KL9A'SQ"/^K^LZ!5(ZT68391 M:13^,NB>3\E3U8.H&JT[^"^1()5:/0E^O^&//L<\#.$4B5?C0"PX4CCG3=-; M[C*Z:0E-ZCJ$>I!RQ)9]`NINX;\?KR;?IVM]NH:CT M"YN4GB:C25T/($6$2^")#1*YTG>:*FJ_8:/V4Z4V`4.3<^,)CFY\,$U7_TX3 M1;5_:Y/:4Z4TH>Y62(6(-XBYP/\=`BHU_.S6BB!\9Q,(>;*;FWA_A;[_,R;/ M>`0!(QAZ7<9"2&43<":)(C+?VX2,DA;,P?,+\?FZE2]GHY0!D\&RUU01CA_L M@R-#:H/A:>R_0[Y&I&(7(4Y)2*/4#`I%4-[;!XI`]WP9QF3B*2Y*CA6+KTS MQ3>/B0C+E1'9:*R*AY6+\0S14]#X4-V3[HX_*'TC/"A/M2B)H`]1NB$K#(%8!&;%?0#MGRR:U_)X\\K]OJ3&X0Y3XB;OT@T MR/?*$W(UZH,=IKAX3<:X?O,%V6UG:N-<2Z_;7I,A2?G#UZ%H)(&Z*BA[S8WM MIY<%3H8"[,!(U*#PP5K\U_DC1$_`YZRR9M`"E+[R("6J\3R#_T+N+I<[D,&(O(`'PHY86P):'E\%] M_L)`_540ND/@$?E(%(GP(2%:QLV(S[7-Q-`0O.9/:NH]&$LD'#[/Z:K)CE%S M@VOE&$5&8RS?4"J`5D$<2PJU\F>\C/;&F1:+1$N+/(V19#H]?3B7D'"P-+6(X9V\EM;&Y=(NZJDF^&#:!LI&C MR]OMVFMI+MM2%(XL:>W`HNEYD;]SSP?(Z^(66*!@?:@P)6S,(E!%YFB[)MK( MY,AN!T!#<2`%0Z\#*$9XRGA\&\[#*`1JPPERD63V4:%5A>V(VR":L*EKQ`X$ M]P74B1?4$3KB/H9A40UX4UPV!&*/IS;0=Y"X)]NM.M8E#3B!WS9QJO M47V^)G)+FA.N;\A7A1V0[55AJGB;E,AT0<,!H"DHPU+4\KPLD\!TI4.9:.7Z MUUL%)#F7[6S%(-_NQ"!K6H=,G`UJ<];6Q2Z9PQ5C^6%&)H')M1WP(1O")XA# MV(.R&&FWH>'8(4?[NPNZ=#%M&;88]_-;0KQH%0+I$W(A&Q%?.G)ETYB.#_2@ MR9?>#I1N*6%L0,E$MF&UU-IY68@%K$*=MX3$=$R@ M!V>N[)9X572[J,\]O^G-$8[N=!'7%B5<2SPMC]!T#60^`$1/()M@6PD7&^4= M'SH4?&JSL>GB15UX)!*?^C"YO,PLU^?V&IHN8-0%,4-2?0`O8P`QG(JLC7D( M;P'"3-@D9'W<>1$J"1&;Q2O(-GR4A2SYI*:+'[6'4E5MV#&8"G8%MWTLEBG] M21<_<1N-%KMRV#*)3!<]%@$L1P.V0=4B.))H#"F?K;>N.92!E4IFNIRQ.%P2 M+=@!V'JVON%2"W81#KFDZQVD:S@A%,;MQN`%LC;_A07(S=O(*=BI\8I(_4GS M8!6>?H24B):H[)K'ZM)]@$P"XS63Q=#/%-T.+X^W+>2KD,TVQFLB=5'8%_#4 M76I9_#2`-$I3B(OB7;[X;2,_#&0YFUQ"XQ66NN`JJL(.5_L5HNF,<]5\XD). M82^W6,0>H@KQI)JH96(6E5"*50FSU_!0##$YX@GQ)&^?KWG&'3QRF2;;H"> MXB*W7"&+]&5/%5$FFKO'L0IKS(Y!^%CQSK$@.D#?&G&0T5,(_PV3#8LQ&4*7 M8!?Y(M.\7CR-26E.>IRWF4Y7EF8DQP3#$G.;BRM,XR]96E4(X:E(I;,H<&3Q M&6*)"2GW8#KM>50T24&EV&0,NYNG<>EZH4WD%%+3:=0WA%]9D877WGPQ\$@8 M-+_ZYLJC$##8AO'_&^I*#I$IE;,I]V$ZVUO:W**O.#L&B7V^=^Z9$'4'KDM# M;LGK0S$ZX*OU9SIC7`"_/`/04:2MQB"YGR+OUH="G9G.*!_!#)15:*L-2"^> M.6`DV.W(='+Z^$.`[%M$3>.N/A.6L4ED/K=],-KZ"COUU$R&Q'$@7,Y^HK0O MXQGR\G84%71F];"0PG\96%N0!S\`L*+(GP3BJUV/$KQK)#EC5Y2YC3+;@#J72@-;7W*E'Z^G?/A!_0]'NXB?;6O1Z M,7ZC4VGV4D1[?TV+,?0-'L>[#>K(-I+__1YZQK&(;(X'I33X_S"1SQ?J1G*T MS<"W-1(AJE"P3Z<`)SER+J^H7V3]R6`3MW@SE,L\(#YR-Z?: MK?+![YV*(U+J/F$\R.9_](>WS5[W/\UQM]]SFKVV<]T<=4=._\89##NC3F^< M?-)J]>][XV[OUAGT[[JM;F=DL)9P4Q\M@AD7V5LJ9U,K&Q>YK*LC%'/FUAFL>2[6ZW9/.;P&8 MP5)GL9J7)VJVAJD?=H>I7G_<<0;-WYO7=QUGV+EKCCMM_O=P;'8@$N=:UWSF MCRQ9[0T.%=LL*3AY)H%A]Y1CL>-O.5(;])0V7(@[Q]+]XOVN7[0[@_ZH.S;H M`M<`?Q$Q&_;&,XHF"E=R95,8=8-([1OE(VL]JTQ]JO2&G20/K3TWT=&*R6ON MPOD<:W7_ZU!S^+H+A49>_ZJ;;:O;&:;&P M\V[9M*$NR`JPV?H$\68MW#%T!3V!$W`"TH8C"Y;TMW:BW4 MG>FC-=H`'Z0V.Y"_9Z*$GP5HSI=XDCS9;COCYUUTL4H7U`X0,M(K0K!7!7=3 M)#=^1D47,BVUV('DZAX09?"R*4R?!M'&*T]X.R#:O4="&:E<0M.G-K0!4U2% M';BU"'8A#N++E(:(?6E1R(,K\9MD:)01F3Y>H3\@YJO`#JQN`*)1*F]C9[V+ MN6SA?#V$9Z.F2&[ZB(0V?EIJ.11)QE>-$3ZURT8M0D=LOJRA^02!"$SC7$=\ M;%I5"'DD%.=4OI&17X[YJXUIRI'5O61+-*KZ:VO@E`75Z#UB8FV M^'92G_4`C>^?3Q]IZX,2SN,QT&5C4\2ATIWU0NMH(A_S/MUDHY7OOHU2#KL0(>P[_B+ MV.K9C&^W.J4@*$V^(RWSEK MRKTT1$ID.ENF;_ER\6U<15>67X6B,H,T-&>09=]?9Y%CW]FR@Z+T&QS5J$]I MUM'1AQV#Y9*_:-]-G#C!GO*8J4)[&C.;AD`'QNZF3\LD18MJ:^IO,RIJ2ULP M?ZVRW:^RE52&K%N<9*5L::4@&8'X(*3NC(^Z`XI<>$-HUGT#HG%&6]/#E:IB M)2(4"/&23\0_C[Q#_N1_4$L#!!0````(`#5:;4,(S&<[?`8``%K=K_H.5I]L$8A\D!D\P4XRB8!5+!428RSW*QA>% M&\>H.77;+J!W;W_[%<'O_'?#0"U*?*^*&MPU;#;B;U`'3T@571%&!%9"!EDE6"WV[BUU2ZJ;#YK7DL3V=]^FE,V%G0&/[Y M7CKX8V..>VK^196.OMS/'CY:I:'GGYAS_C=Y/%']^NG)Z5\/'[G+KR*5Y]*] M(Q.,8)

5'(1/ZQ7.1B;!Z!A>:GZ[83\A4BQNK,I^Q^$[M5J53,D)JPKG'J MF";095.3AUB2%!FH-(>?,JDP70U0!/QB2ZB%A>3!AGAP(<4>`6DL!@3I;>MG&*7;$%)]CQFC$-I0..(5_3:=$IA[\/"+^=ZDU1U#`=@ M*=(7T"Z6,?6BF91VC7E-IJB:Z^H1DQ"Y@*AW4/82,P]%6"@#=FZNPF3``TF\+GL;7D\%D0`3"K5A(1:,6;8(N=AW`W\_ MF84I&T7BA23*>\6]SIE'&$!=8E\7IW-'B))1Q+?0\F-]!`'6S9+$P4Y!4(R" M(IB?498]+,"Q.Z(HF)L7\F7&_/B7=XP_>K6$^L=!Y2,-D.R.NE-]-`(M\:[? M0LN/^NN5J"]`$!^A!MF0UK&\:_G\<;7';.;)C_KQUKV^''^-AT)` M].J&X<"CBGB'M>.[8HP9_2>T!YZ@EUA2"'0OXUG-=7D`#T,V[G&?NI3$&7J6 M9'[>3O1#&$[$/I>!@'<-U.U?U3KVE]K`[G90K=-`ES7'=E"WA7K]IM/L#&)* MO=Z]Z0SLSA7J==MVW6XZ!Y7$#E>DA^=XZ),^`;.(!SU!4?P0$#SNUK76*YS^PIDY^%RFH6G)OKZUK_LVXIC@UVMNQZ MK3/8U%'@8!3K.*PGQ-;N,=!+3[68F"DW*U9IGT:#7D68AY6%W:J@012FONQ@ MH<^5#V2?"EJ3S<^9]3V5%.M"J;+#2N;6:C$RE#A&3]37)HG\Q!WM56Q`!@4H MUI!F[F>^HNC;3!%P4.V7LRU2^7DK[YFW1,F!YRX^G6WNC-N(^9EXO>4H]__N M:_J/_JS?)R,4C@.J^B/S14%2/2DJQ&MW@HQ@#9XS1O)-^"NX5IQ-_(1%0^>, M`\*LK48C5IQ`8.&NH:R-*P"$3TE8<=F91&0Z55H\^[:*M!XH7?,E7/;Q<%^7 M083X/]#7ML9_42=A]^WKY,J&_4&NUA=:7M1A*)U]'5ZNMA_D;R-5DG4WGKJ8 MB[%+?+\ZFCD'Q[E0B*W-=O*&==&8LG"UX<7UT4E`B@YACU?7V@3.[#^7X56A3EWB#L MI%X@X@%MU%DC#D"!UTU;D8GF@D`$`$Q5H#FO!`^F"2,%ECP76YB*\%\FK@G6 M)[#P>S[XL#B3R0&9J4N?N_>)JWO*[.UB-/:OJ@3C!=S4[P]RP%N40>.DV%_, M+E;SN`OG?RZ+.O+Z$T2795Z4TIVYA;B'T1%M&`TW@4"&^H-MUI4)9W!>%_,7 M<*87"/<.GBP]*%;2XL)1F;VWC?BD,]%#4ZWYX@KBO8@SYV;4C>#R7U!+`0(> M`Q0````(`#5:;4/%?)ZBVC$``$I^`0`1`!@```````$```"D@0````!S9VYI M+3(P,3,P.3,P+GAM;%54!0`#)J:#4G5X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`#5:;4/"LSO&@0@``&U3```5`!@```````$```"D@24R``!S9VYI+3(P M,3,P.3,P7V-A;"YX;6Q55`4``R:F@U)U>`L``00E#@``!#D!``!02P$"'@,4 M````"``U6FU#Y+4K?90$``#_&@``%0`8```````!````I('U.@``&UL550%``,FIH-2=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`-5IM0_7+"9Q<%P``22T!`!4`&````````0```*2!V#\``'-G;FDM M,C`Q,S`Y,S!?;&%B+GAM;%54!0`#)J:#4G5X"P`!!"4.```$.0$``%!+`0(> M`Q0````(`#5:;4,,7B9<$@\``+_'```5`!@```````$```"D@8-7``!S9VYI M+3(P,3,P.3,P7W!R92YX;6Q55`4``R:F@U)U>`L``00E#@``!#D!``!02P$" M'@,4````"``U6FU#",QG.WP&``!7)@``$0`8```````!````I('D9@```L``00E#@``!#D!``!02P4&```` /``8`!@`:`@``JVT````` ` end XML 26 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE PAYABLE RELATED PARTIES - Note Payable (Details) (USD $)
 3 Months Ended
Sep. 30, 2013
Jun. 30, 2013
Debt Disclosure [Abstract]    
Additional notes payable issued $ 7,500  
Discount on note payable (11,672)  
Note payable $ 170,828 $ 175,000

XML 27 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE PAYABLE RELATED PARTIES
 3 Months Ended
Sep. 30, 2013
Debt Disclosure [Abstract]  
NOTE PAYABLE RELATED PARTIES

 

NOTE 2 – NOTE PAYABLE RELATED PARTIES, NET

 

On August 8, 2012, the Corporation received an infusion of $10,000 in order to continue its operations in the near-term. The Company executed a $10,000 due on demand note with Mr. Chip Brian, pursuant to which Mr. Brian advanced the Company $10,000 at a rate of 12% per annum. Both the principal and interest are payable to Mr. Brian on or before December 31, 2013. Additionally, the Company granted 1,000,000 shares of restricted common stock and a warrant to purchase an additional 1,000,000 shares of restricted common stock at an exercise price of $0.01 per share as an inducement for Mr. Brian to make the loan. The Company recorded interest expense related to the shares inducement based on the stock price on the grant date and amortized over the term of the loan and the unamortized portion was recorded as discount on note payable. The Company recorded the fair value of the warrants using the Black-Scholes valuation model and the unamortized portion was also recorded as a discount to the note. The amount of discount on note payable recorded as of September 30, 2013 was $34,640. The expected volatility is 78.87% and based on the daily historical volatility of comparative companies, measured over the 5 years expected term of the option. The risk-free rate is 0.71% and based on the implied yield on a U.S. Treasury zero-coupon issue with a remaining term closest to the expected term of the option.

 

 

 

Notes payable:

A summary of the notes payable activity is as follows:

Balance, June 30, 2013   $ 175,000  
Additional notes payable issued     7,500  
Discount on note payable     (11,672 )
Balance, September 30, 2013   $ 170,828  

 

Accrued interest:

 

A summary of the accrued interest activity is as follows:

Balance, June 30, 2013   $ 90,822  
Accrued interest for the three months ended September 30, 2013     5,316  
Balance, September 30, 2013   $ 96,138  

 

Historically, all interest payable incurred is from interest incurred at the stated rate of promissory notes issued by the Company. The payment terms, security and any interest payable are based on the underlying promissory notes payable that the Company has outstanding.

 

During the year ended June 30, 2007, we received $10,000 from Private Capital Group, L.L.C., a shareholder of the Company. This note had an interest rate of 10% per annum, was unsecured and had an original due date of December 31, 2007. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $3,252 and is due at maturity. Accrued interest is included in the notes payable, related parties balance. As an inducement to make the loan, we issued 1,000,000 shares of restricted common stock with a fair market value of $10,000 (par value) and issued a warrant for an additional 1,000,000 shares of restricted common stock with an exercise price of $0.01 per share. The warrants were estimated to have no significant fair market value.

 

During the year ended June 30, 2007, we received $10,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 10% per annum, is unsecured and had an original due date of December 31, 2007. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $3,252 and is due at maturity. Accrued interest is included in the notes payable, related parties balance. As an inducement to make the loan, we issued 1,000,000 shares of restricted common stock with a fair market value of $10,000 (par value) and issued a warrant for an additional 1,000,000 shares of restricted common stock with an exercise price of $.01 per share. The warrants were estimated to have no significant fair market value.

 

On August 24, 2010, these warrants were exercised by using the $10,000 note payable, related party loan balances issued on May 24, 2007 to C.W. Gilluly and Private Capital Group, in lieu of cash. In this transaction, 2,000,000 shares of common stock were issued for a par value of $0.01.

 

During the year ended June 30, 2008, we received an additional $15,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and had an original due date of December 31, 2009. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $10,582 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

During the year ended June 30, 2008, we received an additional $5,000 from Private Capital Group, L.L.C., a shareholder of the Company. This note has an interest rate of 12% per annum, is unsecured and had an original due date of December 31, 2009. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $3,412 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

 

During the year ended June 30, 2008, we received an additional $15,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and had an original due date of December 31, 2009. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $9,498 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

During the year ended June 30, 2009, we received an additional $25,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and had an original due date of December 31, 2009. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $15,129 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

During the year ended June 30, 2009, we received an additional $40,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and had an original due date of December 31, 2009. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $23,448 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

During the year ended June 30, 2009, we received an additional $10,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and had an original due date of December 31, 2009. The note was extended with the same terms and a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $5,431 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

During the year ended June 30, 2010, we received an additional $15,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $7,333 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

During the year ended June 30, 2010, we received an additional $5,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $2,356 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

During the year ended June 30, 2010, we received an additional $5,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $2,213 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

During the year ended June 30, 2010, we received an additional $5,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $2,083 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

During the year ended June 30, 2011, we received an additional $10,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $1,013 and is due at maturity. Accrued interest is included in the notes payable and accrued interest, related parties balance.

 

During the year ended June 30, 2011, we received an additional $10,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $717 and is due at maturity. Accrued interest is included in the notes payable and accrued interest, related parties balance.

 

 

 

During the year ended June 30, 2011, we received an additional $15,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $621 and is due at maturity. Accrued interest is included in the notes payable and accrued interest, related parties balance.

 

During the year ended June 30, 2011, we received an additional $5,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $59 and is due at maturity. Accrued interest is included in the notes payable and accrued interest, related parties balance.

 

On May 31, 2011, Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer, converted $40,000 of the most recent notes into 4,000,000 shares of the Company’s restricted stock common stock.

 

On August 31, 2011, the Corporation received an infusion of $10,000 in order to continue its operations in the near-term. The Company executed a $10,000 due on demand note with Mr. Chip Brian, pursuant to which Mr. Brian advanced the Company $10,000 at a rate of 12% per annum. Both the principal and interest are payable to Mr. Brian on or before September 30, 2013. Additionally, the Company granted 1,000,000 shares of restricted common stock and a warrant to purchase an additional 1,000,000 shares of restricted common stock at an exercise price of $0.01 per share as an inducement for Mr. Brian to make the loan. The Company recorded $20,000 of interest expense related to the shares issued. As of September 30, 2013, accrued interest payable totaled $2,502 and is due at maturity. Accrued interest is included in the notes payable and accrued interest, related parties balance.

 

On January 23, 2012, we received an additional $5,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $1,013 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

On April 25, 2012, we received an additional $2,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $344 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

On August 8, 2012, we received an infusion of $10,000 in order to continue its operations in the near-term. The Company executed a $10,000 due on demand note with Mr. Chip Brian, pursuant to which Mr. Brian advanced the Company $10,000 at a rate of 12% per annum. Both the principal and interest are payable to Mr. Brian on or before September 30, 2013. Additionally, the Company granted 1,000,000 shares of restricted common stock and a warrant to purchase an additional 1,000,000 shares of restricted common stock at an exercise price of $0.01 per share as an inducement for Mr. Brian to make the loan. The Company recorded interest expense related to the shares inducement based on the stock price on the grant date and amortized over the term of the loan and the unamortized portion is recorded as a discount on note payable. The Company recorded the fair value of the warrants using the Black-Scholes valuation model and the unamortized portion was also recorded as a discount to the note and classified to other assets. The amount of discount on note payable recorded as of September 30, 2013 was $57,358. The expected volatility is 78.87% and is based on the daily historical volatility of comparative companies, measured over the 5 years expected term of the option. The risk-free rate is 0.71% and is based on the implied yield on a U.S. Treasury zero-coupon issue with a remaining term closest to the expected term of the option. Both the interest expense recorded from the shares issuance and warrants issuance are amortized over the term of the loan. As of September 30, 2013, accrued interest payable totaled $1,369 and is due at maturity. Accrued interest is included in the notes payable and accrued interest, related parties balance.

 

On October 25, 2012, we received an additional $3,000 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $335 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

 

 

On January 14, 2013, Mr. Chip Brian terminated and cancelled his warrants to purchase 2,000,000 shares of the Company’s common stock.

 

 On April 8, 2013, we received an additional $5,000 from ImaginEquity. This note has an interest rate of 6% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $79 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

On August 21, 2013, we received an additional $7,500 from Dr. C.W. Gilluly, our Chairman of the Board, President and Chief Executive Officer. This note has an interest rate of 12% per annum, is unsecured and has a due date of December 31, 2013. As of September 30, 2013, accrued interest payable totaled $99 and is due at maturity. Accrued interest is included in the notes payable, related parties balance.

 

Effective February 5, 2013, the Company amended its Certificate of Incorporation. As a result of the Amendment, the Company’s corporate name changed from Amasys Corporation to StemGen, Inc and a reverse stock split was effectuated where all the outstanding shares of the Company’s common stock were exchanged at a ratio of one for eighty.
XML 28 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 29 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document and Entity Information (USD $)
 3 Months Ended
Sep. 30, 2013
Nov. 12, 2013
Notes to Financial Statements    
Entity Registrant Name StemGen, Inc.  
Entity Central Index Key 0001023198  
Document Type 10-Q  
Document Period End Date Sep. 30, 2013  
Amendment Flag false  
Current Fiscal Year End Date --06-30  
Is Entity a Well-known Seasoned Issuer? No  
Is Entity a Voluntary Filer? No  
Is Entity's Reporting Status Current? No  
Entity Filer Category Smaller Reporting Company  
Entity Public Float   $ 27,061
Entity Common Stock, Shares Outstanding   183,927
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2014